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Abstract 
Most strains of enterotoxigenic Escherichia coli (ETEC) isolated from neonatal cattle 
with dianhoea expresss the colonization factor antigen, K99. K99 (F5) pili are necessary 
for the bacteria to bind to a receptor, N-glycolylneuraminic acid-GM3 on the cells of the 
bovine small intestine. Bacterial growth in the intestine and secretion of toxins triggers 
diarrhoea that can be fatal due to the loss of water and electrolytes. When the attachment of 
ETEC to host cells is inhibited, bacteria do not accumulate sufficiently in the gut to cause 
disease. Anti-K99 antibodies in the colostrum of vaccinated dams can mediate protection 
against ETEC infection in the neonate through this mechanism, a finding demonstrated by 
several vaccine trials using a variety of preparations containing K99 including whole cell 
bacterins and crude cellular extracts. Passive oral administration of antibody against K99 
antigen also prevents severe fatal enteric colibacillosis in newborn calves. Therefore, the 
K99 adhesin is confirmed as an important virulence factor in bovine colibacillosis induced 
by ETEC strains. 
K99 was chosen as a model target for this study, to explore the application of 
recombinant antibody technology to livestock infection. Our aims were to isolate and 
characterise single-chain Fv antibodies against K99 using phage display. Escherichia coli 
B41, a clinical isolate that expresses K99 fimbriae, was grown and fimbriae were extracted 
by heat-shock treatment and then precipitated by ammonium sulphate. The major K99 
subunit (Fan C) was purified from crude fimbriae extract by an ion-exchange 
chromatography method using SP-XL columns. The method successfully purified a single 
protein of 16.5 kDa with high yield. This purified protein had high activity with 
monoclonal anti-K99 antibody in ELISA, dot blotting and immunoprecipitation. It also 
showed the ability at high dilutions to agglutinate sheep red blood cells. This purification 
protocol proved to be faster, more convenient and cheaper than other previous reported 
methods. 
The purified Fan C was coated to immunotubes and a large human semi-synthetic 
library (Griffin. 1library, Center of Protein Engineering, Cambridge, UK) was screened by 
four rounds of biopmming to extract scFvs able to recognise the fimbrial protein. Phage 
antibodies were isolated and screened by monoclonal phage ELISA. This revealed some 
clones isolated from the library had activity against K99 but the background in this assay 
was generally high. Also PCR analysis of these clones showed that only about one third of 
them carried a full-length scFv inseli. Expression of soluble scFv antibodies was attempted 
by transfection of phage into the non-suppressor E. coli strain HB2151. Expression was not 
XIII 
successful. Recloning the inserts into a vector designed to stabilise scFvs and other 
strategies failed to overcome problems in the expreSSIOn of these soluble fragments. 
Sequencing showed that stop co dons occuned commonly in the CDRs or framework 
regions. Therefore other libraries were used to achieve the aims of the project. 
The semi-synthetic Tomlinson I and J libraries (Center of Protein Engineering, 
Cambridge, UK) were used to select phage antibodies against K99 using immunotubes 
coated with the major fimbrial subunit. After three rounds of selection, phage were 
transfected into E. coli HB2151 for the expression of soluble scFvs. Fifteen scFv clones 
with high activity against K99 fimbriae were identified by ELISA and sequenced. Of these, 
six scFvs carried sequences that were reasonably diverse. These proteins were purified for 
fmiher characterization. The recombinant antibodies were shown to react with fimbriae 
present at the surface of E. coli B41 using immunofluorescence microscopy and 
immunogold electron microscopy. Some of the purified scFv antibodies were also able to 
inhibit the agglutination of sheep erythrocytes by E. coli B41 grown at 37°C. To pursue 
this observation, attempts were made to use the scFvs in an in vitro model of bacterial 
colonisation in which bacteria were tested for attachment to isolated bovine intestinal villi. 
Although bacteria could be observed adhering to the brush border, the scFvs appeared 
unable to prevent this attachment. Further experiments with this in vitro model or a mouse 
model of ETEC infection, allied with epitope mapping studies should determine if anti-
colonisation activity is attributable to binding of scFvs to the receptor-recognition site on 
the major subunit of the adhesin. 
Overall, phage display thus offers a rapid and flexible approach to isolate reagents for 
a better understanding of microbial pathogenesis. Potentially, these reagents may also be of 
value in diagnosis and therapy. 
BSA: bovine serum albumin 
CH : constant region of heavy chain 
CL : constant region of light chain 
CDNA: complementary DNA 
Abbreviations 
CDR: complementary determining region 
FR: framework region 
H chain: heavy chain 
HRP: horse radish peroxidase 
Ig: immunoglobulin 
IPTG: Isopropy 1-~ -D-thiogalactopyranoside 
L chain: light chain 
LB: luria broth 
MAB: monoclonal antibody 
MPBS: milk in phosphate buffered saline 
PBS: phosphate buffered saline 
PCR: polymerase chain reaction 
RT-PCR: reverse transcriptase polymerase chain reaction 
scFv: single chain antibody fragment 
V: variable region 
V H: variable region of heavy chain 
V L: variable region of light chain 




1. General Introduction 
Antibodies for diagnosis and therapeutics 
Antibodies are a component of the immune system, which constitutes a versatile 
system to defend the body against intruders. The main purpose of antibodies is to bind 
pathogens specifically and thereby mark them for attack by other protein components of 
the immune system or its cells (Breitling and Dubel, 1999). Antibodies are capable of 
highly specific interactions with a wide variety of ligands including tumor-associated 
markers, viral coat proteins, and lymphocyte cell surface glycoproteins. They are 
potentially very useful agents for diagnosis and treatment of diseases (Riethmuller et al., 
1993). In recent years, antibodies have become increasingly accepted as therapeutic 
reagents, patiicularly for cancer but also for numerous other disorders. An indication of the 
emerging significance of antibody-based therapeutics is that over a third of the proteins 
currently undergoing clinical testing in the United States are antibodies (Maynard and 
Georgiou, 2000). 
Animals naturally produce antibodies as pati of the protective response against agents 
that are encountered during life. This propeliy is extensively exploited by vaccination 
either to protect the host in advance of infection or to raise antibody responses for passive 
transfer to other animals, for example the neonate. The great variety of antibodies, as well 
as their high specificity and affinity for antigens, makes it possible to use them as tools for 
in vivo and in vitro diagnostics. Antibodies may also have natural enzymatic activities, 
which can be optimised by mutations (Fletcher et a!., 1998). These antibodies, known as 
abzymes, might become a new source of enzymes. Further more, antibodies could be used 
to manage environmental pollution by neutralizing toxic substances (Harris, 1999). 
Antibodies can also mediate protection against intracellular pathogens (Casadevall, 1998). 
In this respect, they could provide a major line of defence against biological attacks 
(Casadevall, 2002). 
Antibodies neutralize pathogens via different mechanisms. It is conventional to view 
the activation of complement or antibody-dependent cellular cytotoxicity (Gura, 2002) as 
the main mechanisms by which antibodies lead to the elimination of pathogens. However, 
simple binding of the antibody to a key molecule of the pathogen may be sufficient to 
inactivate it (for example, by steric obstruction of interaction with a receptor) and thereby 
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provide protection. In this context, recent studies have shown that the simultaneous use of 
monoclonal antibodies directed against several different conformational epitopes of the 
human immunodifficiency virus envelop which binds CD4 in human lymphocytes, 
prevented infection by various mutants of virus (Ferrantelli and Ruprecht, 2002). 
Antibodies can specifically block the action of natural factors in vivo, and are used to 
inhibit rejection mechanisms after organ transplantation. Antibodies can also be used as 
vehicles to target biologically active molecules to specific cells. For instance, radioactive 
ions can be bound to antibodies that specifically recognize tumour cells (Quadri et al., 
1993; Webber, 1998). Toxins bound to antibodies can have similar effects (Baluna et al., 
2000). 
As can be seen, antibodies have a vast range of uses both in vivo and in vitro, all of 
which require different forms ofthese molecules .. 
Antigen-binding sites - structures and generation 
The antigen-binding site of an antibody is created by the non-covalent association of 
the N-terminal "variable" domains of the heavy and light chains. Structural studies of 
antibodies complexed with antigen (Wilson and Stanfield, 1994; MacCallum et al., 1996) 
have shown that the antigen-binding site is formed from the solvent-exposed side chains of 
amino acids in 6 loops, 3 from VH and 3 from VL. These emerge from an underlying 
structure formed by the framework regions of the variable domains. The H3 loop, the most 
variable in sequence and length, and L3, occupy the center of the binding site and tend to 
make most of the key contacts with antigen. These 6 loops are substantially, but not 
exactly, similar in extent to the previously defined complementarity determining regions 
(CDRs) (Wu and Kabat, 1970). The CDRs were initially identified as regions within the 
variable domains that exhibited even greater variability between different antibodies. For 5 
of the 6 loops, it has been possible to identify a small number of canonical conformations 
that each can adopt depending on sequence, length and the identity of key framework 
residues which contact the loops (Chothia and Lesk, 1987; Chothia et al., 1989; 
Tramontano et al., 1990). H3 remains too variable in sequence and length for such 
rationalization. Using this information, predictions can be made about the conformation of 
a newly derived antibody sequence. Some estimate of the likely structure of the antigen-
binding site, based upon sequence analysis, other calculations or structural determination, 
is important for many antibody engineering projects (eg humanization or affinity 
modification). The sequences of H3 and L3 are generated during the process of genomic 
recombination and somatic mutation which occurs during B cell development. 
3 
The coding sequence of H3 is formed when one member from each of 3 genetic 
segments, the VH minigenes, DH (diversity) segments and JH (joining) segments, is 
brought together during the maturation of the Ig heavy chain. The coding sequence for L3 
is formed by recombination of one each from a set of VL minigenes and JL segments 
during the formation of the light chain. HI and H2, and L1 and L2 are derived fi'om the 
coding sequence in the VH and VL minigenes, respectively, but can also be altered later 
during the somatic mutation process (Tramontano et al., 1990). The number of these 
sequences in humans, primates and rodents, their organization into sequence subfamilies 
and their relative utilization in the immune response is of interest to antibody engineering 
projects. Heavy chain recombination occurs before light chain reorganization and the 
heavy chain variable domain appears on the surface of pre-B cells as a membrane bound 
protein associated with a surrogate light chain. Later in B cell development, rearrangement 
of the K locus occurs, and if no productive K chain is made at either of the k alleles then A 
rearrangement occurs until a functional light chain is formed. A functional light chain then 
appears on the B cell surface with a heavy chain. Exposure to antigen and selection for B 
cells expressing binding sites with reasonable affinity for antigen then takes place. Within 
a species, the V mini gene sequences can be grouped into a number of families according to 
amino acid or nucleotide sequence homology. 
Antibody engineering 
Antibody engineering became possible with the development in 1975 of hybridoma 
technology, the fusion of a myeloma with B-cells from an immunised animal to create cells 
able to produce mono specific antibody in culture (Kohler and Milstein, 1975). For the 
production of hybridomas, a laboratory animal (usually a mouse or rat) is immunised to 
raise a high titre of circulating antibodies against the immunising antigen. B lymphocytes 
are then isolated from the spleen. Although each lymphocyte produces antibody with 
affinity for a single antigenic unit or epitope, the proteins cannot be obtained directly from 
isolated B lymphocytes in culture as the life time of these cells is too short in vitro. To 
solve this problem, Kohler and Milstein fused B lymphocytes with plasmacytoma cells, 
descendants of a plasma-cell-tumour. The resulting "hybridoma cells" possess the 
propeliies of both fusion paliners: they are immortalised and produce the monoclonal 
antibody originally secreted by the B lymphocyte partner. Monoclonal antibody 
technology remains one of the core technologies of biotechnology, and thousands of 
medically and diagnostically relevant hybridomas have been developed. In 1980 two 
monoclonal antibodies were subjected to clinical trials (Reicheli, 2001) , but this number 
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has increased considerably over the past 20 years. Currently, approximately 200 antibodies 
and their derivatives are in clinical trials for the treatment of disease (van Dijk and van de 
Winkel, 2001; Brekke and Sandlie, 2003). The majority of monoclonal antibodies 
produced by hybridoma technology are murine antibodies, which are immunogenic when 
used as therapeutic agents in humans (Monzavi-Karbassi and Kieber-Emmons, 2001). The 
induced human anti-mouse antibody (HAMA) response quickly reduces the effectiveness 
of therapy by clearing the murine antibody from the bloodstream. The generation of human 
monoclonal antibodies (Humab) may be performed either by imm01ialization of human B-
lymphocytes through fusion with neoplastic cells or by transformation with Epstein-Barr 
virus. Human hybridoma teclmology has been restricted by the inefficiency of these 
immortalization procedures and the ethical constraints on immunization of humans 
(Monzavi-Karbassi and Kieber-Emmons, 2001). 
A revolution in antibody engineering began in the late 1980s when efficient systems 
for the cloning and expression of antibody genes in bacteria were developed (Winter and 
Milstein, 1991). Cloning the genes of monoclonal antibodies from murine hybridomas was 
greatly simplified by the discovery of the polymerase chain reaction (PCR), and bacterial 
expression systems allowed rapid and straight-forward production of functional 
recombinant antibody fragments for analysis (Pluckthun and Skerra, 1989). 
To clone antibodies, mRNA is isolated from hybridoma, spleen, or lymph cells, 
reverse transcribed into eDNA, and antibody genes are amplified by PCR. This strategy 
requires oligonucleotide primers that can recognise any antibody gene. Numerous primer 
sets have been derived from the N-terminal sequence of purified antibodies (Benhar et aI., 
1994), rapid amplification of eDNA ends (Ruberti et aI., 1997), antibody leader sequences 
(Larrick et aI., 1989) and most popularly, primers based on known variable region 
framework amino acid sequences. 
An artefact of the process used to generate hybridomas is that myeloma cell lines may 
express irrelevant heavy or light chains, in addition to the desired monoclonal antibodies 
(Maynard and Georgiou, 2000). The general cloning strategy outlined above will amplify 
all antibody genes present at the mRNA level, and multiple heavy and light chains, in 
addition to the desired ones, may thus be cloned (Krebber et aI., 1997a). Once the correct 
genes encoding VH and VL domains have been identified, they can be assembled in a 
number of forms suitable for expression or future manipUlation (Maynard and Georgiou, 
2000). 
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Whilst these methods can be applied to the isolation and expression of human 
antibodies, engineering techniques can also overcome the immunogenicity of rodent 
monoclonal antibodies in human patients. 
Humanization of monoclonal antibodies 
Chimeric antibodies 
Chimeric antibodies represented the first attempt to reduce the immunogenicity of 
heterologous monoclonal antibodies. Chimeric monoclonal antibodies are 60-70% human 
and are obtained by exchanging the variable regions (Fv) of human antibody heavy and 
light chain genes for those derived from the rodent monoclonal, thereby imparting the 
desired antigenic specificity. They are constructed by joining the DNA segments encoding 
the mouse variable regions, specific for a certain antigen, to segments of DNA encoding 
human constant regions. This retains variable regions that are of murine sequence, but in 
spite of the possible immunogenicity of these structures, four chimeric monoclonal 
antibodies have reached the market as therapeutic agents (Van den Broeck et ai., 1999; 
Brekke and Sandlie, 2003). 
CDR-Grafted antibodies 
CDR-grafted antibodies, developed in the early 1990s, represented a step closer to the 
complete humanization of murine monoclonal antibodies. Interaction between antibody 
and antigen is typically limited to the CDRs (complementary-determining regions) present 
on each variable domain of the immunoglobulin (V H and V d, the overall conformation of 
the domains being determined by the flanking framework regions (Rees et aI., 1994). 
Mouse CDRs for a specific antigen can be grafted onto a human framework, resulting in an 
antibody that is 90-95% human in sequence, and that retains the affinity and specificity 
characteristics of the original murine monoclonal antibody (McCafferty and Glover, 2000). 
To date, five CDR-grafted antibodies have reached the market for therapeutic application 
(Reichert, 2001). 
Transgenic Antibodies 
A further strategy to obtain fully human antibodies involves the genetic engineering of 
the immune system of the mouse. The basic idea of this technology, introduced in the mid-
1990s, is to generate an immune response in "knock-out" mice that have been engineered 
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to produce human antibodies and then use hybridoma methods to obtain immortalised cell 
lines secreting antibodies. One way to achieve this has been to inactivate the endogenous 
mouse Ig system and subsequently introduce human Ig gene segments, enabling the mouse 
to produce entirely human antibody molecules (including isotype switching and affinity 
maturation) when immunized with a specific target. These animals have been termed 
"HuMab" mice (Neuberger, 1996; Green, 1999). Another strategy is to engineer mice to 
carry human mini chromosomes derived from human chromosomes 14 and 2, containing 
the complete germ-line gene clusters for heavy and K light chains. In these "trans-
chromosomic" mice, the envirom11ent around the human immunoglobulin genes is very 
similar to that in the original host (Tomizuka et al., 2000). A further approach is to 
introduce human lymphocytes from immune donors or cancer patients into SCID (Severe 
Combined Immunodeficiency) mice or into "Trimera" mice (mice lethally irradiated and 
then reconstituted by transplantation of bone-marrow cells from SCID mice) (Reisner and 
Dagan, 1998). Following antigen immunization, mouse spleen cells are fused to myeloma 
cells, as described above, and the resulting hybridomas screened for human antibodies of 
the desired specificity. All these approaches have been used with varying degrees of 
success to produce human antibodies but such is their relative complexity, their application 
has not extended to other mammals (eg livestock animals). 
Recombinant antibodies 
With the development of recombinant antibodies, a new approach for the production of 
antibodies has recently emerged. The antibodies are no longer produced in laboratory 
animals, but in bacteria or in cell culture, in vitro. The focus of attention in these 
technologies is the antigen-binding portion of the antibody. 
In order to obtain higher yields in bacteria, the rest of the antibody molecule is usually 
relinquished. The resulting immunoglobulin fragments can no longer perform all the 
functions of a naturally produced antibody but they can be fused with enzymes or other 
antibodies with comparative ease. In this way recombinant antibodies acquire a completely 
new set of properties given the numerous possibilities of recombination with other gene 
fragments (Breitling and Dlibel, 1999). 
The smallest component of an antibody that retains antigenic specificity is the minimal 
recognition unit (MRU), derived from the peptide sequence of a single CDR (Ritter Mary 
et al., 1995). The binding affinities of these sequences is often low and is only elevated by 
a protein able to bring several MRU s together, eg a single V H domain. These suffer 
different limitations - isolated V H domains are very unstable and prone to aggregation in 
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vivo because the hydrophobic area that normally fmIDs the interface with the V L domain is 
exposed to the solvent. 
In general, the presence of both of V H and V L domains is needed for high stability and 
antigen affinity. V H and V L chains can be expressed as separate peptides in bacteria where 
they spontaneously assemble into Fv fragments. 
In these dimeric proteins, the two peptide chains are held together by noncovalent 
interactions and are therefore prone to dissociation and aggregation. The two chains can be 
covalently assembled by engineering an interchain disulfide bond, to give a dsFv antibody. 
This design is more stable than an Fv fragment, but it is difficult to produce by bacterial 
fermentation, and the disulfide bond can be reduced under mild conditions. A more 
popular strategy is to introduce a short polypeptide linker to fuse the V H and V L chains 
together into a single chain (sc) Fv antibody fragment. ScFvs are relatively small (26-27 
kDa), generally quite stable, and are encoded by a single gene which simplifies later 
manipulations. The most common linker is a flexible (GlY4Ser)3 decapentapeptide (Huston 
et al., 1988).The two variable domains can be connected either as Vwlinker-VL or VL-
linker-V H, with the former being more common. The order of the two domains can affect 
expression efficiency, stability, and the tendency to form dimers in solution (Tsumoto et 
aI., 1994; Merk et aI., 1999). 
In addition to scFvs, the other commonly used recombinant antibody fragments are 
Fabs. Fabs consist of two polypeptide chains, one containing the light chain variable and 
constant domains (VLCK or Ie), the other a truncated heavy chain containing the variable 
domain and one constant domain (V HC H1). Just as in intact IgG immunoglobulins, the two 
chains are linked together by a disulfide bond. The more extensive interface between the 
two chains and the presence of the disulfide bond confer increased stability. Although the 
expression of Fab requires the association of two chains, it often occurs quite efficiently in 
bacteria (Cmier et al., 1992; Skerra, 1994). On the other hand, the presence of the two 
chains somewhat complicates genetic manipulations, and the larger size of these portions 
may limit their bioavai1ablity for certain therapeutic applications. Several Fab fragments 
are more poorly expressed in functional form in E. coli than Fv-fragments and their 
derivatives (Skerra and Pluckthun, 1991). It appears that a higher tendency to aggregate 
can cause this problem. 
The production of whole antibodies in E. coli suffers several limitations. Firstly, the 
proteins lack normal glycosylation in the Fc region that contributes to stability and 
biological functions (Shin et aI., 1992). Yields of these large proteins are often poor. In 
order to preserve the bivalency that is an important feature of native immunoglobulins and 
a very effective means of increasing the functional affinity (avidity) (Crothers and 
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Metzger, 1972) another strategy can be used: the linking of scFv fragments by a small 
modular dimerization domain in the form of one or two amphipathic helices (Pack and 
Pluckthun, 1992; Pack et aI., 1993). These "miniantibodies" (Pack and Pluckthun, 1992; 
Pack et al., 1993) assemble in dimeric form in E. coli, and the binding performance of the 
best of them is indistinguishable from a whole antibody in avidity terms. 
Antibody fragments such as F(ab')2, Fab, and scFvs, may have particular advantages 
over intact antibodies. F(ab')2 is the largest proteolytic fragment that retains the bivalent 
binding sites of an antibody and through its size advantage, remains in the blood much 
longer than smaller antibody fragments, such as Fab or scFv (Chamow and Ashkenazi, 
1999). Some attempts have been made to alter the stability of these smaller antibody 
fragments (Worn and Pluckthun, 2001) and increase their circulation time in vivo by 
chemical linkage to polyethylene glycol (PEG; "pegylation") (Wang et al., 1998; Chapman 
et aI., 1999; Chapman, 2002). However, scFvs or Fabs may be preferred in situations such 
as tumour imaging where tissue penetration and clearance from the circulation is important 
and the effector functions of the Fc portion are dispensable. Once a Fab or scFv fragment 
with high affinity and specificity for a target antigen has been obtained, it may prove useful 
to genetically reconstruct these fragments into an intact fully human antibody (Huls et at., 
2001). The overall advantages of scFv antibodies are their easier and faster production, the 
ability to isolate them from libraries to generate reagents against an enormous number of 
antigens (foreign antigens, self antigens, non-immunogenic antigens and toxic antigens), 
their lower retention times in non-target tissues, their reduced immunogenicity, and the 
ability to fuse them to other proteins and peptides (Little et aI., 2000). 
Fusion and Bispecific Antibodies 
Several approaches have been developed in order to increase the efficiency of 
antibodies or antibody fragments, particularly in regard to their effector functions. 
Chemical conjugation of antibodies to effector compounds such as bacterial or plant toxins 
or cytotoxic drugs allows increased antibody efficiency but can inactivate antibody-binding 
sites or alter the effector agents as a result of the chemical manipulation. Some of these 
problems can be overcome by genetic fusion of the antibody or fragment to the intended 
ligand. In doing this, the ligand must leave the antigen-binding site free. Ligands that have 
been used to improve effector functions are as toxins (commonly used to target cancer 
cells), cytokines, and enzymes (functioning as a drug or pro-drug converting system). 
Fusion proteins can also bring other properties to antibodies such as the introduction of a 
lipid anchor to produce a membrane-bound scFv fusion (Laukkanen et aI., 1993). 
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An alternative method to improve effector functions is to produce bispecific antibodies 
- molecules that have two different specific antigen-binding sites. If one component carries 
a target-binding arm and the other, an effector-binding arm (eg an antibody against a cell 
marker), conventional and novel effector mechanisms can be induced. Bispecific 
antibodies can be generated from scFvs and Fabs by somatic cell hybridization, chemical 
conjugation (heteroconjugates), or genetic engineering. For example, conjugation of Fab 
fragments can give rise to bispecific F(ab')2 molecules or trimeric Fab molecules. These 
proteins can be used in immunoassays, immunodiagnostics, and therapy (Kriangkum et al., 
2000; Schmiedl et al., 2000; Zuo et al., 2000). Recently, fusion proteins comprising scFvs 
or Fabs and peptides that possess antibody effector functions (pepbodies) have been 
expressed in bacteria. These fusion proteins were able to initiate antibody effector 
functions (Lunde et aI., 2002). 
Antibody-Like Structures 
Antibodies can also be engineered into compact and multivalent structures, such as 
diabodies, triabodies, tetrabodies, and minibodies (Adams and Schier, 1999). Changing the 
linker length between V domains of a scFv creates new types of Fv modules (Hudson and 
Kortt, 1999). If the linker is 5-12 residues long, a scFv molecule is constrained, forcing 
association with a second scFv to form a dimer called a diabody (Arndt et aI., 1998; Volkel 
et aI., 2001). When the linker length is reduced to less than 3 residues, three scFvs are 
forced to associate into trivalent (triabody) or a tetravalent structures (tetrabodies), 
depending on the linker length, its composition and the orientation of the V domains (1(ortt 
et aI., 1997; Atwell et al., 1999; Hudson and Kortt, 1999; Kortt et aI., 2001). According to 
the specificity of the variable domains used in construction, it is possible to produce 
bivalent and bispecific antibody fragments (Holliger et aI., 1996), bivalent mono specific 
diabodies (Kortt et aI., 1997), non-functional triabodies (Pei et aI., 1997), monospecific 
trivalent triabodies or tetravalent tetrabodies (Kortt et al., 1997; KOltt et aI., 2001), and 
trispecific and tetraspecific triabodies or tetrabodies (Hudson and Kortt, 1999). The use of 
multimeric antibodies in cancer imaging (Power and Hudson, 2000), therapeutics, targeting 
(Holliger et aI., 1996; FitzGerald et al., 1997; Kortt et al., 2001), and recruitment of 
effector functions (Holliger et al., 1997; Kontermann et al., 1997; Cochlovius et al., 2000) 
has been explored. 
The various formats of engineered antibodies are illustrated in Figure 1. 
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Expression systems for production of recombinant antibodies 
Several systems for production of recombinant antibody fragments have been 
described using bacteria, yeast, plant, insect, and mammalian cells. Each system has 
potential advantages and limitations. Bacteria are particularly suitable for the production of 
antibody fragments but cannot assemble whole glycosylated antibodies. Full-length 
antibodies have been expressed in yeast, but glycolsylation tends to introduce highly 
mmIDosylated and multiply-branched oligosaccharides. These antibodies were shown to be 
defective in effector functions such as complement-mediated lysis. Full-length antibodies 
have also been produced in insect cells via baculovirus vectors. These also contained 
carbohydrate structures that were very different form those produced in mammalian cells. 
Native antibodies with full functionality have been expressed in myeloma and non-
lymphoid mammalian cells where mechanisms required for correct assembly, post-
translational modification, and secretion all exist. The production of antibodies and 
antibody fragments in different expression systems has been reviewed by Kipriyanov and 
Little (Kipriyanov and Little, 1999). 
Expression of antibody fragments in E. coli 
One trigger to the rapid growth of antibody engmeenng was the discovery that 
functional antibody fragments could be secreted into the preplasmic space of E. coli by 
fusion of a bacterial signal peptide to the antibody N-terminus (Better et aI., 1988; Skerra 
and Pluckthun, 1988). After this, the production of antigen-specific antibodies in bacteria 
was attempted (Fuchs et aI., 1992). The goal of capturing large antibody repertoires from 
the immune system was accomplished when it was shown that immunoglobulin families 
could be PeR-amplified from the lymphocytes of immunised mice, cloned into plasmids 
and transformed into bacteria. Immunogen-reactive antibodies were then selected by an 
ELISA using the supernatant of cultured bacteria (Ward et aI., 1989). By inserting the 
antibody operon into bactriophage A, this procedure was improved. Selection systems of 
various formats have been designed to ease the identification of clones of potential interest 
based upon retroviral (Russell et a1., 1993), baculoviral (Boublik et aI., 1995), yeast (Kieke 
et ai., 1997), and cell free ribosome display (Mattheakis et ai., 1994; He and Taussig, 
1997). The most successful selection and expression system remains that founded upon 
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Figure 1.1 The various formats of engineered antibodies 
IgG is composed of two identical heavy chains (VH+CHI +CH2+CH3) and two 
identical light chains (VL+CL). Both chains are organized as domains containing 
about 110 amino acids with each domain possessing an intra-disulfide bond (not 
shown). Inter-disulfide bonds (red lines) link the light chain to the heavy chain and 
the two heavy chains. The variable domains (VH and VL) contain the complementary 
determining regions (CDRs) which bind to the antigen (CDR represented by small 
dots). The Fv fragment (VH and VL domains) possesses the binding activity. The 
scFv corresponds to the VH linked to the VL by a flexible peptide linker (black lines). 
Dia-, tri- and tetrabodies can be obtained by using short linkers (represented by black 
lines or dots). The Figure has been taken from the work ofChames and Baty (Chames 
and Baty, 2000). 
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Antibody phage display 
The principles of phage display are simple and elegant. DNA encoding millions of 
variants of certain ligands (eg peptides, proteins or fragments thereof) is batch-cloned to 
create fusions to one of the genes encoding a phage coat protein (pIlI, p VI or p VIII). Upon 
expression, the fusion protein will be incorporated into new phage particles that are 
assembled in the bacterium. This results in the ligand being presented on the phage surface, 
while its genetic material resides within the phage particle. This connection between ligand 
genotype and phenotype allows the emichment of specific phage using selection on an 
immobilized target. Phage that display a relevant ligand will be retained, while non-
adherent phage will be washed away. Bound phage can be recovered from the surface, 
reinfected into bacteria and re-grown for further rounds of selection. 
The filamentous phage contains a single strand DNA genome that is enclosed in a 
tubular array of approximately 2700 molecules of the major coat protein p VIII (encoded by 
gene 8 or g8p). At the tips of the phage, four minor proteins (g3p, g6p, g7p, g9p) are 
found. Protein pIlI or g3p is present in about five copies per virion and initiates infection 
of E. coli by binding to the F pilus. The pIlI protein has a three domain structure. The two 
N-terminal domains appear to be involved in the infection process but peptides and 
proteins can be introduced at the N-terminus or between the second and third domains 
without destroying this function (Smith, 1985; Parmley and Smith, 1988; Riechmann and 
Holliger, 1997). An important regulatory element of the genome, the intergenic region 
(IR), carries an origin of replication and a DNA packaging signal. A plasmid that carries 
IR, is known as a phagemid because the IR allows packaging of the phagemid into phage 
particles as single-stranded closed circular DNA if other viral functions are brought to the 
system by co-infection with a helper phage. Packaged phagemids can infect bacteria and 
are known as transducing paliicles since on entry to the bacterial host, phagemid functions 
(eg antibiotic resistance) are expressed by the replicating plasmid. 
Filamentous phage are not lytic to the bacterial host - they leave the cell by extrusion 
through the membrane leaving the cell unharmed. Assembly begins with the coating of the 
single-strand of genomic (or phagemid) DNA by g5p. This nucleoprotein complex then 
migrates to the inner membrane. Coat proteins then replace g5p in a vectorial fashion: g7p 
and g9p bind first forming one tip of the viral paliicle, followed by polymerisation of g8p 
on to the DNA rod, and finally g6p and g3p cap the particle. G3p and g8p are exported 
13 
through the cytoplasmic membrane of the bacterial host and become anchored on the 
periplasmic face from where they are assembled to form the surface of the phage. These 
abilities make them ideal targets for fusion with antibody domains not least because 
secretion into the periplasmic space is required for the correct folding and assembly of 
antibodies produced in E. coli. 
For successful phage display, the properties of the helper phage are also important. 
Helper phage such as M13K07 or KM13 are ideal because they form the viral structure but 
package their own DNA into the filament less efficiently than the phagemid. 
Superinfection is usually triggered by addition of 10 helper phage per bacterium. This 
infection process could be by the binding of pIlI fusion proteins translated from the 
phagemid to the pilin subunit of F -pili. This is limited by the accumulation of the protein in 
the cytoplasmic membrane. According to Kay et a!. (Kay et a!., 1996), the most important 
aspects of filamentous phage biology for display methods are: (a) the phages can infect 
special strains of E. coli containing an F-plasmid because they attach to the F-pilus and 
reach the membrane by depolymerization of the F-pilus. (b) depolymerization of the F-
pilus is immediately after infection, resulting in infection of E. coli with only one phage. 
Thus cloning of phage is possible via cloning of E. coli. (c) The size of DNA packed into a 
filamentous phage patiicle is adapted to the size of the packaged DNA during extrusion of 
the phage from E. coli. 
In antibody phage display, combinations of V H/V L able to interact with the target of 
interest are selectively emiched through a series of immunoaffinity steps referred to as 
"library pam1ing". By washing away non-specific phage, the remaining antigen-specific 
phages are extracted and then recovered using acid or alkali (Marks et al., 1991). These 
treatments break the interaction between phage and the target ligand, but fail to prevent the 
infection process when phage are mixed with bacteria. Other elution methods have been 
described. Proteolytic cleavage sites for trypsin (Breitling et a!., 1991) or for Genenase I 
(Ward et a!., 1996) have been introduced between the antibody domain and pIlI. Also the 
competitive elution of bound phage with a monoclonal antibody has been described 
(Meulemans et a!., 1994). The presence of an amber stop codon between the DNA coding 
for the antibody and pIlI facilitates the characterization of selected antibodies. In 
suppressor strains of bacteria, the antibody-pIlI fusion will be translated but on transfer to 
nonsuppressor strains of E. coli, only the antibody domain is synthesised (Hoogenboom et 
a!., 1991). Since the recombinant antibodies lack the features often recognised by species-
specific reagents, marker peptides are often present either at the C-tenninus (Ward et al., 
1989) or N-terminus (Parmley and Smith, 1988) or within the linker peptide between 
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heavy and light chain variable domains (Parmley and Smith, 1988) of a scFv. In a recent 
report, several of these features were incorporated into an improved expression phagemid 
(Hayashi et aI., 1995). This vector also provides the antibodies with a hexahistidine 
sequence for purification by metal chelate chromatography and a C-terminal cysteine to 
facilitate conjugation with other molecules. 
Phage display antibody libraries 
Various methods have been used for the construction of phage display libraries to 
clone antibody repertoires from humans, mice, rabbits, chickens, camels and other animal 
species. These libraries have usually been generated in one of four formats: immune, naIve, 
semi-synthetic and synthetic libraries. 
Immune libraries 
In this strategy, antibody genes are isolated usmg PCR and sets of primers 
homologous to the heavy chain and light chain (K and tv) using RNA from immunised 
donors. A set of primers designed from the amino acid sequence of human 
immunoglobulins has been described by Welschof et al (Welschof et al., 1995). One 
advantage of immune libraries is that they are particularly rich in antibody chains that bind 
to the immunogen with high affinity, since IgGs will have undergone affinity maturation 
during the development of plasma B cells. Clinically useful antibodies against several 
diseases have been isolated from this kind of library by using phage display selection 
systems. 
Na'ive libraries 
Phage display libraries may be produced from human or animal lymphocytes 
following RT -PCR amplification of V H and V L genes. These libraries called "naIve 
libraries" because they are composed of VH and VL genes from non-immune donors who 
do not have ongoing immune responses against a particular antigen. NaIve libraries 
provide a readily available resource of antibody fragments with binding activities against 
many different antigens (Marks et al., 1991; Marks et aI., 1993). It is estimated that about 
106 _108 antibodies with different binding propeliies are present in the human immune 
system at any time. This number is enough to bind most antigens including synthetic 
compounds that the immune system has never encountered. Since IgMs are expressed 
mostly on the surface of non-activated B-lymphocytes, one approach has been to amplify 
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and randomly combine chains of the naive IgM repertoire (Marks et al., 1991). Naive 
libraries are constlUcted by two or three cloning steps. In the two-step strategy, the 
amplified repertoire of light chain genes is cloned into the phage- display vector in the first 
step, because the heavy chain contributes more to diversity owing to its highly variable 
CDR3 region. In the second step, the heavy chain repelioire is cloned into the amplified 
light chain library (Johansen et aI., 1995; Welschof et at., 1997). In the three-step strategy, 
separate heavy and light chain libraries are engineered, and the repertoire of the V H library 
is then excised and cloned into the phage-display vector containing the V L library 
(Welschof et aI., 1997). Another common method that has been used to clone naive scFv 
phage display libraries is assembly PCR. VH and VL genes are amplified separately, 
connected in a subsequent PCR step and then cloned into the vector (McCaffeliy et aI., 
1994; Vaughan et aI., 1996). 
The affinity of antibodies selected from a naive library is relative to the size of the 
library. Affinities in the range of 106_107 1M are typical for a small library with 3 x 107 
clones (Marks et at., 1991; Griffiths et at., 1993; de Wildt et aI., 1996), whereas 108_10 10 
1M has been achieved for a very large library with 1010 clones made by blUte force cloning 
(Vaughan et aI., 1996). Several problems may impact upon the use of na'ive libraries. 
Firstly, there is very little information on the exact nature of the V -gene repertoire 
contained in the library. Poor expression and toxicity to the host bacteria can also arise. 
Semi-synthetic and synthetic libraries 
This approach is founded upon the assembly in vitro of V -gene segments that carry a 
predetermined level of randomisation in CDR regions and (in some libraries) bordering 
framework-regions. Diversity can be introduced into gennline V -gene segments 
(Hoogenboom and Winter, 1992), or rearranged V -genes (Barbas et al., 1992). The regions 
and degree of diversity may be chosen to correspond to areas of highest natural diversity of 
the antibody repertoire. Most natural structural and sequence diversity is found in the loop 
most central to the antigen combining site, the CDR3 of the heavy chain, while the five 
other CDRs have limited variation. In some cases, the framework of a well-known 
antibody has been used as a scaffold on which to integrate new, randomly created CDR3 of 
the heavy chain and CDR3 of the light chain regions (Barbas et al., 1992; Desiderio et al., 
2001). Jirholt et al. (Jirholt et aI., 1998) and Soderlind et al. (Jirholt et al., 1998) amplified 
all CDRs derived from B cells and then shuffled them into a single antibody framework in 
an assembly PCR step. Fully synthetic libraries are constlUcted from different or unique 
V H and V L germline frameworks combined with six synthetically created CDR cassettes 
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(Knappik et a!., 2000). As an example of a completely synthetic library, Knappick et al. 
(Knappik et a!., 2000) used seven different VH and VL germline frameworks combined 
with six synthetically created CDR cassettes. In one of the largest synthetic libraries 
(Griffiths et a!., 1994), 49 human heavy chain segments were combined with a collection 
of 47 human kappa and lambda light chain segments with partially randomized CDR3 
regions. The heavy and light chain V -gene repertoires were combined on a phage vector in 
bacteria using the lox-Cre site-specific recombination system to create a large 6.5 x 1010 
clone repertoire of Fab fragments. Although some good antibodies were isolated from this 
library that had nanomolar affinities for their targets (Griffiths et a!., 1994; de Wildt et al., 
1996), the library proved to be difficult to re-propagate without significant loss of 
diversity. Ultimately, there must be a physical limitation to the emichment that may be 
achieved in selection, and this may limit value of extremely large synthetic libraries. The 
source of antibody genes for naIve, semi-synthetic and synthetic libraries - sometimes 
referred to as "single pot libraries" because antibodies against virtually any antigen can be 
extracted - are presented in Table 1.1 (Rust and Dubel, 2004). 
Synthetic antibody libraries have a significant advantage over naIve libraries that use 
naturally rearranged V -genes. Importantly, the choice of V -gene segments may be guided 
by factors that will increase the overall performance of the library, such as good expression 
and folding and low toxicity in E. coli. This will increase the functional library size. Large 
differences in V-gene usage both in vivo and in phage repertoires (Griffiths et al., 1994) 
also suggest that some frameworks may be better suited to form antigen-binders than 
others. Second generation synthetic antibody libraries have been built using 'master' 
frameworks representing each of the Kabat subclasses. In principle, this should make it 
possible to choose only well expressed frameworks. To overcome the problem of 
introducing stop-codons during in vitro diversification, V -genes were assembled with 
oligonuceotides made from trinucleotides instead of from single bases (Virnekas et al., 
1994). To improve the performance of synthetic libraries, pre-selection of amplified and 
displayed synthetic V -domains on Ig-domain binding proteins (protein A for V H, protein L 
for V te, etc.) (Akerstrom et al., 1994) enables elimination of clones that carry stop codons 
and frameshifts, and selection of correctly folded V -domains (Tomlinson, unpublished). 
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Table 1.1. The sorce of antibody genes for construction of different antibody libraries 
Library vector Library type Antibody Library cloning strategy Library size 
type 
pHENl Naive scFv Assembly PCR 2 x 105/2 X 106 
pCANTAB3his Naive' scFv Assembly PCR 1.2 x 106 
pSEX81 Naive ScFvb Four-step cloning 1.6 x 107/1.8 x 107/4 x 107 
pSEX81 Naive scFvb Two-step cloning 4 x 107 
pCANTAB 5 Naive' scFv Assembly PCR 4.5 x 107 
pHENl Naive scFv Assembly PCR 107-108 
pFAB60 Naive' Fab Two-step cloning >108 
fdTet Naive scFv Reclonlng of a naive library" 5 X 108 
pSEX81 Naive scFvb Two-step cloning 4 x 109 
pHENl Naive scFv Assem bly PCR 6.7 x 109 
pCANTAB 6 Naive, scFv Assembly PCR 1.4 X 1010 
pCESl Naive Fab Three-step cloning (L chain, VH) 3.7X WO 
pDAN5 Naive scFv Cre-Iox 3 x 1011 
pAP-lila scFv Naive scFv Assembly PCR NDd 
pEXmide5 Semi-synthetic (germ line VH DP47 scFv Assembly PCR, CDR shuffling 9 X 106 
and VWPL3 framework) 
pHEN1-V,3 Semi-synthetic (V,3 anti-BSA Ab scFv PCR with random CDR H3 primers 107 
light chain) 
pScUAGDcp3 Semi-~ynthetlc scFv Three-step cloning with random 1.7 x 107 
connected CDR3 primers 
to C. 
pDN322 Semi-synthetic (anti-AMCV CP ab scFv Random CDR3 primer, assembly 3.75 X 107 
framework) PCR 
pComb3 Semi-synthetic (anti·tetanus Ab Fab PCR with random CDR H3 primers 5 x 107 
framework 0) 
pComb3 Semi-synthetic (anti-tetanus Ab Fab PCR with random CDR H3 primers >108 
framework 0) 
pHEN1·V,3 Semi·synthetic (V,3 anti·BSA Ab scFv PCR with random CDR H3 primers >108 
light chain) 
1.47 x 108/1.37 X 108 plT2 (Tomlinson I/J) Semi·synthetic (3 VH and 4 V. genes) scFv PCR with random CDR2 and CDR3 
primers 
pAALFab Semi-synthetic (anti-hen egg white Fab PCR with random CDR primers, 2 X 108 
lysozyme Ab framework) assembly PCR 
pLG18 Semi-synthetic (anti·HER2 Ab Fab PCR with random CDR primers, two- 2-3 x 108 
framework) step cloning 
pDN322 Semi-synthetic (VH DP47 and scFv Random CDR3 primer, assembly 3 X 108 
V.DPK22 V genes) PCR 
pHEN1-V.3 Semi-synthetic (VH)/naive (VLl scFv Three-step cloning, PCR with 3.6x 108 
Pdnek (ETH2) Semi-synthetic (Vu DP47, VA DPL16 scFv 
random CDR H3 primers 
Random CDR3 primer, assembly 5 X 108 
and V. DPK 22 V genes) PCR 
pHEN2 (Griffin 1) Semi-synthetic scFv Recloning of the lox library in scFv 1,2 X 109 
formatf 
pFAB5c-His Semi-synthetic (germ line VH DP47 scFv Assembly PCR, CDR shuffling 2 X 109 
(n·CoDeR) and VA DPL3 framework) 
fdDOG-210x, Semi-synthetic Fab PCR with random CDR3 primers, 6.5 X 1010 
pUC19-210x Cre-Iox 
pMorph series Synthetic scFv Two·step cloning plus two-step 2 X 109 
(HuCAL) CDR3 replacement 
"Mouse library, 
bwith N·terrninus of CH 1 and CL, 
CSheets et at, [36), 
dNot determined, 
"Persson et at, [81). 
'Griffiths et at, [38). 
Uhttp://www,mrC'cpe, cam,ac,uk. 
The table has been taken from the work of Bust and Dubel (2004). 
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Phage antibody selection procedure 
The selection of recombinant antibodies from phage libraries consists of two main 
steps: panning and screening. During panning, library phage are incubated with the antigen 
of choice, unbound phage are discarded during several washing steps and remaining phage 
are recovered by elution to retrieve those with specific binding activity. Any method that 
separates clones that bind from those that do not, can be used as a selection method, and as 
such, many different selection methods have been used. In the top panel of Figure 2, the 
most popular procedures are shown. These include biopam1ing on immobilized antigen 
coated onto solid supports, columns or BIAcore sensorchips (Clackson et al., 1991; Marks 
et al., 1991; Griffiths et aI., 1994; Malmborg et al., 1996), selection using biotinylated 
antigen (Hawkins et al., 1992), panning on fixed prokayotic cells (Bradbury et al., 1993) 
and on mammalian cells (Cai and Garen, 1995), subtractive selection using sorting 
procedures (de Kruif et al., 1995b; Van Ewijk et al., 1997), enrichment on tissue sections 
or pieces of tissue (Van Ewijk et al., 1997), and, in principle, selections using living 
animals, as reported for peptide phage libraries (Pasqualini and Ruoslahti, 1996). The 
selection methods described in Figure 2, panels A-F, have been extensively described and 
have been reviewed elsewhere (Winter et al., 1994; Hoogenboom, 1997). 
The simplest approach to selecting specific phage is to use purified antigen coated 
directly onto a plastic surface, incorporated in an affinity column (McCafferty et al., 1990; 
Marks et al., 1991) or biotinylated and subsequently captured onto a streptavidin-coated 
solid surface (Hawkins et al., 1992). While the purification of soluble proteins in a 
functional form may be achievable, many membrane proteins are modified by purification 
leading to loss of biological activity. Leaving these proteins in situ and using whole cells as 
the target for selection may be of some value but the biochemical complexity of the cell 
surface may bring its own problems. A variety of techniques have been developed to direct 
phage selection to particular proteins on the cell surface and other complex substrates. The 
simplest technique is to use a combination of negative and positive selection, whereby 
phage libraries are pre-absorbed on cells lacking antigen (negative selection) prior to 
selection on cells expressing the antigen (positive selection). When variation between 
individuals is a consideration, pre-absorption of a phage is best achieved by repeated 
rounds of absorption on cells from a number (5-10) of antigen-negative donors prior to the 
positive selection (Watkins and Ouwehand, 2000). 
A. Panning on B. Pannining using C. Using D. Affinity E. Direct 
immubilized antigen specific elution Byotinylated antigen purifications panning 
On columns on cells 
I~I~ 
F. Subtractive G. Selection on H. selection on 
Selection on cells tissue (crvo) sections western blots 
J. Pathfinder selection 
Biotinllyramid Aclivated biotin * 




K. Selective infective phage 
! IIIIC.t(tUI1. domain] ,.' :;' lltllltJOOY fusion E.c(}li ~ i antigen F-pilus ;, pili - Nlandlor N2 ligand lusiotl -;.," 
Figure 1.2 Selection strategies for obtaining specific phage ligands. 
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Affinity selection of phage (antibody) libraries by (A) panning on antigen adsorbed onto a 
solid support. After washing, specific phage are eluted with acid or basic solutions; (B) 
alternatively elution with antibody or an excess of the antigen is possible. (C) To avoid 
conformational changes during coating, selection of specific antibodies to biotinylated 
antigen in solution is preferable. Bound and unbound phage antibodies are separated using 
streptavidin-coated magnetic beads. (D) Antigen can be immobilized onto a column for 
affinity selection. (E) Selection on cells can be done directly by panning on cell 
monolayers or cells in suspension. (F) Subtraction via F ACS: the cells of interest are 
fluorescently labeled and separated from the others by cell sOliing. (G) Tissue and organ 
specific phage antibodies might be obtained by selection on tissue slides. (H) Non-
purifiable or unknown antigens may be separated on SDS-P AGE and blotted onto 
membranes for selection. (I) In vivo selection. (J) The procedure of 'Pathfinder' selection, 
and (K) infection-mediated selection. Specific phage calTY a white ligand, ilTelevant phage 
a black one. The Figure has been taken from the work of Hoogenboom, et a!. 
(Hoogenboom et a!., 1998). 
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Phage antibodies bound to antigen can be eluted in different ways: with a single 
aliquot or gradients of an acidic solution such as HCl or glycine buffers (Kang et aI., 1991; 
Robetis et aI., 1992), with basic solutions like triethylamine (Marks et al., 1991), with 
chaotropic agents, with DTT (dithiothreitol; Cleland's reagent) when biotin is linked to 
antigen by a disulphide bridge (Griffiths et al., 1993), by enzymatic cleavage ofa protease 
site engineered between the antibody and gene III (Ward et aI., 1996), or by competition 
with excess antigen (Clackson et aI., 1991) or antibodies to the antigen (Meulemans et al., 
1994). 
The power of these method is evident from the observation that a single round of 
selection can emich for specific phage by 20 to 1000-fold and repeating the selection 
procedure increases further the enrichment (McCafferty et aI., 1990; Marks et al., 1991). 
Many factors affect the selection efficiency of the panning process. For instance, the 
selection of antibodies with low binding affinities is encouraged by fewer washes, 
multivalent display or a high coating level of antigen. In contrast, the isolation of 
antibodies with a high affinity for antigen is favored by exhaustive washing, a low level of 
antigen coating and monovalent display (Winter et al., 1994). Phage antibodies with higher 
affinity may be enriched during successive rounds of selection by decreasing the 
concentration of antigen. This is similar in concept to during B-cell selection in vivo 
(Hawkins et al., 1992). In one of the most complete studies on antibody affinity 
maturation carried out (Schier et aI., 1996), it was necessary to empirically determine the 
antigen concentration to be used for selection, as well as the elution condition for phage 
retrieval (Schier and Marks, 1996). 
Phage antibody screening 
After selection, a mixture of binding ligands with differing properties are likely to be 
recovered. It may be necessary to screen large numbers of antibodies to identify those 
variants with the most optimal characteristics. The best screening assays are fast, strong, 
amenable to automation (eg 96-well format), and able to use unpurified phage antibodies, 
or the soluble antibody fragments from the bacterial supernatant. The screening assay 
should test as closely as possible the functional requirements of the ligand. Binding of 
polyclonal or monoclonal phage antibodies to the antigen has been tested with different 
assays, ranging from a simple ELISA (Marks et aI., 1991), to bioassays that screen for 
direct neutralization upon binding (Zaccolo et al' J 1997), and whole cell ELISA or flow 
cytometry. Normally, for a first screen, ELISA-based assays are used in combination with 
restriction-fingerprinting of the antibody-DNA to identify different clones (Marks et aI., 
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1991). Further, the specificity of antibodies may be tested (Carnemolla et aI., 1996; de 
Wildt et aI., 1996; Van Ewijk et aI., 1997). 
To improve the speed of screening, phagemid vectors that incorporate dual function 
have been developed. These allow both monovalent display of antibody fragments and the 
production of soluble antibody fragments for screening without the necessity to sub clone 
the antibody V -genes. In such systems, an amber codon is positioned between the antibody 
and pIlI genes (Hoogenboom et aI., 1991). A variety of tags have been described that can 
be appended to the antibody fragment for detection, including the myc-derived tag 
recognized by the antibody 9E 1 0 (Marks et aI., 1991), and the Flag sequence (Lah et aI., 
1994; Lindner et aI., 1997). This set-up allows the use of unpurified phage antibodies or 
antibody fragments derived from crude supernatant or periplasmic extracts. Another useful 
modification is the incorporation of a histidine tag between the antibody and gIll, for 
purification of antibodies using immobilized metal affinity chromatography (Hochuli et aI., 
1988; McCaffeliy et al., 1994). 
Recloning of selected phage antibodies 
Recombinant antibodies isolated by phage display can be recloned for expression in 
other hosts. Expression levels in E. coli are dependent on the primary sequence of the 
individual antibody, and can be extremely variable (from 10 I-lg to 100 mg/l). When yields 
in this host are low, recloning may increase the expression level (Strachan et al., 2002). 
Unless yields are sufficient, it is worth recalling that phage display vectors are rarely 
designed with high-level expression as a primary purpose (Pluckthun and Pack, 1997). 
Eukaryotic expression vectors have been described that may be used for one-step recloning 
of V -genes derived from any phage repertoire for expression as Fab fragments or whole 
antibodies, and for targeting to different intracellular compartments (Persic et aI., 1997a; 
Persic et al., 1997b). This facilitates either transient or stable expression in mammalian 
cells. By carefully choosing restriction sites that are rare in human V genes, 
immunoglobulin genes may be batch-cloned into these expression vectors. All the 
important elements in the vectors (promoter, leader sequence, constant domains and 
selectable markers) are flanked by unique restriction sites, allowing simple substitution of 
elements and fmiher engineering. 
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Production of recombinant antibodies 
When yields permit, rcombinant antibodies can be conveniently expressed in 
microorganisms, particularly in E. coli. ScFv antibodies contain two disulfide bonds, 
whereas Fabs contain five disulfides that must all form for stable folding. NOlmally, the 
oxidation of cysteine thiols into disulfides occurs only after a protein has been exported 
from the highly reduced enviromnent of the cytoplasm to a more oxidizing secretory 
compartment. Therefore, in order for antibody fragments to fold into their native, 
functional state in E. coli, they must be expOlied into the periplasmic space. This can be 
accomplished by in-frame fusion of a well-characterized bacterial leader peptides (PelB, 
Pho A, Omp A) to the N terminus of the antibody fragment. Proteins located within the 
periplasm can be recovered by osmotic shock or from total cell lysates. Prolonged high-
level expression of antibodies at 37 DC often renders the outer membrane permeable, and 
the protein can be recovered from the culture media (Skerra and Pluckthun, 1988; Skerra, 
1993). Very high levels of scFv, exceeding 1-2 giL, have been achieved in a fermenter by 
periplasmic expression (Kipriyanov, 2002) but levels of expression can vary widely on a 
case by case basis. Antibodies, especially scFvs, often fail to fold properly and aggregate 
within the bacterial periplasm, or they can be toxic to the host cell. Toxicity most likely 
occurs because the export of these proteins interferes with the normal function of the 
secretory machinery of the cell. Protein misfolding and aggregation can be reduced by 
growing the cells at 30 or 25DC (Somerville et al., 1994), using tightly regulated promoters 
such as the pBAD arabinose-inducible promoter (Clark et a!., 1997), or by co-expression 
of proteins that assist folding. Such proteins include enzymes that catalyse disulfide bond 
formation, isomerization or chaperones such as Skp (Skerra and Pluckthun, 1991; 
Humphreys et aI., 1996; Bothmann and Pluckthun, 1998; Hayhurst and Harris, 1999). 
Addition of non-metabolized additives that induce osmotic stress, such as sucrose or 
sorbitol and glycine betaine, can increase the proportion of correctly folded antibodies 
(Kipriyanov et a!., 1997; Kipriyanov et a!., 1999). Amino acid replacements can have 
dramatic effects on protein solubility, and therefore on the levels of functional antibody 
expressed (Duenas et al., 1995; Forsberg et a!., 1997). Also CDR grafting to the 
framework of well-expressed antibodies has been used to generate scFvs with improved 
stability that result in better production (Jung and Pluckthun, 1997; Worn and Pluckthun, 
1999). 
High-level production of antibody fragments in the cytoplasm of E. coli often results 
in extensive aggregation and the formation of inclusion bodies. These can be solubilized by 
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adding strong detergents and a reducing agent, and correctly folded antibody fragments 
have been recovered by removal of the denaturant and refolding. This topic has been 
reviewed (Rudolph and Lilie, 1996; Clark, 1998; Lilie et al., 1998). 
Improving affinities 
Selection from very large libraries with more than 1010 antibody variants can yield 
antibodies with nanomolar affinities or less (Griffiths et aI., 1994; Vaughan et aI., 1996). 
The affinities of antibodies from more modest-sized naIve, synthetic or immune libraries 
are typically sufficient for use as research reagents but often too low for therapeutic 
applications such as tumour targeting and virus neutralization. In vivo, antibodies are 
matured stepwise; by the progressive introduction of mutations that each causes a small 
incremental improvement of the affinity. Mutations may affect affinity indirectly by 
influencing the positioning of side chains contacting the antigen, by providing new contact 
residues or by replacing repulsive or low-affinity contact residues with more favourable 
interactions. This process can be imitated in vitro to improve the properties of recombinant 
antibodies by: (1) introducing diversity in the antibody V -genes, thereby creating a 
secondary library; (2) selection of the higher-affinity variants; (3) screening to discriminate 
variants with differences in affinity or kinetics of binding. The selection may be chosen to 
favour kinetic parameters (Hawkins and Winter, 1992) such as off-rate or affinity. This 
hinges on the use of limited and decreasing amounts of antigen, and on performing the 
selections in solution rather than by avidity-prone panning. For instance, antibodies of the 
highest affinity can be preferentially selected by using the antigen concentration at or 
below the desired dissociation constant (Hawkins and Winter, 1992). 
The best area for mutagenesis will differ for each individual antibody. Diversity may 
be introduced more or less randomly in the V -genes by error-prone PCR, using mutator 
strains of bacteria that are deficient in DNA repair functions, chain shuffling or by DNA 
shuffling. Alternatively, the CDR regions may be targeted for oligonucleotide-directed or 
random mutagenesis. Another way to raise the affinity is to artificially extend the regions 
that make contact with the antibody. Other strategies for improving the affinity of 
antibodies have been reviewed by Maynard and Georgiou (Maynard and Georgiou, 2000) 
and Hoogenboom (Hoogenboom, 1997; Hoogenboom et aI., 1998). 
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Storage of purified recombinant antibodies 
The long-term storage of some forms of recombinant antibody can be problematic. 
IgG molecules and Fab or F(ab')2 fragments present the fewest difficulties and the addition 
of antibacterial agents, such as thiomersal or sodium azide, is recommended in every case. 
However, for long-time storage, the antibodies should be frozen at -70°C in aliquots. Care 
must be taken that the solutions are not too dilute when frozen (not less than roughly 0.1 
gil total protein). ScFvs are a special case because they aggregate at high protein 
concentrations. This aggregation can be attributed to two propedies. First, a podion of the 
surface of Fv fragments comprises a surface that is not solvent exposed in the intact 
immunoglobulin molecule. This can mediate increased non-specific protein interactions. 
Secondly, the interaction between V H and V L is of low affinity, enabling the assembly of 
oligomers and finally aggregates. For Fabs, the constant domains assist the stability of the 
heterodimer. Having said this, some scFv fragments have proved to be very stable and 
have been stored in a functional form for more than one year at 4 °c without protective 
protein. For scFvs without this advantage, the addition of a protective protein in high 
concentrations (BSA at 10-20 mg/ml) is recommended followed by storage in aliquots at-
70°C. When the addition of protective protein is not possible, recombinant antibody 
fragments can be stored at -20°C after the addition of cryoprotectants such as glycerine 
(Breitling and Dilbel, 1999). 
Application of phage display antibodies to studies of infectious 
diseases 
Although widely used for the isolation of antibodies for cancer biology, phage display 
has yet to take a prominent role in the identification of antibodies against antigens and 
virulence factors from pathogens other than viruses. A selection of examples in which 
phage display has been used are discussed briefly in the following sections. 
Parasites and fungi 
Haemonchus contorlus 
An immune scFv phage antibody library was constructed from the abomasal lymph 
node of a sheep immunized with Haemonchous contortus (White et al., 2001). The phage 
antibodies were selected by palming the library against a purified outer membrane protein. 
The result of screening of 960 clones showed that only low affinity antibodies were 
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isolated. The authors attributed this outcome to limitations in their selection strategies. 
Given the success of other investigators in generating ovine phage display libraries and 
isolating high affinity scFvs, this seems the most likely explanation of the findings of the 
above work. 
Candida albicans 
A combinatorial human phage display scFv library was used to identify antigens 
specific for the filamentous form of Candida albicans (Bliss et al., 2003). Two isolated 
single-chain antibody variable fragments (scFv) were characterized in detail. Filament-
specific antigen expression was detected by an indirect immunofluorescence assay. Using 
these antibodies antigen epitopes were detected on clinical specimens obtained from 
infants with thrush and urinary candidiasis without passage of the organisms on laboratory 
media, confirming epitope expression in human infection. The availability of a monoclonal 
reagent that recognizes filaments from both C. albicans and C. dubliniensis and another 
specific only to C. albicans adds to the repertoire of potential diagnostic reagents for 
differentiation between these closely related species. 
Viruses 
The isolation of recombinant antibodies with antiviral activities have been reviewed 
(Parren and Burton, 2001). In the last few years, numerous investigations have used phage 
display to study a number of viruses of importance in human and animal disease. Two 
examples ofrecombinant antiviral antibodies are presented below. 
HIV-1 
A phage display antibody library was prepared from patients with lupus and scFv were 
isolated with the ability to bind gp120 and the conserved gp120 determinant composed of 
residues 421-436. The scFv neutralized R5 and X 4-dependent HIV -1 strains from clades B, 
C, and D. The autors attributed the lupus repertoire may be useful as a source of 
neutralizing antibodies to HIV (Karle et al., 2004). 
FMDV 
To study the bovine antibody response at a molecular level, phage display technology 
was used to produce Fabs against bovine foot-and-mouth disease virus (FMDV). Heavy 
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chains with FMDV specific binding were isolated after selection from a library made from 
vaccinated cattle. Some of these proteins possessed viral neutralizing activity and showed 
homologies with integrin (36 chain in the CDRs. Though the involvement of these 
antibodies in the bovine immune response to FMDV remains to be established, the selected 
VB domains could shed light on the basis of FMDV type receptor specificities (Kim et at., 
2004). 
Bacteria 
Considering the range of bacterial pathogens of impOliance to human and animal 
health, the detailed understanding of the process of pathogenesis and the rapid 
accumulation of genomic data on these organisms, it is surprising that phage display 
technology has yet to make substantial impact in this area. The following examples 
illustrate the scope of what has been accomplished and the potential in this area. 
Clostridium perfringens 
A scFv antibody against alpha-toxin of Clostridium peljringens type A, has been 
assembled from a hybridoma cell line producing a mouse monoclonal antibody against this 
toxin. The scFv gene was amplified, inserted into the expression vector pBOG21 and 
transformed into E. coli XL I-Blue. The scFv was highly expressed in recombinant bacteria 
and a neutralization assay showed that the expressed protein could neutralize the 
phospholipase C activities of alpha-toxin (Zhao and Xu, 2001). 
Bordetella pertussis 
A scFv phage display library was constructed from the peripheral blood of two 
patients recently recovered from peliussis infection. Ten scFv were isolated by panning the 
library against pertussis toxin. One scFv accounted for 33% of clones after panning. Six of 
the panned scFv bound to peliussis toxin. The ability of the scFv to neutralise pertussis 
toxin was assessed using the Chinese hamster ovary cell assay. The three scFvs were able 
to neutralise the pertussis toxin (Williamson and Matthews, 1999). 
Bacillus anthracis 
To isolate antibodies against spores of the genus Bacillus, a naive, human scFv phage 
display library was used in panning against live, native spores of Bacillus anthracis. Direct 
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in vitro panning and ELISA-based selection isolated a panel of nine scFv-phage clones of 
which two were chosen for fmiher study. These clones differed in their relative specificity 
and affinity for bacillus spores. A variety of ELISA protocols indicated these scFv-phage 
clones recognized different spore epitopes. A Fab chain-shuffled sub-library was 
constructed from the nine positive clones and a subtractive panning strategy was used to 
remove cross-reactivity with B. licheniformis 5A24. The study provided a foundation to 
discover human antibodies specific for native spores of B. anthracis that can be developed 
as diagnostic and therapeutic reagents (Zhou et al., 2002). 
Clostridium botulinum 
Several groups have attempted to use phage display antibodies against the botulinum 
toxin which is the most potent natural toxin known. In one recent example, the immune 
response to the binding domain (HC) of botulinum neurotoxin serotype A was studied at 
the molecular level using immune and non-immune human scFv phage libraries. A large 
panel of serotype specific phage expressing botulinum-binding scFv were selected from 
both libraries. Neutralizing activity of the isolated scFvs was evaluated using a mouse 
hemidiaphragm assay revealed that only a limited number of scFv from the immune library 
had toxin-neutralizing activity at biologically significant concentrations (Amersdorfer et 
al., 2002). 
Mycobacterium tuberculosis 
An immune mouse library was generated and scFvs reactive with mycobacterial 
proteins were isolated by phage display. None of the extracted antibodies showed reaction 
with the immunodominant 65 kDa M tuberculosis antigen, highlighting the potential of 
phage display systems to generate a diverse population of reagents that may prove useful 
for investigating the immune response to mycobacterial infection and vaccination 
(Cummings et at., 1998) 
Meningococci Group B 
Using phage display, anti-idiotypic scFvs were obtained from mice immunized with 
the Seam 3 monoclonal antibody. Two Seam 3-specific scFvs competed with Group B 
capsular polysaccharide for binding to either the Seam 3 monoclonal or rabbit antibodies 
present in typing sera. Moreover, the scFvs could in turn act as an antigen in mice and 
rabbits, eliciting the production of antibodies that were reactive with both capsule and 
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whole meningococci, but not with human polysialic acid. The predominance of IgG2a in 
these scFv-induced responses indicated a Thl type response. In addition, passive transfer 
of sera from scFv-immunized animals patiially protected neonatal mice from experimental 
infection with group B meningococci (Beninati et al., 2004). 
Streptococcus suis 
In this example, a human semi-synthetic library was used to select recombinant 
antibodies directed against surface components and the extracellular factor (EF) of a 
pathogenic strain of Streptococcus suis serotype 2. Whole cells and purified EF were used 
as targets for panning of the library. Clones were identified in each panning which bound 
to the antigen of interest (de Greeff et a!., 2000). 
Helicobacter pylori 
Human scFv antibodies against proteins present in a H. pylori cell lysate and the H. 
pylori urease were isolated from an immune phage display library, constructed from 
peripheral blood lymphocytes of an H. pylori-infected patient. After selection, 23% of the 
scFv clones tested showed binding activity against a lysate from the H. pylori Sydney 
strain in ELISA and 9% bound the urease. Further characterization by PCR-fingerprint 
analysis and sequencing revealed that two closely related H. pylori binders and one anti-
urease scFv could be identified. The selected scFvs were highly specific as analysed by 
ELISA and immunoblots using various bacteriallysates and recombinant proteins (Reiche 
et a!., 2002). 
Cyanobacterial hepatotoxin 
A naive human semi-synthetic phage display library was used to isolate recombinant 
antibody fragments against the cyanobacterial hepatotoxin microcystin-LR. The scFvs that 
emerged from selection were modified by fusion to a human kappa constant domain to 
create single-chain antibodies (scAbs). The scAbs with the best propeliies were capable of 
detecting microcystin-LR at levels below the World Health Organization limit in drinking 
water (1 f!gl lit) and cross-reacted with tlu'ee other purified microcystin variants 
(microcystin-RR, -L W, and -LF) and the related cyanotoxin nodularin. These antibodies 
were used for purification of the toxins by immobilizing the scAbs on columns via a 
hexahistidine tag. The authors suggested that these antibodies could be used as biosensors 
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and components in on-line monitoring systems for the cleanup and concentration of these 
toxins from environmental samples (McElhiney et aI., 2002). 
Bacillus thuringiensis 
A synthetic scFv library was used to map the epitopes on cadherin-like receptors 
involved in the interaction between Bacillus thuringiensis Cry1A toxin and insect intestinal 
cells. After isolating Cry1A-binding phages, one purified scFv showed affinities to 
Cry1Aa, Cry1Ab, and Cry1Ac toxins in the range of20-S1 nM. Analysis showed this scFv 
molecule has a CDR3 sequence with significant homology to part of the cadherin-like 
protein from M sexta (Bt-R,), Bombyx mori (Bt-R175), and Lymantria dispar. By doing 
further experiments, the investigators identified the amino acid region of Bt-R, and Bt-R175 
involved in CrylA toxin interaction (Gomez et al., 2001). 
Clostridium difficile (Toxin B) 
Phage display technologies were used to produce a scFv against Clostridium difficile 
toxin B. The statiing material was the mouse B cell hybridoma line SA8, which secretes a 
monoclonal antibody against the toxin. The sensitivity of one of the scFvs was reported to 
be significantly higher than the original monoclonal antibody and could detect a minimum 
of 10 ng of toxin B/well in ELISA. Competitive ELISA established that the affinity of the 
SA8 parent antibody and the best representative of the scFvs were similar and in the range 
of 10-8 M (Deng et a!., 2003). 
Pseudomonas aeruginosa 
A Fab was constructed from a conventional monoclonal antibody against the 0 
antigen of Pseudomonas aeruginosa. The parent antibody bound to the 0 antigen of the 
most clinically important serotypes. Immunotherapy with the antibodies against the LPS of 
Pseudomonas aeruginosa might form an alternative to LPS-based vaccines and antibiotics. 
The recombinant Fab antibody was shown to be specific for the LPS of most serotype 06 
isolates (Tout and Lam, 1997). 
Moraxella catarrhalis 
Using a synthetic scFv phage library (de Kruif et al., 1995a), specific antibodies were 
isolated that recognised the high molecular weight outer membrane protein (HMW -OMP) 
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of complement-resistant strains of Moraxella catarrhalis. BMW-OMP is not found on 
complement-sensitive strains, a property which was exploited in the selection procedure to 
deplete the library of scFvs against surface components common to complement-sensitive 
and complement-resistant strains (Boe1 et al., 1998). 
Listeria monocytogenes 
In order to find a species-specific antibody against Listeria monocytogenes strains, a 
pool of random scFvs expressed on the surface of bacteriophage were used for biopanning. 
Panning against L. monocytogenes was used to emich for phage clones with the desired 
binding affinity, and negative selection using L. innocua and L. ivanovii was used to 
remove phage expressing cross-reactive antibody fragments. After several stages of 
screening, the authors reported the isolation of a species-specific antibody for viable cells 
of L. monocytogenes (Paoli et al., 2004). 
Goals of this project 
The studies outlined above show that phage display is gradually gaining acceptance as a 
technology for the understanding of microbial infection. Many of these investigations have 
isolated recombinant antibodies against virulence factors or surface proteins and then used 
these reagents for the specific identification of the pathogens concerned; rather few have 
used the isolated scFvs or Fabs as tools to define the structure, location or mode of action 
of the target and thereby aid an understanding of its contribution to disease. The general 
goal of this project was to address these issues using as a model, the bacterial colonisation 
factor K99. As described in the following chapter, much is known about the role of K99 
fimbriae in the pathogenesis of Escherichia coli infection. The aims of this project were to 
purify this virulence factor, to isolate recombinant antibodies against it, and to determine 
the extent to which these reagents could be used in confirming the identity of the target, its 




2. K99 Fimbriae 
Introduction 
Escherichia coli infection 
Escherichia coli is a Gram-negative, rod-shaped bacterium. It belongs to the 
Enterobacteriaceae. Most members of this family are 'normal' members of the intestinal 
flora of mammals. Colonisation of the intestinal tract by E. coli takes place soon after birth. 
Pathogenic E. coli strains have the general ability to form a persistent interaction with the 
epithelium whereas non-pathogenic strains would only bind transiently or proliferate free 
in the lumen (Finlay and Falkow, 1989; Mol and Oudega, 1996). The pathogenic strains of 
Escherichia coli recovered from the intestinal tract of animals fall into four categories that 
are designated enterotoxigenic (ETEC) , enteropathogenic (EPEC), enterohemorrhagic 
(EHEC), and necrotoxigenic (NTEC). Two other categories described in human infection -
enteroinvasive (EIEC) and enteroaggregative (EAEC) have not been reported in animals 
(DebRoy and Maddox, 2001; Rodriguez-Angeles, 2002). The enterotoxigenic Escherichia 
coli (ETEC) strains cause neonatal dia11'hoea in piglets and calves and travellers diarrhoea 
in humans. They appear less common in dogs and cats and so far, little information has 
been published about disease caused by ETEC strains in birds or reptiles (Nagy and 
Fekete, 1999). In humans, millions of people are affected by ETEC every year following 
ingestion of contaminated water or food (Organization, 1999). The subject of ETEC in 
farm animals has always attracted much interest because it can be related to human disease 
in many aspects and causes significant losses and animal welfar problems. 
Enterotoxigenic Escherichia coli strains remain one of the leading causes of diarrhoea 
in calves and piglets. The expression of the K99 fimbrial colonisation factor (or F5+ 
ETEC) is noted in nearly all ETEC infection found in newborn calves, sometimes 
accompanied by co-expression of F41 fimbriae (Gaastra and de Graaf, 1982). The so-
called F17 (described in the earlier literature as FY and Att 25) adhesin is found less 
commonly (Lintermans et al., 1988). ETEC strains responsible for diarrhoea in newborn 
calves often produce the heat-stable STaP enterotoxin and usually belong to the 08, 09, 
020 and 0101 serogroups. Heat-labile toxin is also commonly produced. These strains 
often produce an acidic polysaccharide K (A) antigen (K25, K28, K30, K35), making the 
colonies of such strains more compact and less transparent. It seems that these capsular 
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polysaccharide antigens increase colonisation of the intestinal epithelium mediated by K99 
(Hadad and Gyles, 1982). 
Aetiology and pathology 
The common characteristics of ETEC strains isolated from different species are that 
the bacteria adhere to the epithelial cells of the small intestine (overwhelmingly in 
newbom or very young animals), thereby colonising the gut. They also secrete proteins or 
peptides (enterotoxins), which stimulate increased water and electrolyte secretion and/or 
decreased fluid absorption in the small intestine. The ability of ETEC to adhere to 
intestinal epithelial cells is mostly due to production of fimbriae or pilli. With the help of 
these adhesins, the bacteria are able to attach themselves to the microvilli and thereby 
deliver the enterotoxins that cause disease to the target cells. The pathogenic process is 
therefore highly dependent upon synthesis by the host of receptors for adhesion and 
enterotoxins released by the bacteria. In this way, ETEC are limited in their host range, 
illustrating the co-evolution of ETEC strains and their hosts is illustrated (Nagy and 
Fekete, 1999). The characteristics of fimbriae and enterotoxins from ETEC strains isolated 
from farm animals are summarised in Tables 2.1 and 2.2. 
Structure and formation of K99 
K99 is a filamentous polymeric protein structure located at the surface of ETEC. It has 
a diameter of 5 run and is made up of monomers of major subunit of 16.5 kDa and minor 
subunits (Altmann et al., 1982; Nagy and Fekete, 1999). The genes responsible for the 
biogenesis of the K99 adhesin are present on an 87.8 kb non-conjugative plasmid (Isaacson 
and Start, 1992; Lee and Isaacson, 1995). The K99 genes have been cloned and shown to 
reside on a 7.1 kb Bam HI fragment (de Graaf et al., 1980b; van Embden et al., 1980; de 
Graaf et al., 1984). This fragment encodes eight gene products (Fan A to Fan H), and each 
is required for the successful biosynthesis ofK99 (van Embden et al., 1980; de Graaf et al., 
1984; Roosendaal et a!., 1987; Lee and Isaacson, 1995). The genetic organisation of the 
K99 gene cluster is shown in Figure 2.1 with brief descriptions of the role contributed by 
the different proteins to the synthesis and assembly of fimbriae (Mol and Oudega, 1996). 
Previous investigations have demonstrated that K99 expression IS dependent on 
variety of factors, including growth rate (van Verseveld et al., 1985), growth phase 
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Table 2.1 Designation and characterisation of fimbriae of enterotoxigenic E. coli isolated 
from farm animals. 
Fimbriae Mean Major Mannose Associated Location of 




F4 (K88) 2.1 27.6 R 08,0141,0149 plasmid 
F5 (K99) 5 16.5 R 08,020,0101 plasmid 
F6 (987P) 7 17.2 NH 09,020 plasmid 
F17 Family 3.4 20 chromosome 
F18 R 0139,0141, plasmid 
0147,0157 
F41 3.2 29 R 0101 chromosome 
F42 32 R ? plasmid 
F165 4-6 17.5,19 R 0115 chromosome 
R: mannose resistant 
S: mannose sensitive 
NH: non-haem agglutinating 
Table 2.2 Designation and characterisation of toxins of enterotoxigenic E. coli isolated from 
farm animals. 
Enterotoxin Variant Molecular size Action Receptor 
LT-J LTh-1, LTp-I 1A (28kDa) 58 (1l.5 kDa) Hypersecretion: LTI: OMI 
LT-IJ L TIIa, L TIIb Stimulation of adenylate- LTIIa: ODlb 
cyclase system LTIIb: ODla 
STa STaH, STaP 18 or 19 aa. Hypersecretion: POCc 
Peptide (2 kDa) Stimulation of guanylate-
cyclase system 
STb 48 aa. Peptide Malabsorption: o protein 
(5 kDa) Opening O-protein linked linked Ca++ 
Ca ++ plasma membrane channel 
channel 
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11 11.7 16.5 84.5 23.2 33.9 16.9 16.7 
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Major Chaperone Components 
Component 
Figure 2.1 Genetic organisation of the K99 gene cluster. 
Genes are represented by boxes. The designations of the genes are given in the boxes and 
the relative molecular masses of the mature proteins are given in kDa. A short description 
of the function of different proteins is given. T, terminator; P, promoter. Arrows indicate 
direction of transcription. 
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(Isaacson, 1983), temperature (de Graaf et aZ., 1980a), alanine concentration (de Graaf et 
aZ., 1980a; Isaacson, 1983), and cellular levels of cyclic AMP, cAMP receptor protein 
(CRP) (Isaacson, 1983; Inoue et al., 1993) and leucine-responsive protein (LRP) (Braaten 
et al., 1992). K99 production is clearly highly regulated reflecting its critical contribution 
to virulence. Northern blot analyses have shown that the transcriptional organisation of 
K99 is complex and that it appears to be divided into three separately regulated gene 
clusters, regions I to III (Inoue et aZ., 1993). Roosendaal et aZ. (Roosendaal et aZ., 1989) 
detected a promotor at the 5'end of Jan A and a second promoter at the 5' end ofJanB. They 
presumed that these promoters were responsible for transcription of JanA, JanB, JanC and 
JanD, the region I genes. They also identified a strong transcription terminator between 
JanC and JanD. The results from Northern blots suggest that additional promoters exist in 
other regions of the K 99 genes and are responsible for the transcription of fanE to JanH 
(Inoue et al., 1993). 
The receptor for K99 fimbriae was first isolated from equine erythrocytes and was 
identified as Neu5Gc-a(2-3)Galp-~(1-4)Glcp-~(1-1)-Ceramide (de_Graaf et aZ., 1981; 
Roosendaal et al., 1984; Smit et aZ., 1984; Teneberg et al., 1990). This ganglioside 
receptor molecule was also detected in mucosal scrapings of piglet and calf small intestine. 
Investigations strongly suggest that this ganglioside represents the in vivo receptor for K99 
fimbriae (Teneberg et al., 1990). The major subunit FanC was found to be required for 
interaction with the receptor. Detailed analysis revealed that the residues Lys-132 and Arg-
136 of Fan C are essential for receptor binding and most probably constitute a part of the 
receptor binding domain (Jacobs et az', 1987). 
From the nucleotide sequence of the FanC gene it can be predicted that it is composed 
of 159 amino acids preceded by an N-terminal signal sequence of22 residues (Roosendaal 
et aZ., 1984). Taking published data (Roosendaal et az', 1984; Jacobs et az', 1987; Simons 
et al., 1990a) Genebank deposition 
(http://www .nc bi .nih. gov / entrez/ query. fc gi? d b=nucleotide&cmd=search&term=M3 5282& 
doptcmdl=GenBank) and ExPASy data (http://ca.expasy.org/cgi-bin/niceprot.pl?P18103) 
the amino acid sequence of Fan C is presented in Figure 2.2. 
Binding of K99 fimbriae to receptor 
Fimbriae commonly confer adhesive properties upon pathogenic strains of Escherichia 
coZi. For K99 fimbriae, recognition of the NeuGca3Gal~4Glc~ motif of the ganglioside N-
glycolyl-GM3 appears responsible for this property. For some colonisation factors (eg P 
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Key From Length Description To 
SIGNAL 1 - 22 22 
CHAIN 23 - 181 159 K99 fimbrial protein. 
DISULFIDE 38 - 79 Probable. 
SITE 154 - 154 1 REQUIRED FOR RECEPTOR BINDING. 
SITE 158 - 158 1 REQUIRED FOR RECEPTOR BINDING. 
SITE 180 - 180 1 REQUIRED FOR STABILITY AND TRANSPORT. 
10 20 30 40 50 60 
MKKTLLAIIL GGMAFATTNA SANTGTINFN GKITSATCTI DPEVNGNRTS TIDLGQMIS 
70 80 90 100 110 120 
GHGTVVDFKL KPAPGSNDCL AKTNARIDWS GSMNSLGFNN TASGNTMKG YHMTLRATNV 
130 140 150 160 170 180 
GNGSGGANIN TSFTTAEYTH TSAIQSFNYS AQLKKDDRAP SNGGYKAGVF TTSASFLVTY 
181 
M 
Figure 2.2 The amino acid sequence of Fan C 
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fimbriae) pili (Lindberg et a!., 1987) adhesion is mediated by minor protein subunits of the 
structure but in K88, K99 and colonization factor antigen I, it is the major fimbrial subunit 
that acts as the adhesive component (Jacobs et al., 1987; Simons et al., 1990b; Simons et 
a!., 1991; Bakker et al., 1992a; Bakker et a!., 1992b). This has been confirmed by the 
observation that these fimbriae still display adhesive properties after deletion of their minor 
fimbrial components either by mutation or treatment with 2M urea (Bakker et at., 1992b). 
Although the major subunit of different types of fimbriae acts as an adhesin, differences in 
the number of adhesin sites per fimbria have been noted. For structures like colonization 
factor antigen I, it is only the binding site calTied by the major subunit at the very tip that is 
exposed and available for interaction with host receptor molecules (Buhler et a!., 1991). In 
contrast, the major subunit of K99 fimbriae (FanC) acts as an adhesin at numerous 
positions along the fimbrial structure, resulting in a multivalent interaction of fimbriae and 
receptors (Willemsen and de Graaf, 1993). Electron microscopy studies of the binding of 
gold particles coated with N-glycolyl-GM3 to K99 fimbriae has shown that receptor 
interaction is predominantly lateral and spaced at approximately 20 nm intervals along the 
length of fimbriae and occasionally at the tip (Willemsen and de Graaf, 1993). Studies of 
the immunological properties of the structure suggest that B-cell epitopes of FanC are 
likely to be continuous, with a potentially immunodominant epitope at the carboxy-
terminus (Ogunniyi et at., 2002). 
Other fimbriae 
It seems that K99 and F 41 are frequently produced concurrently by bacteria of the 
same ETEC strain. There are different receptors for K99 (sheep and horse haemagglutinin) 
and F41 reflected by their agglutination of sheep and horse, or guinea pig and human 
erythrocytes respectively. K99 and F41 also differ in that the genes for K99 are carried on 
a plasmid while those for F41 are chromosomal. K99, F41 and F17 fimbriae can, however, 
adhere to the porcine small intestinal brush border and can induce porcine enterotoxic 
colibacillosis (Nagy and Fekete, 1999). The association ofF17 expression with enterotoxin 
production is not clear. Original description repOlied co-expression of F 17 with enterotoxic 
activities (Lintermans et al., 1988) but studies in recent years have revealed that F17 
fimbrial adhesins are somewhat heterogeneous, forming a so-called F17 family (F17a, 
F17b, F17c, F17d and g fimbriae) based on their receptor specificities (Le Bouguenec and 
Beliin, 1999) and toxin production across this wide group of pathogens is variable. 
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It should also be mentioned that a non-fimbrial surface protein (CS31A) has also been 
associated with calf diarrhoea (Girardeau et at., 1988) but this colonisation factor is also 
detected on septicaemic strains of E. coli isolated from calves, in marked contrast to K99 
or F41 (Nagy and Fekete, 1999). 
STa toxin 
STa is a 2 kDa peptide comprising 11 to 18 amino acids that is secreted into the 
culture medium or the intestinal fluid by producing strains of E. coli. Receptors for STa 
toxin are thought to be heterogeneous, the leading candidates being glycoproteins at the 
epithelial cell surface and particulate, transmembrane form of the enzyme guanylate 
cyclase (pGC-c) (Gardner, 1979; Frantz et at., 1984). The effects of STa on mammalian 
cells are reversible but this does not appear to result from loss of interaction between the 
toxin and its receptor(s), suggesting that this association is not a typical reversible binding 
system (Gardner, 1979). The biological activity of STa is exerted through stimulation of 
guanylate cyclase leading to accumulation of intracellular cGMP and reduced absorption 
of water and electrolytes (Na+ coupled with Cl-) at the tips of epithelial villus, and 
simultaneous elevation of secretion of CI- and H20 in crypt cells (FOlie et al., 1992). STa 
toxins produced by human and animal strains of ETEC seems to differ in length and show 
differences in amino acid sequence (Moseley et aI., 1983). Depending on the origin of the 
enterotoxigenic strain and the propeliies of the peptide, the toxins are designated as STaH 
and STaP. However, human ETEC strains may produce STaP and STaH while ETEC from 
calves and pigs only appear to produce STaP. The genes encoding the STa toxins are 
located on plasmids and are pati of a transposon (Tn1681) that is flanked by insertion 
sequences (So and McCarthy, 1980). 
Protective capacity of vaccines against K99 
Conventional vaccines against bovine ETEC have been shown to provide varying 
levels of immunity (Moon and BUID1, 1993; Ascon et aI., 1998). Fimbrial vaccines are 
routinely given parentally to pregnant cattle, sheep and swine to protect suckling newborn 
calves, lambs and pigs against ETEC infections. Such vaccines are practical and effective 
because (a) most fatal ETEC infections in farm animals occur in the early neonatal period 
when the antibody titres in colostrum and milk are highest. (b) more than 90% of the 
ETEC strains that infect farm animals belong to a small family of fimbrial antigen types. 
(c) the fimbriae themselves are antigenic components of the bacterial surface and in this 
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location, are readily available to antibody. (d) fimbriae are required for a critical step early 
in the pathogenesis of the disease (Moon and Bunn, 1993). Neonatal calves cannot be 
directly vaccinated because their immune systems take several months to achieve maturity. 
The vaccines for use in cattle all include fimbrial antigen FS (K99) whereas those for 
swine all include F4 (K88), FS and F6. Some vaccines also include F41. The vaccines 
themselves - bacterins and K99 preparations to varying degrees of purity - can be 
produced directly from field isolates but increasingly, E. coli strains are used that carry 
plasmids constructed by the use of recombinant DNA technology. Most products are 
designed for parental vaccination with two doses during the first pregnancy and a single 
booster during each subsequent pregnancy (Moon and Bunn, 1993). 
The efficacy with which the vaccination of dams with fimbriae protects the suckling 
neonate against ETEC infection via passive lacteal immunity was first convincingly 
demonstrated by Rutter and Jones, using F4 fimbriae in swine (Rutter and Jones, 1973). 
Subsequent work confirmed the efficacy of the approach and generalised the concept by 
extending it to other ETEC fimbriae and other animal species (Morgan et al., 1978; Nagy 
et al., 1978; Acres et al., 1979; Nagy, 1980). It also demonstrated that ETEC fimbriae 
apparently do not have cross-protective epitopes and therefore vaccines are most useful if 
they contain the fimbrial antigens prevalent in the target host species (Morgan et al., 1978). 
Hence vaccination of dams with FS protects calves and pigs against ETEC strains bearing 
both FS and F41 (FS+ F41+) (RUlmels et al., 1987; Moon, 1990) whereas vaccination with 
either F1 or F41 did not (Morgan et al., 1978; To et al., 1984; Runnels et al., 1987). 
Interestingly, F 41 vaccines are apparently more effective than FS vaccines in protecting 
mice against FS+ F41+ ETEC (Runnels et al., 1987; Duchet-Suchaux, 1988). In 
consequence, most of the vaccines in current use achieve best effect by including FS in 
vaccines for cattle or by combining F4, FS and F6 in those for swine. Although F1 and F41 
fimbriae are prevalent among animal ETEC strains, their efficacy as protective antigens in 
cattle and swine is less well defined than for F4, FS and F6 (Morris et al., 1982; Wilson 
and Francis, 1986; Runnels et al., 1987; Moon, 1990). 
There is less uniformity with regard to the inclusion of other ETEC virulence factors 
in vaccines. The STa toxin has not been an effective protective antigen when used as a 
hapten in vaccines, and the stimulation of STa neutralising antibodies appears difficult 
(Moon et at., 1983; Frantz et al., 1987). Some vaccines include polysaccharide 0 (cell 
wall) and K (capsular) antigens from the most common porcine or bovine ETEC strains. 
However, the evidence on their value is contradictory. In one series of experiments, 0 
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antigens were not effective, but a true capsular polysaccharide K antigen of the A (mucoid, 
heat stable) variety did appear to be effective. Regardless of their efficacy, the practical 
value of 0 or polysaccharide K antigens is limited by the multiplicity of 0 and K antigens 
that commonly occur among ETEC strains and it is therefore unreasonable to expect 
vaccines of limited valency to provide broad efficacy in the field. FUlihermore, many 
ETEC lack true polysaccharide capsules (Moon and Bunn, 1993). 
New approaches to these issues are starting to appear. A new attenuated Salmonella 
vaccine designed for oral delivery effectively delivered K99 fimbriae to mucosal sites 
resulting in sustained elevation of IgA and IgG antibodies and eliciting protective 
immunity (As con et aI., 1998). It has also been shown that three DNA vaccine 
formulations against human ETEC could elicit CF All -specific immune responses and 
hence DNA vaccines may also represent a promising approach against enteric bacterial 
pathogens (Alves et al., 1999). 
In conclusion, limited protection with purified K99 fimbriae or formalin-inactivated 
ETEC has been demonstrated but the need for an efficacious vaccine against bovine ETEC 
still exists (Moon and Bunn, 1993). 
Administration of anti-K99 antibodies 
Since colonization is considered to be an essential step in the pathogenesis of enteric 
colibacillosis, it has been postulated that prevention of bacterial adherence in the small 
intestine would reduce the severity of the disease. This could be achieved by introducing 
K99-specific antibody into the gut lumen of newborn calves. This concept is well-
established in practice: ingestion of colostrum taken from cows vaccinated with purified 
K99 antigen, whole cell bacterins or crude fimbrial extracts protects newborn calves from 
fatal diarrhoea (Myers, 1978; Acres et al., 1979; Myers, 1980; Nagy, 1980; Acres et al., 
1982). It is generally assumed that anti- K99 antibody prevents diarrhoea by acting locally 
in the small intestine to prevent colonization. 
Other products are designed to protect against E. coli bacteraemia and septicaemia in 
hypogammaglobulinaemic neonates. Hypogammaglobulinaemia is common in calves 
because there is no passive Ig transfer from dam to foetus in vivo because of the structure 
of the bovine placenta. Also, independent Ig synthesis in young calves takes several weeks 
to establish and hence the neonate is heavily dependent upon antibody acquired passively 
from the dam. Under farm or ranch conditions, the levels of Ig transfelTed in this way are 
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frequently insufficient. Several of the products designed for oral administration to calves 
contain antibody against fimbriae and are designed to prevent ETEC infections. This 
approach is rational because a high proportion of fatal ETEC infection occurs during the 
first few days after birth and calves are only susceptible to colonisation by ETEC that 
express F5 during this period (Smith and Halls, 1967; Acres, 1985). 
In all these studies, K99 antibody was administered to suckling calves through the 
colostrum of dams that were vaccinated before patiurition. However, commercial vaccines 
have some recognizable disadvantages. Pregnant cows must be handled for vaccination 
twice during the first year and once during each following year of the vaccination 
programme. Some livestock owners are reluctant to accept the cost and inconvenience of 
preventative vaccination unless they have recently experienced on outbreak of enteric 
colibacillosis in their herds. Such outbreaks are difficult to predict because occurrence 
depends upon a variety of management and environmental factors as well as several 
different etiological agents. These concerns prompted investigation of an alternative 
method for direct passive immunization of newborn calves, namely, the oral administration 
ofK99-specific antibodies shortly after birth. For example, it has been found that feeding 1 
ml of mouse ascitic fluid containing K99-specific monoclonal antibody significantly 
reduced the degree of clinical dehydration and mortality rate in calves challenged with 
ETEC (Sherman et al., 1983). Anti-K99 antibodies also have a broad range of 
investigative, diagnostic and clinical applications. Methods used for the detection of 
fimbrial expression in ETEC include agglutination, fluorescent-antibody tests (Arbuckle, 
1970; Belischinger et a!., 1972) and ELISAs (Mooi et a!., 1979; de_Graaf et al., 1981; 
Mills et a!., 1982). Some of these assays are applicable without the need for sophisticated 
equipment. For example it has been shown that slide agglutination tests with an anti -K99 
monoclonal antibody can be highly specific and possess excellent stability (Angulo et al., 
1986). Capture ELISAs also enable direct detection of fimbriae in faecal specimens from 
calves with diarrhoea without the necessity for bacterial culture (Raybould et al., 1987). 
In conclusion, rapid detection of ETEC organisms in faecal specimens is possible via 
their fimbriae enabling specific diagnosis of the cause of diarrhoea outbreaks in calves. 
The antibodies that make this possible can also be applied in immmunotherapy to improve 
the management of neonatal diarrhoea caused by ETEC strains. 
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Objectives 
The objectives of this aspect of the study were to isolate K99 fimbriae from B41 E. 
coli strain and purify its major subunit (Fan C). Subsequent objectives were to detect 
biological activities of the purified material and then to use for screening phage display the 
libraries of recombinant antibodies. 
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Materials and methods: 
Bacterial strain 
Escherichia coli strain B41, an 0101 serotype of bovine origin produces the heat-
stable toxin STa, K99 (F5) and F41 fimbriae. It has become established as the K99 
reference strain (Orskov et al., 1975). The bacterium was obtained as freeze-dried culture 
from the Central Veterinary Laboratory (New Haw, Addlestone, Surrey KT15 3NB, UK), 
and stored initially at room temperature, in the dark. 
Growing bacteria 
To grow bacteria for expression of K99 fimbriae, a loopful of bacteria was taken from 
stock and plated onto sheep blood agar. The plate was incubated at 37 DC overnight. The 
following day, a single bacterial colony was added to 5 ml of Minca medium (KH2P04, 
1.36 g; Na2HP04 2H20, 10.1 g; glucose, 1 g; trace salts solution, 1 ml; Casamino Acids, 1 
g; and distilled water, 1,000 ml. The pH is 7.5. The trace salts solution contained, per liter: 
MgS04.7H20, 10 g; MnCh 4H20, 1 g; FeCI.6H20, 0.135 g; and CaCh 2H20, 0.4 g) 
(Guinee et al., 1976) and grown overnight at 37 DC with shaking at 200 rpm. For large-
scale production of fimbriae, 1 ml of this culture was inoculated to 1 litre of Minca media 
and grown again overnight. 
peR confirmation of genes encoding K99 and F41 fimbrial 
subunits 
To confirm the presence in E. coli B41 of genes encoding K99 and F41 fimbriae, two 
PCR reactions were set up using gene-specific primers designed from published sequences 
(Franck et al., 1998). The 40 f.LI PCR mixtures contained 0.5 f.LM concentrations of forward 
(5' TATTATCTTAGGTGGTATGG 3') and reverse pnmers 
(5' GGTATCCTTAGCAGCAGTATTTC 3') for a fragment from the K99 operon, or 
forward (5' GCATCAGCGGCAGTATCT 3') and reverse pnmers 
(5' GTCCCTAGCTCAGTATTATCACCT 3') for isolation of pali of the F41 gene. Also 
present were 1 x AmpliTaq Mg free Gold buffer (Promega), 4f.LI of 25mM MgCh, 5U of 
AmpliTaq Gold DNA polymerase (Promega UK), 0.2 mM concentrations of each dNTP 
(Promega), and 19 f.LI of a crude bacterial lysate. The lysate was prepared by suspending a 
colony of bacteria grown overnight on sheep blood agar in 50 f.Ll of H20 and boiling for 10 
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min. After addition of all PCR reaction materials, samples were amplified in a Hybrid PCR 
Express thermal cycler under the following conditions: 25 cycles beginning with 30 s 
denaturation at 94°C, primer annealing at 55 °c for 1 min, followed by extension for 1 min 
at 72°C, and a final extension for 10 min at 72°C. Products were analysed on a 1 % 
agarose gel, run for 1h at 100 V, stained with ethidium bromide, and photographed under 
UV light. 
Fimbrial extraction 
After growing the bacteria, fimbriae were extracted using a method based on that 
described previously (Vazquez et al., 1996). Bacteria were harvested by centrifugation at 
3300g for 10 minutes. The supernatant was discarded and the bacterial pellet was 
resuspended in 40 ml of 50 mM phosphate buffer pH 7.2 containing 2M urea (PU) as 
described earlier (de Graaf et aI., 1980b). Then, the bacterial suspension was heated at 65 
°c for 30 min to release fimbriae followed by centrifugation at 5200g for 30 min to pellet 
bacterial cells. The supernatant was carefully recovered and fimbriae were precipitated by 
adding solid ammonium sUlphate to 60% saturation (de Graaf et aI., 1981) and incubation 
for 1 hI' on ice. The precipitate was collected by centrifugation at 5200 g for 1 h at 4 °c and 
dissolved in 2 ml of PU. The solution was then dialysed overnight at 4 ° C, typically 
against phosphate buffered saline. 
Detection of K99 antigen in fimbrial extract 
Detection by Fimbrex K99 kit 
The presence of K99 fimbriae in dialysed extracts was tested using a latex 
agglutination test (Fimbrex K99 kit, Veterinary Laboratories Agency, Surrey). The test is 
based upon the agglutination of latex beads coated with anti-K99 antibody in the presence 
of K99 fimbriae in solution or on the surface of bacteria. Two drops of dialysed extract 
were added to defined regions on the test card at room temperature. Reagents from the kit 
were added following the manufacturer's instructions, and the reaction was compared with 
controls. 
ELISA 
To assess the recognition of fimbriae extracts by anti-K99 antibodies, two rows of an 
ELISA plate (Iwaki, Japan) were coated with 100 III of two-fold serial dilutions of fimbriae 
45 
extract in PBS. As negative control, PBS was coated added to other wells. The plate was 
incubated at 4 °c ovemight to allow antigen binding. The following day, coating reagents 
were discarded by inveliing the plate and shaking it, and wells were washed three times 
with PBS. The wells were then blocked by adding 200 III of 0.1 % of BSAIPBS and 
incubating for 2 hrs at 37°C. After washing three times with PBS, 100 III of a 1:1000 
dilution of sheep polyclonal anti-K99 antibody (Biogenesis, UK) in blocking buffer was 
added to half of the coated and control wells, and 100 III of a 1: 1000 dilution of mouse 
monoclonal anti-K99 (Biogenesis, UK) in blocking buffer was added to the remainder. 
Incubation was for 1 hr at 37°C. Next, wells were washed three times with PBS containing 
0.05 % Tween. To detect bound antibodies, 100 III of 1: 1 000 dilutions of anti-sheep-HRP 
was added to the first series of wells and 100 III of 1: 1000 dilutions of anti-mouse-HRP 
was added to the second series. The plate was incubated for a fmiher 1hr at 37°C and then 
was washed three times with PBS containing 0.05 % Tween. The reaction was developed 
with 100 III of substrate solution (1 mg/ml OPD in 0.1 M citrate buffer pH 4.5 and 0.012% 
(v/v) H20 2) and the absorbance was measured at 450 nm after 15 minutes. 
SDS-PAGE gel electrophoresis 
Electrophoresis in SDS-PAGE was carried out by the method of Laemmli (Laemmli, 
1970). Polyacrylamide gels were routinely cast with (5%) stacking and (12%) separating 
layers (Sambrook et al., 1989). Twenty III of fimbrial extract was boiled in 10 III of 3 x 
sample buffer for 5 minutes. 10 ml of 3 x stock was made up with 2.4 ml of 1M Tris-HCI 
pH 6.8, 3 ml of 20% SDS, 3 ml of glycerol, 1.6 ml of ~-mercaptoethanol and 0.006g of 
Bromophenol Blue. Twenty III of each boiled sample was loaded to one lane of the 
polyacrylamyde gel. Electrophoresis was carried out in 25 mM Tris, 0.2 M glycine buffer 
containing 0.1% (w/v) SDS at 200 volts for 1h. The gel was stained with Coomassie 
Brilliant Blue solution for 30 min. Then staining solution was discarded and gel was 
destained with destaining solution for ovemight. 
Immunoblotting 
After electrophoresis, proteins were transferred from SDS gels to nitrocellulose 
membrane (Amersham Life Science, UK) following two blotting methods. 
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Electroblotting 
This method was as the same as that described as standard protocol for Western 
blotting (Sambrook et al' J 1989). A nitrocellulose membrane (Amersham Pharmacia 
Biotech, UK) and four pieces of Watman filter paper were cut to the same size as the gel 
and soaked with the gel in transfer buffer (25 mM Tris base, 192 mM glycine, 20 % (v/v) 
methanol) for 20 min. For transfer, a fibre pad was overlayed with two pieces of filter 
paper, the gel, nitrocellulose membrane, and the final two layers of filter paper. After 
addition of a second fibre pad, the sandwich was assembled into a blotting cassette and 
loaded into a BioRad electrophoresis tank. Transfer buffer was added along with a frozen 
insert to avoid overheating during transfer. Care was taken to ensure that the gel lay to the 
anode (-) side of the assembly and the membrane lay to the cathode (+) side. Proteins were 
transferred from the gel to the membrane for 1 hr at 100 volts. After transfer, the 
membrane was carefully separated, washed three times with PBS and stained with Ponceau 
red dye (Sigma, USA) by shaking for 5 min at room temperature to confirm that proteins 
had been transferred from the gel to the membrane. The membrane was then washed with 
distilled water to remove the dye. The membrane was blocked with 3% MPBS (Dried 
skimmed milk 3g and PBS up to 100 ml) for 1 hr at room temperature with shaking. After 
that, the membrane was washed and probed with a 1: 1 000 dilution of polyclonal anti-K99 
for 90 minutes at 37 DC and 200 rpm shaking. The unbound antibody was washed out with 
three changes of PBS containing 0.05 % Tween. The membrane was then incubated in a 
1 :1000 dilution of anti-sheep-HRP for 90 minutes at 37 DC and 200 rpm shaking. Then the 
membrane was washed as before and developed using diamino benzidine substrate (2mg 
diamino benzidine, 4 f.Ll of 30 % hydrogen peroxide and 20 ml ofTBS). 
Diffusion blotting 
Since experience revealed that K99 hardly transfers from the gel to nitrocellulose 
membrane by electroblotting, we applied a method similar to that described by other 
investigators (Brian Bowen, 1980; Heukeshoven and Demick, 1995; Olsen and Wiker, 
1998; Chen and Chang, 2001). 
A Whatman filter paper was wrapped around a plastic box (10 cm x 7 cm x 5 cm). The 
box was then put inside a container. Then two pieces of filter paper, the gel, nitrocellulose 
membrane, and the final two layers of filter papers were added to the top of the box. Next, 
some paper towels were cut to the same size as the nitrocellulose membrane. These were 
stacked on top of the other layers. Finally, a heavy box (about 1 Kg) was added to 
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L7 PU buffer 
LiJ Plastic box with wrapped paper 
L7 Whatman filter paper 
L7 Polyacrylamide gel 
L7 Nitrocellulose membrane 
&I Paper towels 
LiJ A Heavy material 
Figure 2.3 Assembling materials for diffusion blotting 
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compress the assembly. One litre ofPU buffer was added to the container, which was then 
covered with a plastic sheet to prevent evaporation of the buffer. The assembled diffusion 
blot was incubated overnight at room temperature. This method is illustrated in Figure 2.3. 
Purification of K99 by ion-exchange chromatography 
As experiments showed that a crude fimbrial extract was not sufficiently pure for 
isolation of antibodies specific for K99, the extract was purified by ion-exchange 
chromatography. 
Preparation of sample for chromatography 
After dialysis of the fimbriae extract into PBS, conditions were not appropriate for 
binding to the ion exchange column. Dialysis into distilled water was found to cause some 
aggregation of the protein. To solve these problems, fimbriae precipitated with ammonium 
sulphate was dissolved prior to purification at 1 :50 of culture volume in 2M of warm urea 
solution. It was then exchanged into binding buffer of the same volume using an Amicon 
Ultra-4 centrifugal filter (Millipore, UK). Finally, the sample was filtered by passing 
through a 0.45 ).un filter before running onto the column. 
Choice of starting buffer 
Based upon the isoelecteric point (pI) of the K99 protein (http://ca.expasy.org/cgi-
bin/protparaml ?PI8103@noft@) (Roosendaal et a!., 1984), two binding buffers of 50 mM 
phosphate buffer and 25 mM Tris base pH 7.0 and 7.5 were checked on an SP XL column 
to assess which resulted in higher binding of K.99 to the column matrix. After purification, 
the initial sample, flow through and eluted fractions were run on SDS PAGE to assess the 
outcome of the experiment. From these experiments, a binding buffer of 25 mM Tris base 
pH 7.0 was chosen for subsequent purification. 
Purification procedure 
Before running the sample on a 5 ml HiTrap SP XL column, the column was washed 
with 5 column volumes (25 ml) of binding buffer using a Phannacia Biotech P-l peristaltic 
pump (Sweden), at a flow rate of 5ml/min. Then the column was charged by washing with 
10 column volumes of binding buffer containing 2M NaCl and finally it was equilibrated 
with 5-10 column volumes of binding buffer. 
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Next, 5-10 ml of sample for purification was applied at 5 mlimin and the column was 
washed with at least 5 column volumes of starting buffer or until no material appeared in 
the effluent. Contaminating proteins were eluted with 5 column volumes of 25 mM Tris 
base pH 7.0containing 20 mM NaCl. K99 was then recovered by pumping through 5 
column volumes of the second elution buffer (25 mM Tris base pH 7.0 containing 80mM 
NaCl). 
Fractions containing K99 were identified by SDS PAGE then pooled, concentrated to 
1/3 initial volume using an Amicon Ultra-4 centrifugal filter (Millipore, UK) and dialysed 
overnight against PBS at 4°C. 
Protein assay 
Protein concentrations were measured using a BCA Protein Assay Kit (Collins et al.). 
After preparation of BSA standards of known concentration and the working reagent, 0.1 
ml samples of each standard and the fimbrial extract were added to 2.0ml of the working 
reagent. All tubes were incubated at 37°C for 30 minutes and then cooled to room 
temperature. The colorimetric reaction in each tube was measured at 562 nm using Unicam 
UV NIS spectrometer. The concentration of the fimbrial extract was determined by 
comparison against a standard curve. 
Biological activity of purified K99 
The biological activity of purified K99 was tested by experiments to compare its 
properties with those of the starting extract. 
Detection by Fimbrex K99 kit 
Two drops of purified K99 antigen was added to a test card and after addition of latex 
agglutination, the reaction was compared with controls. 
Detection by ELISA 
To coat an ELISA plate, 100 III of purified K99 fimbriae (approximately 30 Ilg/ml) 
and 100 III of 2 % MPBS (as a negative control) were added to wells of an ELISA plate. 
The plate was incubated at room temperature overnight. The following day the wells were 
washed three times with PBS and were blocked with 0.1 % BSAIPBS for 2 hI's at 37°C. 
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After washing wells as above, they were probed with 100 III of anti-K99 mouse 
monoclonal antibody (Biogenesis, UK) at 1: 1 000 dilution for 1 hr at 37°C. The wells were 
then washed three times with PBS containing 0.05 % Tween and the bound antibodies 
were detected by adding 100 III of a rabbit anti-mouse HRP conjugate (Sigma, UK) at a 
dilution of 1: 1 000. The reaction was developed with 100 III of developer solution 
containing OPD substrate. The absorbance was measured after 10 min at 450nm. 
Biotinylation of K99 fimbriae 
Since heating the K99 fimbriae appeared to destroy the epitope recognised by the 
monoclonal anti-K99 antibody, alternative methods were sought to test the specificity of 
antibody recognition of the bacterial protein. In preparation for immunoprecipation, 
purified K99 was biotinylated using an EZ-LinkTM Sulfo-NHS-LC-Biotinylation Kit 
(Collins et al.). In this strategy, biotinylated protein would be detectable using ExtrAvidin-
Peroxidase. The biotinylation procedure was based on the method of Hnatowich 
(Hnatowich et a!., 1987) and instructions provided with the kit were followed. 
EZ-LinkTM Su/fo-NHS-LC-Biotiny/ation Kit 
Biotin is a small naturally occUlTing vitamin that binds with high affinity to avidin and 
streptavidin proteins. As it is so small (244 Da), biotin can be conjugated to many proteins 
without altering their biological activities. The labelled protein or other molecule may then 
be detected easily in ELISA, dot blot or Western blot applications using streptavidin or 
avidin probes. N-hydroxysuccinimide (NHS) esters of biotin are a popular type of 
biotinylation reagent. NHS-activated biotins react efficiently with primary amino groups (-
NH2) in buffers of pH 7-9 to form stable amide bonds (Figure 2.4). Proteins generally have 
several primary amines in the side chain of lysine (K) residues and at the N-terminus that 
are available as targets for labeling with NHS-activated biotin reagents. 
The EZ-Link™ S ulfo-NHS-LC-Biotiny lation Kit was containing; EZ-Linl(® Sulfo-
NHS-LC-Biotin (25 mg), BupHTM Phosphate Buffered Saline Pack (1 pack, 0.1 M sodium 
phosphate, 0.15 M NaCl, pH 7.2 when reconstituted in 500 ml of ultrapure water), D-
SaItTM Dextran Desalting Column (10 ml), HABA (4'-hydroxyazobenzene-2-carboxylic 
acid) (1 ml) and Affinity Purified Avidin, 10 mg. 
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Figure 2.4 The reaction of sulfo-NHS-LC-Biotin with a protein 
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Sample preparation 
Purified K99 was concentrated to approximately 2 mg/ml using an Amicon Ultra-4 
centrifugal filter with a 10 KDa cut off. The buffer was exchanged with three volumes of 
PBS solution from the biotinylation kit (0.1 M sodium phosphate, 0.15 M NaCl, pH 7.2) 
using the same filter. The molar concentration of the K99 was then calculated. 
Biotinylation procedure 
The Sulfo-NHS-LC-Biotin was warmed to room temperature. Two mg of Sulfo-NHS-
LC-Biotin was added to 200 III of ultrapure water and used immediately. A 20-fold (130 
Ill) molar excess of this reagent was added to a 2mg/ml solution of K99. The mixture was 
incubated on ice for 2 hrs. Next, a 10 ml desalting column supplied with the kit was 
equilibrated with 30 ml of the PBS buffer. After addition of 1 ml of sample to the column, 
it was allowed to permeate the gel. Then 12 ml ofreconstituted PBS solution was added to 
the column and the biotinylated protein was recovered in twelve 1 ml fractions. To monitor 
the presence of protein, 100 III from each fraction was tested at 280 nm using a 
spectrophotometer. Fractions 5 and 6 were judged from this assay to contain the K99 
protein. 
HABA assay for measuring biotin incorporation 
To quantitate incorporation of biotin label, a solution containing the biotinylated 
protein was added to a mixture of HABA and avidin. Since it has a higher affinity for 
avidin, biotin displaces the HABA from its interaction with avidin and the absorption at 
500 nm decreases propOliionately. By this method, an unknown amount of biotin present 
in a solution can be quantitated in a single cuvette by measuring the absorbance of the 
HABA-avidin solution before and after addition of the biotin-containing sample. The 
change in absorbance relates to the amount of biotin in the sample. 
Reagent Preparation 
One mg of avidin and 60 ~d of 10 mM HABA was added to 1.94 ml of reconstituted 
PBS. The absorbance of this solution was measured at 500 nm. The absorbance was 
recorded as 0.966. 
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HABA assay procedure 
Fractions 5 and 6 from the gel filtration column were pooled. One hundred III of a 1 in 
10 dilution of the mixture was added to 900 III of the avidin-HABA reagent. After mixing 
well, the absorbance was measured at 500 run with spectrophotometer. Then the value 
moles biotin / mole protein was calculated as protocol instruction. 
Detection of biotinylated K99 protein 
Dot blotting 
Fractions from gel chromatography judged by spectrophotometery to contain protein 
were analysed by dot blotting. Three III samples from each fraction were spotted three 
times on a nitrocellulose membrane. After drying the spotted proteins, the membrane was 
blocked in 3 % MPBS for 1 hr at room temperature with shaking at 100 rpm. The 
membrane was then washed three times with PBS and incubated in a 1 :500 dilution of 
ExtrAvidin-Peroxidase (Sigma, UK) for 90 minutes at 37°C with shaking at 200 rpm. 
Then the membrane was washed three times with PBS containing 0.05 % Tween and was 
developed using 4-chloro-1-naphthol substrate. 
50S-PAGE analysis and Western blotting 
The fractions that had the best reactions in dot blotting were fmiher analysed by SDS-
PAGE and Western blotting. Fractions 5 and 6 and also 7 and 8 were mixed and were run 
on two 12 % SDS acrylamide gels following a standard protocol. A sample of the 
biotinylated protein prior to desalting and a sample of unbiotinylated K99 were used as 
positive and negative controls. After running for 1 hr at 200 volts, one gel was stained with 
Commassie Brilliant Blue solution and the second was used for Western blotting. The 
proteins were transferred from the gel to a nitrocellulose membrane by diffusion blotting 
using PU buffer (50 mM phosphate buffer pH 7.2) as described previously. The membrane 
was then blocked and probed with ExtrAvidin-Peroxidase as described for dot blotting. 
The membrane was developed using diaminobenzidine substrate. 
Immunoprecipitation of biotinylated K99 
To provide further confirmation that the purified protein was K99, the biotinylated K99 
was used for immunoprecipitation experiments. Seven III of monoclonal anti-K99 antibody 
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was added to 400 III of biotinylated K99 and was incubated for overnight on a turntable at 
4 °c to allow interaction of antigen and antibody. The following day, 100 III of Protein G 
agarose (Sigma,UK) was washed three times with PBS and was added to the above 
mixture for rotating incubation for 2 hrs at 4 0c. The mixture was then spun at 10000g for 
1 minute to pellet the Protein G agarose. The pellet was washed three times with PBS by 
centrifugation (10000g, 30 seconds) and resuspension. To release the antibody-antigen 
complex, 50 III of 3 x SDS sample buffer was added to the pellet and after mixing it was 
boiled for 5 minutes and then centrifuged at 10000g for 1 minute. As a control, a sample 
was also taken from the first supernatant (free antibody) for analysis. A sample of 
biotinylated K99 was also boiled for analysis. 
50S-PAGE analysis and Western blotting 
The test sample and controls were run on two 12 % SDS acrylamide gels following a 
standard protocol. One gel was stained using a silver staining method; the second was used 
for diffusion blotting by overnight transfer from the gel to a nitrocellulose membrane 
overnight using PU buffer (50 mM phosphate buffer pH 7.2) as described previously. The 
membrane was then washed with PBS, blocked and probed with ExtrAvidin-Peroxidase as 
described for dot blotting. The membrane was developed using diaminobenzidine 
substrate. 
Haemagglutination assay 
Some erythrocytes (RBCs) such as those from sheep have on their surface receptors to 
which K99 fimbriae can bind, thereby modelling the interaction of the adhesion factor with 
enterocytes (Burrows et al., 1976). Haemagglutination (HA) can thus occur with purified 
fimbriae or with bacteria such as the enterotoxigenic strain of E.coli B41 that express K99 
(Vazquez et al., 1996). In order to show that purified K99 has the haem agglutination 
activity, the following experiment was set up. 
Titration of the haemagglutinating activity 
This was assessed with a test for direct haemagglutinating activity. One colony of 
E.colf B41 grown on sheep blood agar was grown on in 5 ml of Minca medium at 37°C 
overnight with shaking at 200 rpm. Following previous investigations (Orskov et al., 
1975), another colony was grown as a negative control in the same medium at 18°C since 
under these conditions, K99 fimbriae are not expressed. 50 III of each culture was added to 
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the first well of a 96 well microplate (Iwaki, Japan). 25 /-LI aliquots were diluted two fold in 
PBS containing 1 % mannose across the plate. Since the interaction between K99 and its 
receptor is resistant to mannose, this was intended to inhibit non-specific 
haemagglutination or the interaction of mannose-sensitive factors with erythrocyte 
receptors. Bacteria were not added to the last well to provide an additional negative 
control. To the second row, 50 /-LI of purified K99 at the concentration of about 100 /-Lg/ml 
was added to the first well and diluted across as above. To prepare washed suspensions of 
sheep red blood cells at a density of about 1.5 % (v/v), 270 /-LI of defibrinated sheep blood 
(E and 0 Laboratories, Scotland) was centrifuged at 13000 rpm for 4 min. The pellet was 
then washed three times with PBS containing 1 % mannose (Sigma, UK) by resuspension 
and spinning for 4 min. Finally the pellet (about 100 /-LI volume) was resuspended in 7.5 ml 
PBS containing 1 % mannose. 
25 /-LI of this suspension was added to each well containing bacteria and, after mixing, 
the plate was incubated at 4 DC overnight. The titre was defined as the highest dilution of 
bacterial suspension that showed complete haemagglutination. 
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Results 
Amplification of genes encoding fimbrial subunits of K99 and F41 
The presence of genes encoding subunits of K99 and F 41 fimbriae in E. coli B41 was 
assessed using PCR with specific primers and a bacterial lysate as template. Analysis of 
the PCR products on 1 % agarose gels showed that amplicons of the predicted sizes (314 bp 
for the K99 product (Roosendaal et al., 1984), 380 bp for the F41 amplicon (Fidock et aI., 
1989) were present (Figure 2.5). 
Fimbrial extraction and analysis 
Fimbriae were extracted from E. coli B41 by resuspension in phosphate urea (PU) 
buffer and heat shock. The fimbriae were then precipitated by ammonium sulphate, 
resuspended again in PU buffer and dialysed against PBS. Several methods were used to 
test for the presence of K99 fimbriae in the crude extract. 
Experiments with the Fimbrex K99 kit revealed the agglutination by latex coated 
with monoclonal antibody against K99 in the presence of the fimbrial extract. No 
agglutination was seen in negative controls and the reaction was similar to the positive 
control antigen provided with the kit (Figure 2.6). 
In an ELISA experiment, plates were coated with two-fold serial dilutions of the 
fimbrial extract and probed with polyclonal and monoclonal anti-K99 antibodies. Both 
experiments showed recognition of components of the extract by the antibodies. The 
reaction of the extract with sheep polyclonal anti-K99 antibody is shown in Figure 2.7 and 
Figure 2.8 shows the reaction with mouse monoclonal anti-K99 antibody. In both cases, 
the ELISA reaction achieves its strongest response not at the highest coating concentration 







Figure 2.5 Amplification of genes of encoding K99 and F41 subunits by peR 
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A crude lysate of E. coli B41 was amplified using primers specific for parts of the F41 
(lane 1) and K99 operons (lane 2). The lane marked M shows the migration of a 1 kb DNA 
ladder (Invitrogen). The migration of markers of 506 bp and 396, 344 and 298 bp is 
indicated. The predicted size of the K99 product was 314 bp and that for the F 41 product 
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Figure 2.6 Detection of K99 fimbriae in a crude extract using the Fimbrex K99 kit 
A. The antigen provided as a positive control was used with reagent 1 and reagent 2 
B. The crude fimbrial extract from E. coli B41 strain was used. Aggultination of latex 
coated with monoclonal anti- K99 antibody (reagent 1) was detected whereas unconjugated 
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Figure 2. 7 Reaction of polyclonal anti-K99 antibody with crude fimbrial extract 
Two-fold serial dilutions of the crude fimbrial extract were coated to wells of an ELISA 
plate. The samples were probed with polyclonal anti-K99 antibody and anti-sheep HRP 
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Figure 2. 8 Reaction of monoclonal anti-K99 antibody with crude fimbrial extract 
Two-fold serial dilutions of the crude fimbrial extract were coated to wells of an ELISA 
plate. The samples were probed with monoclonal anti-K99 antibody and anti-mouse HRP 
conjugate. The reaction was measured at 450 nm. 
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To assess the composition of the crude extract and the presence of subunits of K99 
fimbriae, samples were run on a 12 % SDS polyacrylamide gel. The result of this analysis 
showed that the major constituent in the fimbrial extract was a protein of 16.5 kDa. The 
size of this protein was similar to that reported previously for the major fimbrial subunit 
(Vazquez et a!., 1996). Other proteins with molecular weights ranging from 30 to more 
than 100 kDa were also present but at much lower concentrations (Figure 2.9). 
After separating the crude fimbrial extract by SDS-PAGE, proteins were transferred to 
a nitrocellulose membrane by electroblotting (Western blotting). The membrane was 
probed with polyclonal anti-K99 antibody and anti-sheep peroxidase conjugate. Figure 
2.10 shows the resulting Western blot. A protein of 16.5 kDa, consistent with the size of 
the major fimbrial subunit reacted with the anti-K99 antibody but extensive cross-reaction 
with many other proteins was also evident. The reaction of the antibody with proteins on 
the blot was clearly disproportional to the overall composition of the extract (Figure 2.11). 
Staining of the membrane with Ponceau red dye immediately after electrotransfer revealed 
that the 16.5 kDa protein band was transferred poorly to the membrane by this method 
(data not shown). 
Given the poor efficiency of electrotransfer of the 16.5 kDa component from the 
fimbrial extract, diffusion blotting was attempted. Staining with Ponceau red dye revealed 
transfer of this protein to nitrocellulose was much-improved. When blots were probed with 
polyclonal anti-K99 antibody, recognition of the 16.5 kDa protein was much improved and 
background reaction was significantly reduced (Figure 2.11). The antibody also cross-
reacted strongly with two other proteins in the fimbrial extract that in terms of overall 
composition (Figure 2.11) were minor components. When diffusion blots were probed with 
a monoclonal anti-K99 antibody, no reaction was detectable. 
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Figure 2.9 SDS-PAGE analysis of crude fimbrial extract 
A sample of the extract was run on a 12% polyacrylamide gel. After electrophoresis, the 
gel was stained with Coomassie Blue and photographed. Lane M shows the migration of 
Rainbow molecular weight markers. The migration of standards of 14, 20.1 and 30 kDa is 
indicated. The predicted molecular weight of the major K99 subunit is 16.5 kDa. 
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Figure 2.10 Western blotting analysis of the fimbrial extract using polyclonal anti-K99 
antibody 
The fimbrial extract was separated by SDS-PAGE and tranferred to a nitrocellulose 
membrane by electroblotting. The membrane was probed with sheep polyclonal anti-K99 
antibody. Lane M shows the migration of Rainbow molecular weight markers. The 
migration of standards of 14, 20.1 and 30 kDa is indicated. The predicted molecular weight 
of the major K99 subunit is 16.5 kDa. 
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Figure 2.11 Diffusion blotting analysis of the fimbrial extract using polyclonal anti-K99 
antibody 
The fimbrial extract was separated by SDS-PAGE and transferred to a nitrocellulose 
membrane by diffusion blotting. The membrane was probed with sheep polyclonal anti-
K99 antibody. Lane M shows the migration of Rainbow molecular weight markers. The 
migration of standards of 14, 20.1 and 30 kDa is indicated. The predicted molecular weight 
of the major K99 subunit is 16.5 kDa. 
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Purification of K99 fimbriae by ion-exchange chromatography 
Isolation of K99 fimbriae by the methods described did not provide material of 
sufficient purity for the isolation of recombinant antibodies. To overcome this, protein was 
purified by ion-exchange clu·omatography. After an initial trial experiment, the best results 
were achieved using SP XL columns, a binding buffer of 25 mM Tris base pH 7.0 and 
elution buffers of 25 mM Tris base containing 20 mM and 80mM NaCl. The results are 
shown in Figure 2.12. After binding protein to the SP XL column, a mixture of proteins 
could be eluted with binding buffer containing 20 mM NaCl. These conditions released 
many of the components of the initial extract but there was little evidence of elution of the 
16.5 kDa protein, the single most abundant protein in the starting material. By raising the 
NaCI concentration to 80 mM, the protein of interest (the 16.5 kDa protein), presumed to 
be the major subunit of K99 was eluted. Figure 2.12B shows the purity of this material 
after concentration. The preparation appears free of other protein components present in 
the starting extract (Figure 2.12A). 
Biological activity of purified K99 
The purified K99 was tested using the Fimbrex K99 kit as described earlier. The 
reaction - agglutination of the antibody-coated latex beads - was similar to that of the 
fimbrial extract and positive the control antigen (Figure 2.6). Given the homogeneity of the 
purified material (Figure 2.12B) and the specificity of the assay, the result supports 
presumptive identification of the 16.5 kDa protein as the major subunit ofK99 fimbriae, 
The protein purified by ion-exchange clu'omatography was coated to an ELISA plate 
and assessed using monoclonal anti-K99 antibody. Figure 2.13 shows it was recognised 
successfully and strongly. This data further supports identification of the protein as the 
major subunit of K99 fimbriae and shows that so far as recognition by the monoclonal 
antibody is concerned, it was not denatured during purification. 
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Figure 2.12 SDS-PAGE analysis of K99 protein purified by ion-exchange chromatography 
Panel A. SDS-PAGE analysis of fractions recovered during the purification of K99. 
Fimbrial extract was equilibrated with column binding buffer by buffer exchange (lane a). 
After binding to the column, contaminants were eluted with binding buffer containing 20 
mM of NaCI (lane c). By then raising the concentration of NaCI in binding buffer to 80 
mM, a single protein of 16.5 kDa could be eluted (lane b). 
Panel B. SDS-PAGE analysis of the purified K99 subunit concentrated to approximately 
300 /-lg/ml. 
M: Rainbow protein molecular weight markers (Pharmacia). The migration of standards of 





















Figure 2.13 Reaction of monoclonal anti-K99 with purified 16.5 kOa protein in ELISA 
Purified protein was coated to an ELISA plate and probed with monoclonal anti-K99 and 
HRP-conjugated antibodies to test for recognition. Negative control wells were coated with 
2%MPBS. 
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/mmunob/otting of purified K99 
Effect of preparation conditions on the K99 antigen 
Attempts were made to test the reactivity of the monoclonal anti-K99 antibody against 
purified fimbrial protein using electro blotting or diffusion blotting. These were 
unsuccessful. In order to determine the reasons for this, a dot blotting experiment was 
performed using different conditions for preparation of the sample. Purified K99 was 
prepared with sample buffers with different additives. Half of these samples were boiled 
and the remainder were not. After spotting on a strip of nitrocellulose membrane and 
blocking with 3% BSAIPBS, the samples were probed with monoclonal anti-K99 and anti-
mouse peroxidase antibodies using the same reagent concentrations as for ELISA analysis. 
The result (Figure 2.14) revealed that recognition of K99 antigen with the monoclonal 
antibody was unaffected by the presence of SDS or ~-mercaptoethanol in the sample 
buffer. In contrast, the epitope recognised by the antibody was highly dependent upon 
heating ofthe sample. 
Effect of heating of K99 to different temperatures 
To find out the temperature at which the K99 epitope was denatured, samples of 
purified protein were heated in sample buffer to different temperatures. The result of dot 
blotting (Figure 2.15) showed that recognition of the antigen by monoclonal anti-K99 
antibody was retained to a maximum of 50°C. When samples prepared in this way were 
analysed by SDS-PAGE (Figure 2.16), it was found that at 40°C, the 16.5 kDa protein 
could not be observed, presumably because it was present in the sample in the form of 
multiple oligomeric forms of insufficient concentration to be visible. When samples were 
heated to 50°C or more, migration of the 16.5 kDa monomer was evident. Overall, these 
results indicate the heat-sensitivity of the K99 protein. 
Biotiny/ation of K99 fimbriae 
To enable its detection in blotting and immunoprecipitation, purified K99 was 
concentrated and biotinylated. To separate protein from free biotin, the labelling mixture 
was mn through a desalting column and 12 eluted fractions were screened by 
spectrophotometry for the presence of protein. Samples from fractions with significant 
absorbance at 280 run were spotted to nitrocellulose and probed with Extravidin peroxidase 
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a b c d Control 
Heated -
Unheated -
Figure 2.14 Sample preparation and recognition of purified K99 fimbriae by monoclonal 
antibody 
Samples of purified protein were prepared in buffers of the following composition and dot 
blots were probed with anti-K99 monoclonal antibody and anti-mouse HRP conjugate: 
sample buffer containing both SDS and ~-mercaptoethanol (column a); sample buffer 
containing SDS but not ~-mercaptoethanol ( column b); sample buffer containing only ~­
mercaptoethanol (column c); sample buffer without ~-mercaptoethanol or SDS (column d). 
Half of the samples were boiled for 5 minutes (top row) and the remainder were not boiled 
(bottom row) prior to spotting out. BSA was spotted as a negative control. 
Unheated 40 DC 50 DC 60 DC 70 DC 95 DC 
Figure 2.15 Sample heating and recognition of purified K99 fimbriae by monoclonal 
antibody 
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Purified K99 fimbrial protein was heated in sample buffer to the indicated temperatures 
before dot blot analysis with monoclonal anti-K99 and HRP-conjugate antibodies. 
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Figure 2.16 Migration of K99 in SDS_PAGE after heating to different temperatures 
Purified K99 was heated in sample buffer to the indicated temperatures. An equal volume 
of each sample was nm on a 12 % polyacrylamide gel and stained with Coomassie 
Brilliant Blue. M: Rainbow protein molecular weight markers (Pharmacia). The migration 
of standards of 14,20.1 and 30 kDa is indicated. 
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9 10 11 12 
Figure 2.17 Dot blot analysis of fractions after biotinylation of purified K99 
Fractions from a desalting column were screened by spectrophotometry for the presence of 
protein. Samples from those with significant absorbance at 280 nm (fractions 5-12 as 
indicated) were spotted to nitrocellulose and probed with Extravidin proxidase. 
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(Figure 2.17). As shown in Figure 2.17, fraction 5 showed strong reaction, the strength of 
signal decreasing steadily through to fraction 9. 
To visualise the biotinylated protein, fractions 5 and 6 were pooled and a sample was 
separated on SDS-P AGE along with a sample of the biotinylation reaction before desalting 
and ulli110dified K99. Figure 2.18 shows that desalting lead to significant dilution of the 
purified K99 but that a faint band at around 16.5 lilla remained visible. To test if the 
biotinylated protein was detectable after blotting, samples separated by SDS-PAGE were 
transferred to a nitrocellulose membrane and probed with Extravidin peroxidase. The result 
is shown in Figure 2.l9. Despite the low concentration of K99 in the desalted fractions, the 
16.5 kDa protein was readily and specifically detected with peroxidase conjugate. The 
analysis revealed that this was the only biotinylated protein present in the desalted 
preparation. The level of biotin incorporation into the labeled K99 was calculated by 
HABA assay and found to be 0.133 moles biotin per mole K99 protein. Although this ratio 
was low, it is clear from Figure 2.19 that the sensitivity of Extravidin peroxidase enabled 
detection of that fraction of K99 to which biotin was bound. 
Immunoprecipitation of biotinylated K99 
To provide further confirmation that the protein purified by ion-exchange 
chromatography was derived from K99, biotinylated material was used for 
immunoprecipitation with a monoclonal anti-K99 antibody. After incubation, immune 
complexes were captured with Protein G agarose and then released by boiling in SDS 
sample buffer for analysis by SDS-PAGE and Western blotting. 
Silver staining was used to reveal proteins separated by SDS-PAGE (Figure 2.20). By 
comparison with lane c (biotinylated K99), the presence of K99 in the antibody - antigen 
mixture is evident in lane b and its appears from lane a that the material becomes captured 
to Protein G, indicating the formation of immune complexes. Bands of higher molecular 
weight in lane b are likely to be the antibody heavy and light chains although the presence 
of a protein band close to the 30 kDa marker is higher than might normally be expected for 
an immunoglobulin light chain (25 kDa). In lane a, proteins of a range of molecular 
weights appear to have been released from the Protein G agarose by boiling in SDS sample 
buffer. 
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Figure 2.18 SOS-PAGE analysis of biotinylated K99 fimbriae 
Biotinylated protein, after desalting, was run on a 12 % polyacrylamide gel (lane a) with a 
sample of the biotinylation reaction before purification (lane b) and purified, unmodified 
K99 (lane c). The gel was stained with Coomassie Brilliant Blue. M: Rainbow protein 
molecular weight markers (Pharmacia). The migration of standards of 14, 20.1 and 30 kDa 
is indicated. 
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Figure 2.19 Western blotting of biotinylated K99 
Proteins from a 12 % polyacrylamide gel were transferred to nitrocellulose membrane by 
Western blotting. The membrane was then probed with Exteravidin peroxidase. Lane a 
shows biotinylated K99 after desalting, lane b shows biotinylated K99 before desalting 
and lane c shows purified, non-biotinylated K99. M: Rainbow protein molecular weight 
markers (Pharmacia). The migration of standards of 14, 20.1 and 30 kDa is indicated. 
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Figure 2.20 SOS-PAGE analysis of immunoprecipitated K99 
After release of complexes of the antigen (biotinylated K99) and antibody (anti-K99) from 
Protein G agarose, the mixture was spun and the supematant was run on an acrylamide gel 
(lane a). A sample taken before incubation with Protein G agarose (lane b) and a sample of 
biotinylated K99 before addition of antibody (lane c) were used as controls. After 
separation, the gel was stained by silver staining. M: Rainbow protein molecular weight 
markers (Pharmacia). The migration of standards of 14, 20.1 and 30 kDa is indicated. 
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These tentative findings were strengthened when proteins were transferred from the gel to 
nitrocellulose and probed with Extavidin peroxidase (Figure 2.21). The efficiency of 
detection was demonstrated by the strength of signal from a sample of biotinylated K99 
alone (lance c). In lane b (mixture of K99 and anti-K99 monoclonal antibody) and lane a 
(complexes captured to Protein G agarose), the presence of K99 was detectable if faint. 
Over all, the Figure indicates that the purified protein isolated by ion-exchange 
chromatography and then biotinylated was successfully recognised by monoclonal anti-
K99 antibody. 
Haemagglutination assay 
The ability of purified K99 major subunit (Fan C) to haemagglutinate sheep RBC was 
tested in parallel with B41 bacterial cell. The results showed that the purified K99 can 
haemagglutinate sheep red blood cells at high dilutions (1 in 32). 
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Figure 2.21 Western blotting of immunoprecipitated K99 
SDS-P AGE acrylamide gel to nitrocellulose membrane and probed with Extravidin 
peroxidase to detect biotinylated material. Lane a: immune complexes release from Protein 
G agarose by boiling in SDS amples buffer. Lane b: antigen-antibody mixture prior to 
capture to Protein G agarose. Lane c: sample of biotinylated K99 alone. 
M: Rainbow protein molecular weight markers (Pharmacia). The migration of standards of 
14, 20.1 and 30 kDa is indicated. 
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Discussion 
K99 fimbriae are expressed by strains of enterotoxigenic Escherichia coli such as 
B41 strain that cause diarrhoea in calves. The aims of this part of the proj ect were to isolate 
K99 fimbriae from B41, to purify the major subunit (FanC) and to check the biological 
activity of the purified protein so that it could be later used as a target for isolation of 
recombinant antibodies from phage display libraries. 
Initial work focussed upon characterisation of E. coli B41, specifically to confirm the 
presence of genes encoding the K99 and F 41 fimbriae using PCR. The K99 operon is 
carried upon a 7.1 kb region of a plasmid of 87.8 kb. Primers were designed using the 
published sequence of fanC, the forward primer corresponding to nt 21-40 of the coding 
sequence and the reverse primer annealing to nt 311-334 (Roosendaal et al., 1984). Hence 
the predicted size of the product was 314 bp. In contrast, the F 41 operon is somewhat 
larger (10.1 kb) and is located on the bacterial chromosome. Again, primers were designed 
from published sequences corresponding to nt 34-51 (forward) and 390-413 (reverse) of 
the gene for the fimbrial subunit (Fidock et al., 1989). It was predicted that the amplified 
product would be 380 bp in size. Successful amplification of products of the expected size 
from E. coli B41 provided preliminary indication of the presence of K99 and F 41 genes 
although this characterisation was not taken on to sequencing to formally confirm this. 
This approach was however shown to be specific and sensitive and of potential value in the 
identification of E. coli strains capable of causing diarrhoea in calves (Franck et a!., 1998). 
The bacteria grew well in Minca medium and the expression of K99 fimbriae could be 
detected using the fimbrex test which is based upon agglutination of latex beads coated 
with anti-K99 antibody. The test could also be used to demonstrate that thermal shock of 
bacteria in PU buffer detached the fimbriae. The presence of K99 in the extracts was 
confirmed with ELISA using polyclonal and monoclonal anti-K99 antibodies. Other 
authors such as Vasquez (Vazquez et al., 1996) and de Graaf (de Graaf et al., 1981) have 
also used buffers containing urea for this purpose. In the method described by Vasquez, the 
final stage of isolation involved dialysis of the fimbrial extract into distilled water. When 
attempted in this project, overnight dialysing against distilled water at 4 °c led to the 
formation of dense aggregates. Similar results have been reported previously by Karkhanis 
and Bhogal (Karkhanis and Bhogal, 1986) and de Graaf (de Graaf et al., 1981). To 
overcome this problem, the fimbriae could be kept in soluble form by dialysis against PBS. 
This made possible a thorough characterisation of the isolated K99. 
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As pati of this characterisation, SDS-PAGE was used to reveal the protein 
composition of fimbrial extracts. Several protein bands could be observed. The strongest 
band on the gel was of 16.5 kDa, corresponding to the size of the major subunit of K99 
(Yoshimatsu et al., 1991; Nagy and Fekete, 1999). A protein band of 30.9 kDa also was 
seen on the gel. This agrees with the size of the F 41 subunit as reported by several different 
authors (To, 1984; Jacobs, 1985; Raybould et al., 1987; Vazquez et aI., 1996). Other bands 
might have been contaminating components from the bacterial outer membrane given the 
ability of urea to solubilise mildly hydrophobic proteins. 
This preliminary identification of the 16.5 kDa structure was suppOlied by its reaction 
on blots with a polyclonal antibody raised against K99. However, other protein bands were 
also detected in these experiments. Since detailed information was unavailable on the 
preparation of this polyclonal antibody, various explanations are possible. Binding to 
proteins other than the 16.5 kDa target might be the result of immunological cross-
reactivity amongst the proteins on the blot. It is also possible that antigen used to develop 
the antibody in sheep was not completely pure and hence a proportion of the antibodies 
present in the serum bound to other proteins isolated from E. coli B41. In order to carry out 
these experiments, teclmical problems were encountered in transferring the 16.5 kDa 
protein band from the SDS gel to the nitrocellulose membrane using electroblotting. For 
this reason, diffusion blotting was more commonly applied: this was found to be more 
efficient than electroblotting. Although diffusion blotting has been described for a range of 
applications by other authors (Brian Bowen, 1980; Heukeshoven and Demick, 1995; Olsen 
and Wiker, 1998; Chen and Chang, 2001) , electrotransfer remains by far the most 
common method used for the preparation of Western blots. Its failure in this instance might 
have been attributable to the composition of the transfer buffer. Typically, these are 
prepared with Tris glycine buffers which have a pH close to the pI of FanC. It has been 
noted by others that the conditions of electrophoretic transfer can have a significant effect 
on the transfer of some outer membrane proteins in Western blotting (Davies et al., 1990). 
Although transfer of the 16.5 kDa protein band to nitrocellulose was much better by 
diffusion blotting than by electroblotting, some other proteins present on SDS gels did not 
transfer well by diffusion blotting. This indicates that to some extent, the choice of transfer 
method and its conditions may depend upon the properties of the protein of interest. This 
contrasts with the findings of Olsen and Wiker (Olsen and Wiker, 1998) who reported that 
in diffusion blotting, the same transfer rate could be determined for proteins of different 
Sizes. 
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Given the presence of other proteins in the bacterial extracts, methods were sought to 
purify the major subunit of K99 as a preliminary for its use in phage display. Several 
strategies and methods have been attempted to purify K99 fimbriae. One of the oldest 
methods was described by Brinton (Brinton, 1965) who devised a series of steps involving 
mild blending of the bacterial suspension, precipitation at pH 3.9 and aggregation with 
MgCh . In contrast, Isaacson (Isaacson, 1977) attempted to purify this protein, after 
ammOnIum sUlphate precipitation, by an extended series of chromatography steps 
including ion-exchange and gel filtration chromatography coupled with isoelectric 
focusing and ultracentrifugation on sucrose density gradients. The method of de Graaf(de 
Graaf et al., 1981) was less complex. A concentrated preparation of K99 was fractionated 
on a Sepharose CL-4B column then dialysed against phosphate buffer followed by sodium 
deoxycholate over a period of more than 5 days. Altmann (Altmann et al., 1983) extracted 
fimbriae from bacteria using 3 M potassium thiocyanate then fractionated the material by 
gel filtration and ion-exchange chromatography. All these methods are technically 
complex and time consuming and were rejected for these reasons when seeking a method 
to use in this project. One less complex method for the isolation of K99 fimbriae from E. 
coli B44 was described by Karkhanis and Bhogal (Karkhanis and Bhogal, 1986). These 
authors employed heat shock treatment to extract fimbriae from the bacterial surface. The 
extracted material was aggregated by incubation at 4 °C for 16 hrs and then centrifuged at 
39000g. The pellet was washed two times with phosphate buffer or 4M urea and 
chromatographed on a Sepharose CL-4B column. Another simple method published by 
Kuzuya (Kuzuya et a!., 1988) purified K99 protein using affinity chromatography. 
Y oshimatsu (Y oshimatsu et al., 1991) described two purification methods. In both, heat 
treatment was first used to release fimbriae for purification on a Sepharose 4B gel filtration 
column. In one method, K99 proteins were separated from F41 fimbrial components by 
salting-out. In the second method, ultracentrifugation for 4 hrs achieved better objective. 
The goal for this project was to find a fast, convenient and inexpensive method for 
purification of K99 to provide protein of high purity and good biological activity. Attempts 
were made to purify K99 on a range of ion-exchange chromatography and gel filtration 
media similar to some of those described ithe reports outlined above. These preliminary 
efforts were not successful. Two problems were encoun ntered: solubility and binding to 
the columns under test. It was found that if the fimbrial extract was dialysed against 
distilled water, most proteins aggregated, rendering the material unsuitable for column 
chromatography. If the fimbrial extract was dialysed against PBS or phosphate buffer, the 
properties of these buffers inhibited full binding of the K99 major subunit (16.5 kDa) to 
ion-exchange media. To overcome these problems, the precipitated fimbrial extract was 
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redissolved in a warm buffer containing 2 M urea immediately before application to the 
chromatography column. Thus the fimbriae extract was dissolved almost completely. To 
ensure optimal binding to the column, the composition of this buffer was changed to avoid 
pH values close to the pI of the major subunit of K99. This achieved high yields of 
material of good purity. The biological activity of this protein was confirmed by several 
tests. It had similar reaction in Fimbrex tests as the original fimbrial extract from which it 
was derived, it had high activity in ELISA using anti-K99 monoclonal antibody, and could 
be recognised in dot blotting and immunoprecipitation assays. Most impOliantly, the 
protein showed a high agglutinating activity with sheep red blood cells. 
Comparison of this new purification method with other repOlied protocols reveals 
several significant advantages. The K99 major subunit can be purified in a single 
chromatography step whereas most other published methods involve at least two steps. The 
aggregation of the protein during extraction and purification can be easily controlled. In the 
method described by Karkhanis and Bhogal (Karkhanis and Bhogal, 1986) for E. coli B44, 
the protein initially aggregates and then dissolves. The SDS-PAGE analysis of protein 
repOlied here showed a single band at the expected molecular weight of 16.5 kDa whereas 
in some methods, particularly those from the older literature, different molecular weight 
for the K99 subunit were reported. The materials used during purification by the method 
described here are cheap and available to many labs, in contrast to the requirements 
stipulated by Altmann et al. (Altmann et al., 1982), Isaacson (Isaacson, 1977) and Kuzuya 
(Kuzuya et al., 1988). As described in this chapter, the purified K99 protein was 
exchanged into PBS. It remained soluble and stable in this buffer for several years when 
stored at -20°C, but this appeared equally true of the protein when eluted in 25mM Tris 
base pH 7.0 containing 80 mM NaCl. Significantly, the biological activity of the purified 
protein was also excellent. In an effort to ensure this, the method repOlied here excluded 
the use of strong detergents or denaturants such as SDS, guanidine hydrochloride or high 
concentrations of urea. Surprisingly, except one investigator (Yoshimatsu et a!., 1991), not 
all authors who have repOlied K99 purification methods appear to have tested biological 
activity and in one example, when haem agglutination was tested, it was negative (Altmann 
et a!., 1982). Overall, the average yield of pure K99 antigen from a one-litre culture of E. 
coli B41 was about 3.5 mg using the method reported here, a little higher than that repOlied 
by de Graaf (de Graaf et a!., 1981). Together, the simplicity, inexpense, yield, purity and 
stability of K99 purified by this method make it suitable for many purposes including 
vaccination. As a first step, this could be tested in vivo in the infant mouse diarrhoea model 
ofK99 ETEC infection (Duchet-Suchaux, 1988). 
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Analysis of purified K99 in this study revealed that heating appeared to destroy the 
epitope that is recognized by a monoclonal anti-K99 antibody. The heat sensitivity of this 
antigen has not been reported in the wider literature. The observation might therefore 
simply reflect the specificity of the monoclonal anti-K99 antibody available for this study. 
It does however raise the opportunity of further investigations to find monoclonal 
antibodies that recognise linear epitopes of native or recombinant (Jay et al., 2004) K99. 
One repOli in the literature has suggested a possible role for LPS in the formation of 
K99 fimbriae (Pilipcinec et al., 1994). In this report, isolated K99 fimbriae were subjected 
to polyacrylamide gel electrophoresis and then tested in Western blotting with LPS 
antiserum. It was observed that the K99 major subunit reacted specifically in this analysis 
suggesting covalent association of LPS with the purified protein. In contrast, it has been 
repOlied that purified K99 from E. coli strains C1443 and B44 strains was not 
contaminated with LPS after purification (Altmmm et a!., 1983; Karkhanis and Bhogal, 
1986). This may depend to some extent on the purification method employed. No 
experiments were done in the present study to test for level of LPS associated with the 
purified K99 but in future, this could be addressed using commercial endotoxin detection 
reagents based upon the limulus amoebocyte lysis test. Clearly, this would be necessary 
before any attempts to assess vaccine potential in vivo. 
The K99 purified in this study might find other uses. It has been reported that the 
protein can be used in inhibition assays to detecte the presence of specific fimbrial 
receptors on enterocytes (Isaacson et aI., 1981; Dean and Isaacson, 1982). FanC has been 
cloned in combination with other genes of the K99 operon or as a single or truncated unit 
(van Embden et al., 1980; Ogmmiyi et a!., 2002). From natural or recombinant sources, it 
is possible that purified K99 could be used to block the binding of ETEC bacteria to 
receptors in an in vit1'O model (Jay et a!., 2004) and to block bacterial attachment to 
enterocytes in vivo as a disease prevention strategy based upon competitive inhibition. 
Overall, the work reported in this chapter fulfills the initial aim to prepare a pure and 
biologically active antigen for the isolation of recombinant anti-K99 antibodies. In meeting 
this goal, an improved method for the purification of the major subunit of K99 has been 
devised that has potential in several areas of application. 
Chapter 3 
Griffin.1 scFv library 
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3. Griffin.1 scFv library 
Introduction 
The Griffin.1 library is one of the largest synthetic human single chain libraries 
distributed by the Medical Research Council Centre for Protein Engineering. The library is 
composed of human scFvs containing highly diverse VH and VL CDR3 sequences, 
prepared from human synthetic Fab lox library vectors (Griffiths et al., 1994) and then 
cloned into the phage mid vector pHEN2 (Figure 3.1) (Hoogenboom et al., 1991).The 
resulting library, distributed in E. coli TG 1, contains more than 109 different clones. The 
kappa and lambda light chain variable regions were PCR amplified from the fdDOG-
210xVk and VL constructs. The PCR fragments were purified and digested with Apall and 
NotI. The gel purified fragments were then ligated into pHEN2. Heavy chain variable 
regions were PCR amplified from the pUC19-210xVH vector. The products were purified 
and digested with Sfil or Ncol and Xl1OI. The gel purified fragments were then ligated into 
Vk-pHEN2 or VL-pHEN2. As cloned, the VH and VL fragments are attached to one 
another by a flexible Glycine-Serine linker. This vector also contains a c-myc tag that can 
be used for detection of the expressed antibody fragments. It also provides a HlS6 tag, 
allowing purification of scFv antibodies using nickel affinity columns (Figure 3.2). 
The VH and VL lox libraries form the foundation for the Griffin.1 library. The 
repelioire of heavy chains (> 1 08 different clones) was built from 49 cloned V H segments 
(Tomlinson et al., 1992), with CDR3 loops of 4 to 12 residues of random sequence. The 
repertoire of K light chains (9x 1 04 clones) was built from 26 cloned V K segments (Cox et 
aI., 1994) with CDR3 loops of 8 to 10 residues that included one, two or three residues of 
random sequence in all cases. The repertoire of A, light chains (7 Ax 1 05 clones) was built 
from 21 cloned V A segments(Williams and Winter, 1993), with CDR3 loops of 8 to 13 
residues that included zero, one, two, three, four or five residues of random sequence. 
The Griffin. 1 library can be produced to select specific binders to target molecules that 
are attached to the surface of a tube or biotinylated and captured by streptavidin coated 
beads. By panning the library for two or tlu'ee rounds, high affinity and specific phage 
antibodies can be selected. The monoclonal scFvs can then be screened for binding and 
used for further analysis of the target molecules. 
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Figure 3.1 Structure of the pHEN2phagemid. 
The main features of the vector are indicated. Transcription takes place from a lac 
promoter and in a suppressor strain of E. coli, the translated product comprises a PelB 
leader, the single-chain antibody created by insertion of VH and VL sequences at the sites 







ACAGTCATA ATG AAA TAC CTA TTG CCT ACG GCA GCC GCT GGA TTG TTA 
M K y L L p T A A A G L 
Sfil Neal 
TTA TTA CTC GCG GCC CAG CCG GCC ATG GCC CAGGTGCAGCTGCAGTGGGTC 
L L L A A Q p A M A 
XhoI FOR-Link seq 
GACC TCG AGT GGT GGA GGC GGT TCA GGC GGA GGT GGC TCT GGC GGT 
S S G G G G s G G G G S G G 
~----------------------------------
ApaU Natl 
AGT GCA CAG GTCCAACTGCAGGAGCTCGATATCAAACGG GCG GCC GCA 
S A A A A 
HIS-tag 
CAT CAT CAT CAC CAT CAC GGG GCC GCA GAA CAA AAA CTC ATC TCA 
H H H H H H G A A E Q K LIS 
myc-tag Amber 
GAA GAG GAT CTG AAT GGG GCC GCA TAG ACT GTT GAA AGT TGT TTA 
E E D L N G A A * T v E s C L 
~---------------------------
pHEN seq 
GCA AAA CCT CAT ACA GAA AAT TCA TTT ... 
A K P H T E N S F 
~-----------------------------fdSeq1 
Figure 3.2 DNA sequence of pHEN2 vector 
The Figure presents a part of DNA sequence of pHEN2 vector. The restriction enzyme 
sites are underlined. The whole VH sequence locates between Neal and Xhal and the 
whole VL sequence locates between Apall and Natl. Primers are shown by dotted arrows. 
The amino acid sequences of HIS and myc tags and PelB leader are underlined. 
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VCS M13 he/per phage 
In scFv libraries such as Griffin.l, the encoded antibody is genetically fused to the 
phage coat protein, pIlI, in a phagemid vector. These are plasmids containing a phage 
origin of replication and morphogenetic signal, both required for packaging of the 
phagemid into phage particles. The pIlI protein, present in three to five copies per phage 
particle, consists ofN-terminal NI and N2 domains involved in phage infectivity and a C-
terminal domain essential for phage assembly. ImpOliantly, fusion of scFv to the N-
terminus ofN1 does not abolish functional activity of the pIlI protein. Transformation of a 
phagemid library into bacteria enables propagation of the DNA but for selection, phage 
assembly is required. Since the phagemid carries insufficient information to achieve this, 
bacteria carrying the phagemid need to be infected by helper phage such as VCSMI3 that 
provides all the genes required. When the extruded phage patiicle is packaged with DNA, 
it is the scFv-encoding phagemid that enters the capsid with greatest frequency, and viral 
assembly is completed by capping with a variable propOliion of wild-type and scFv-linked 
pIlI molecules translated from helper phage and phagemid copies of the gene respectively. 
This physical association of the scFv protein at the viral surface and the encoding gene 
carried on the phagemid within the capsid enables selection of antigen-specific phages 
from libraries by incubation with the antigen, removal of non-bound phages and elution of 
bound phages. Phage carrying irrelevant scFv or entirely wild-type copies of pIlI are lost in 
the selection process. Phage that successfully attach to the target are usually recovered by 
incubation at low or high pH, conditions that do not impair the ability of the NI and N2 
domains of pIlI to interact with the bacterial receptor (the F pilus) and thereby mediate 
infection. Since the phagemid encodes ampicillin resistance, successfully infected bacteria 
can be isolated on antibiotic-containing media, a step that eliminates any virus carrying 
helper phage DNA. Culture of bacteria that now harbour phagemids emerging from 
selection is possible and a further round of superinfection with helper phage prepares 
stocks for further emichment. 
Application of Griffin. 1 library 
The Griffin.1 scFv library has the potential to carry high affinity antibodies against 
any target antigen including foreign antigens, self antigens, non-immunogenic antigens and 
toxic antigens (Winter et aZ., 1994). The isolated antibodies can be used for many purposes 
such as research, diagnostic and therapeutics applications. Some examples follow of the 
previous use of this library for isolation of scFv antibodies by phage display technology. 
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Antibodies against leukemic cells 
To select phage antibodies with therapeutic potential, the Griffin.1 library was panned 
on a premyelocytic leukemia cell line (HL60). Phage that bound to targets shared with 
non-leukemic cells were subtracted by incubating the library with human glioma cells. 
Phage carrying high affinity scFvs to HL60 cells were emiched by fluorescence-activated 
cell sOliing. The selection procedure was repeated for six rounds to show significant 
binding to HL60 cells. Also, the inhibitory effect of isolated antibodies on HL60 cell 
proliferation was tested (Shadidi and Sioud, 2001). 
Streptococcus suis 
The Griffin. 1 antibody phage display library was used to select recombinant antibodies 
directed against surface components of a pathogenic strain of Streptococcus suis serotype 
2 and against extracellular factor (EF), a protein known to be exclusively associated with 
pathogenic S. suts serotype 2 strains. The investigators applied a subtractive selection 
procedure, to isolate antibody fragments that recognized epitopes specific for a pathogenic 
S. suis serotype 2 strain, compared to a non-pathogenic serotype 2 strain (de Greeff et aI., 
2000). After 5 and 6 rounds of selection, tlu'ee phage antibodies from each selection were 
chosen for further analysis. 
Anti-hapten antibodies 
The hapten target investigated in this study was microcystin LR (1000 Da), a 
hepatotoxin produced by celiain strains of cyanobacteria (Codd et at., 1997). To isolate 
antibodies against this hapten, microcystin LR was conjugated to either bovine serum 
albumin or keyhole limpet haemocyanin. The Griffin.1 library and Tomlinson library I 
were used for screening. Three rounds of panning were performed on antigen-coated 
immunotubes. After screening, a selection of scFv antibodies that showed reaction with 
free microcystin were recloned into pIMS 147 vector for expression of soluble scFv 
fragments. Finally, the activity of the purified antibodies isolated from each library were 
compared by a competition ELISA test (Strachan et al., 2002). 
Antibodies against an N-glycosylation site 
To identify antibodies that recognize the Asn-X-Ser/Tlu' N-glycosylation site that 
guides oligosaccharyltransferase activity, the Griffin. 1 library was used to select antibodies 
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against synthetic Asn-Cys-Ser/Thr tripeptides conjugated to bovine serum albumin. The 
selection was performed over several rounds and soluble scFv fragments were expressed in 
E. coli HB2151 for purification on an immobilised nickel column. The interaction between 
the isolated scFv and Asn-X-Ser/Thr was characterized (Kikuchi et aI., 2004). 
Sickle cell disease 
Sickle red blood cells have enhanced adhesion to the plasma and extracellular matrix 
protein thrombospondin-1 (TSP) in vitro. In this study, the authors aimed to isolate 
antibodies from the Griffin. 1 library that bind TSP. Following three rounds of selection, six 
unique scFvs that bound to purified TSP were isolated. Using an in vitro flow adhesion 
assay, the isolated scFvs were assessed for their inhibition of the adhesion of sickle red 
cells to immobilized TSP. Antibodies that had an inhibitory effect were used in epitope 
mapping studies to identify the binding site for sickle cells (Watkins et at., 2003). 
Protein disulphide-isomerase (PDI) 
The Griffin.1 phage display library was used in this study to isolate antibodies that 
cross-react with all proteins in the PDI family through recognition of the motif Cys-X-X-
Cys. After selection, the binding of scFvs to synthetic peptides and to mutant members of 
the PDI family was assessed by surface plasmon resonance. Clones that recognized 
sequences containing the CGHC or CGHCK motif were identified (Kimura et at., 2004). 
Objectives 
The mam objective of this part of the project was to use human semi-synthetic 
Griffin.1 library for the isolation of recombinant single-chain antibodies against purified 
K99 major subunit (Fan C). It was planned to characterise the isolated antibodies and then 
assess their biological activity to determine whether they have the ability to neutralise K99 
function. 
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Materials and Methods 
Griffin1. library 
The Griffin.1 library was obtained from the Centre for Protein Engineering (CPE), 
Cambridge (http://www.mrc-cpe.cam.ac.uk/phage/glmtaf.html) and used to select phage 
antibodies. Griffin.1 is a semi-synthetic phage library containing more than 10 9 different 
scFv antibodies and was constructed by recoloning the V H and V L variable regions from 
lox library vectors into the phagemid vector pHEN2 (Tomlinson et al., 1992; Griffiths et 
al., 1994; Nissim et al., 1994; Winter et aI., 1994). 
The materials supplied from the CPE comprised a tube of the semi-synthetic library in 
E. coli TG 1 cells, a glycerol stock of the positive control (TG 1 containing an anti-
thyroglobulin clone), a glycerol stock of the negative control (TG 1 containing the empty 
pHEN2 vector), a glycerol stock of T -phage resistant E. coli TG 1 for propagation of phage 
(K12 iJ.(lac-proAB) supE thi hsdD5IF' traD36 proA+B laclq lacZiJ.MJ5), and a glycerol 
stock of E. coli HB2151 for expression of antibody fragments (K12 ara iJ.(lac-proAB) 
thilF' proA+ B laclq lacZiJ.MJ5). 
The helper phage VCS-M13 (Stratagene, La Jolla, California) was provided by Dr. P. 
Ogston, University of Glasgow. The titre of helper phage was 2.2x 1 0 14 pfu/ml. 
Growing a secondary stock of library 
To make a secondary stock, 1 x 1010 clones ofthe Griffin.l library in E coli TG 1 were 
inoculated into 100 ml of 2xTY (Tryptone 16g, Yeast Extract 109, NaCl 5g and distilled 
water up to 1 litre) containing 100 /lg/ml ampicillin and 1 % glucose and grown with 
shaking at 37°C until the OD at 600 nm was approximately 0.5. At this OD, 10 ml of the 
library culture was used for phage rescue. The remaining culture (90 ml) was allowed to 
continue growing for a further two hours and the cells were then collected by 
centrifugation at 3300g for 10 minutes. The pellet was resuspended in 4 ml of fresh 2xTY 
media and after addition of glycerol to a final concentration of 15 %, it was stored at -70 
°c. 
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Phage rescue of the library 
To rescue the library, ten millilitres of library culture at an OD 600 nm of about 0.5, 
was infected with VCS-M13 helper phage, added in the ratio of bacteria to phage of 1 in 
20. Appropriate volumes were calculated from the titre of helper phage and the fact that a 
bacterial culture of 1 OD unit at 600 nm represents a bacterial density of around 8x 1 08 
bacteria per ml. The mixture of phage and bacteria was incubated for 30 minutes at 37°C in 
a water bath. The infected cells were then collected by centrifugation (10 min at 3,300 g) 
and resuspended in 2 ml of 2x TY broth containing 100 flg Iml ampicillin and 25 flg/ml 
kanamycin (Sigma). Subsequently, the cells were incubated overnight at 30°C and with 
shaking at 200 rpm. Bacterial cells were removed by centrifugation (30 min at 3,300 g), 
and phage presented in the supernatant (8 ml) were precipitated with 1.6 ml of 
polyethylene glycol-NaCl (20% polyethylene glycol 6000, 2.5 M NaCl). The mixture was 
left for 1 hour at 4 °c and was spun at 3300g for 30 minutes. The pellet was then 
resuspended in 4 ml of PBS and spun at 11600g for 10 minutes to remove most of the 
remaining bacterial debris. The phage supernatant was stored at 4 °c and for long term 
storage, after addition of glycerol (15 % final concentration), at -70°C. 
Titration of phage library 
To titre the phage stock, 1 fll of phage was diluted into 1 ml of PBS and 1 fll of this 
was used to infect 1 ml of TG 1 at an OD 600 nm about 0.5. The culture was incubated at 
37°C water bath for 30 minutes. 50 III of this, 50 fll of a 1: 1 02 dilution and 50 III of 1: 104 
were plated on TYE (Tryptone 109, Yeast Extract 5g, NaCl 8g, Agar 15g and distilled 
water up to 1 litre) plates containing 100 Ilglml ampicillin and 1 % glucose. The plates 
were incubated at 37°C overnight. The following day, the number of colonies on each 
plate was counted and titre of phage was determined. 
peR screening for full-length scFv genes 
To estimate the frequency of full-length inserts in the secondary stock of the library, 
20 colonies were picked at random from TYE plates used for library titration. Bacterial 
DNA was obtained by suspending each colony in 50 III of H20 and boiling at 100°C for 10 
minutes. Primers LMB3 and gIll were used to amplify across the inserts in 25-lll PCR 
reactions containing 0.5 flM concentrations of each primer, 0.25 mM concentrations of 
each dNTP (Promega), 4 mM MgCh, Ix reaction buffer (containing 50 mM KCL, 10 mM 
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Tris-HCL pH 9.0 and 0.1% Triton®X-100), 2.5 units ofTaq DNA polymerase (Promega) 
and 19 fll of bacterial lysate. Samples were amplified on a Techne thermal cycler under the 
following conditions: the reaction was heated to 94°C for 3 min and then 30 cycles of 30 
second denaturation at 94 °c, 1 min annealing at 55°C, 1 min extension at 72 °c. Final 
extension was for 10 min at 72 °c. As a positive control, an anti-thyroglobulin scFv in the 
pHEN2 vector was used for amplified since this carries a full-length scFv insert. 
PCR products were analysed on a 1 % agarose gel for 45 min at 100 V, stained with 
ethidium bromide, and photographed under UV light. 
Restriction analysis of plasm ids from secondary stock of library 
To confirm the presence of full-length inserts, plasmid DNA was isolated from 12 
clones picked at random and digested with two restriction enzymes. Plasmids were isolated 
and purified using Qiagen miniprep reagents following the instruction provided with the 
kit. 20 fll reaction mixtures were set up for each sample comprising 5 fll of plasmid DNA, 
1 fll (10U) of Ncol (Promega, UK), 1 ~ll (IOU) of Notl (Promega, UK), 1.8 fll of distilled 
water, 0.2 fll of BSA and 2 fll of buffer D (60 mM Tris-HCL (pH 7.9), 1.5 M NaCl, 60 
mM MgCb and 10 mM DTT). The reaction mixtures were incubated at 37°C for 1.5 hrs. 
5 fll of the digestion products were analysed on a 1 % agarose gel for 45 min at 100 V, 
stained with ethidium bromide, and photographed under UV light. 
Selection procedure 
Panning against purified K99 
First round of selection 
To select recombinant phage antibodies against purified K99, one immunotube (Nunc, 
Denmark) was coated overnight at room temperature with 4 ml of purified K99 at 90 
mg/ml in PBS. The following day, the immunotube was washed 3 times with PBS by 
pouring into the tube and pouring out again immediately to remove unbound antigen. The 
immunotube was then blocked by filling with 4 ml of 2 % MPBS and incubating at 37°C 
for 2 hours. The immunotube was washed again three times with PBS. Then about Ix 10 13 
pfu of phage from the Griffin.1 library was made up to a total volume of 4 ml with 2 % 
MPBS. To block phage that might be specific for milk constituents, the phage suspension 
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was incubated for about 30 minutes at room temperature before transfer to the K99-coated 
immunotube. After addition of the phage library, the tube was incubated on a turntable for 
30 min at room temperature, followed by a standing incubation for 90 min at room 
temperature. The supernatant was discarded and the tube was washed 10 times with PBS 
containing 0.1 % Tween 20 and 10 times with PBS. After shaking out the excess PBS, 
phage were eluted by adding 1 ml 100 mM triethylamine (700 III of triethylamine (7.18 M) 
in 50 ml water, diluted on the day of use) and rotating continuously for 20 minutes at room 
temperature (de Bruin et a!., 1999). The eluted phage suspension was neutralized with 
0.5 ml of 1 M Tris-HCl (pH 7.4). A further 200 III of Tris buffer was added to the 
immunotube to neutralise the phage remaining in the tube. Elutes were stored at 4DC to use 
in the next round of selection and for titration. 
Infecting TG1 with eluted phage antibodies 
The day before selection, one colony of E. coli TO 1 was taken from a minimal 
medium plate and grown in 5 ml of 2xTY overnight at 37 DC with shaking at 200 rpm. On 
the day of selection, 5 0 ~ll of this culture was inoculated to 50 ml of 2xTY and incubated at 
37 DC with shaking until the culture entered exponential growth and the OD 600nm reached 
0.5. At this point, 750 III of the eluted phage was added to 9.25 ml of exponentially 
growing TO 1 cells. Four ml of bacterial culture was also added to the tubes used for 
selection in order to recover any phage remaining in the tube. Both mixtures were 
incubated at 37 DC in a water bath for 30 minutes to allow infection to take place. After 
incubation, the 10 ml and 4 ml cultures were pooled. 100 III of culture was used for 
titration of output phage. This was done by making 5, 100-fold serial dilutions of 100 III of 
culture in 2xTY media and plating all 100111 of each dilution on TYE plates containing 100 
Ilg/ml of ampicillin and 1 % glucose. The plates were then incubated at 37 DC overnight. 
The following day, the number of colonies on the plates was counted and from this, the 
titre of output phage was determined. The plates were then stored at 4 DC for analysis of 
those phage recovered from the first round of selection. 
The remaining culture of infected E. co!; TO 1 was spun at 3300g for 10 minutes. The 
pellet was resuspended in 2 ml of 2xTY and was plated onto a large Nunc Bio-Assay dish 
(Oibco-BRL) containing TYE, 1 00 ~lg/ml of ampicillin and 1 % glucose. The plate was 
incubated at 30 DC overnight. The following day, bacterial colonies were collected from 
plate by addition of 5 ml of 2xTY containing 15 % glycerol and cells were loosened into 
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suspension with a glass spreader. 50 ~ll of the bacterial suspension was used for phage 
rescue for the second round of selection and the remainder was stored at -70 DC. 
Rescue of selected phage antibodies 
To rescue the phage antibodies fi:om clones selected at round 1, 50 ~l of bacteria 
recovered from the Nunc Bio-Assay dish were inoculated to 100 ml of 2xTY containing 
1 00 ~g/ml ampicillin and 1 % glucose, and were grown at 37 DC with shaking at 200 rpm 
until OD 60011111 was approximately 0.5. Then 10 ml of bacterial culture was infected with 
VCS-M13 helper phage at a bacteria: phage ratio of 1 in 20 and the mixture incubated 
without shaking at 37 DC in a water bath for 30 minutes. After that, the infected cells were 
centrifuged at 3300g for 10 minutes. The pelleted bacteria were then resuspended in 50 ml 
of 2xTY containing 1 00 ~g/ml ampicillin, 50 ~g/ml kanamycin and incubated with 
shaking at 30 DC overnight. The following day, 40 ml of overnight cultures was spun at 
3300g for 30 minutes. 
To precipitate phage from the culture supernatants, 8 ml of cold PEGlNaCI (20% 
polyethylene glycol 6000, 2.5 M NaCI) was added to 40 ml of each supernatant. After 
mixing well, the mixtures were left for 1 hI' on ice and then centrifuged at 3300g for 30 
minutes. Next, the supernatants were poured away to remove PEGlNaCI and the 
precipitated phage were resuspended in 2 ml of PBS and spun at 11600g for 10 minutes in 
a micro centrifuge to remove remaining bacterial debris. 1 ml of the supernatant containing 
the rescued phage was stored at 4 DC and remainder was used for the next round of 
selection. 
Titration of rescued phage 
To titre phage rescued from the first round of selection and thereby determine the 
phage input for the second round of selection, 50 ~ll of rescued phage was diluted into 50 
~l PBS. 1 ~l of this and 1 ~l of5, 100-fold serial dilutions were used to infect 1 mlofTGl 
culture previously grown to an OD 60011111 of about 0.5. The cultures were then incubated 
at 37 DC water bath for 30 minutes. 50 ~ll of each dilution was spread onto a TYE plate 
containing 100 ~lg/ml ampicillin and 1 % glucose and grown overnight at 30 DC. The next 
day, the number of colonies was counted and from this, the titre of phage was determined. 
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Second round of selection 
In the second round of selection, one immunotube (Nunc, Denmark) was coated 
overnight at room temperature with a lower concentration of purified K99 (30 /-Lg/ml) to 
isolate phage antibodies with higher specificity and affinity. The following day the 
immunotube was washed and blocked as described for the first round of selection. 3.2 x 10 
13 pfu of PEG precipitated phage in 2% MPBS recovered from the first round of selection 
was added to the immunotube as input phage. The immunotube was then incubated for 30 
minutes with rotation and for 90 minutes standing at room temperature and then was 
washed 20 times with PBS containing 0.1% Tween 20 and 20 times with PBS. The 
remaining procedures including elution of selected phage, infection of TG 1 cells, 
superinfection with VCS-MI3 helper phage, recovery of phage and titration were done as 
described for the first round. 
Third round and fourth round of selection 
All procedures in the third round and fourth round of selections were done as for 
previous rounds. The coating of immunotubes with purified K99 and washing steps were 
carried out as for round two. The titre of input phage antibodies for the third round was 2.6 
x 1014 and for the fourth round, it was 5.3 x 1014 pfu in 2% MPBS. 
Screening by monoclonal phage ELISA 
The activity of 96 individual isolated clones from each round of selection against 
purified K99 was assessed by ELISA screening. 
Preparation monoclonal phage antibodies 
From plates used to titre phage recovered after selection, 96 individual colonies were 
picked at random and inoculated into 100 /-LI of 2xTY containing 100 /-Lg/ml ampicillin and 
1 % glucose. A separate microtitre plate (Iwaki, Japan) was prepared from each round of 
selection. The plates were incubated overnight at 37°C with shaking at 200 rpm. The 
following day, using a multi-chmmel pipette, approximately 2 /-LI of overnight culture was 
transferred to further 96 well plates containing 200 ~tl of 2xTY, containing 100 /-Lg/ml 
ampicillin and 1 % glucose per well. Plates were incubated at 37°C for 1.5 hrs to reach to 
an OD 600 nm of about 0.4. Then 25 ~Ll of 2xTY containing 100 /-Lg/ml ampicillin, 1% 
glucose and 10 9 pfu helper phage (final concentration) was added to each well for 
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superinfection. Plates were left to stand at 37°C for 30 minutes and then shaken at 200 rpm 
for a further 1 hour at 37°C. The plates were then centrifuged at 1800g for 10 minutes in a 
Sigma centrifuge fitted with appropriate carriers and the supernatants were aspirated off. 
Each pellet was resuspended in 200 fll of 2xTY containing 100 flg/ml ampicillin and 50 
flg/ml kanamycin. Cells were grown overnight at 30 °c with shaking at 200 rpm to allow 
replication and rescue of the phage antibodies. The next day, plates were spun at 1800g for 
10 minutes. Each supernatant was then recovered for use as monoclonal phage antibody in 
ELISA assay. 
Antigen coating 
Wells of an ELISA plate (Nunc, Denmark) were coated with 100 fll per well of 20 
flg/ml of purified K99 in PBS. Plates were left overnight at room temperature to allow the 
K99 antigen to bind to the plastic wells. Four plates were coated in all so that individual 
plated were available for screening phage from each round of selection. To screen clones 
from each round of selection for reaction against dry skimmed milk, wells of another four 
ELISA plates (one plate for each round) were coated with 100 fll of2 % MPBS. These 
plates were also left overnight at room temperature. 
Blocking 
The next day, unbound antigen was discarded and the wells were washed three times 
with PBS. The wells were then blocked by addition of 200 fll of 3% BSAIPBS and 
incubation for 2 hrs at 37°C. 
Addition of monoclonal phage antibodies 
After washing the wells three times with PBS, each culture supernatant containing 
phage antibodies was diluted 1/2 in 3% BSA/PBS.1 00 fll of each was added to the wells of 
a plate coated with K99, and 1 00 ~tl was added to the wells of a plate coated with 2 % 
MPBS. Plates were left for 90 minutes at room temperature to allow phage attachment. 
Detection of bound phage antibodies 
After washing three times with PBS containing 0.05% Tween 20 to remove unbound 
phage antibodies, 100 fll of 1: 1000 dilution of monoclonal anti-M13-HRP antibody 
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(Amersham Phannacia Biotech, UK) in 3% BSA/PBS was added to all wells. Plates were 
then incubated at room temperature for 90 minutes. 
Development 
Wells were washed three times with PBS containing O.OS% Tween 20 and three times 
with PBS to remove unbound antibodies.l 00 ~ll of developer solution (composition as 
described previously) was added to each well. The colorimetric reactions were read at 4S0 
run in an ELISA reader. 
Restriction analysis of clones from round 4 
Thirteen clones showed higher than average activity against K99 antigen in 
monoclonal phage ELISA. These were taken for fmiher analysis. Each was grown in S ml 
of 2xTY containing 1 00 ~g/ml ampicillin, 1% glucose, overnight at 37°C and 200rpm 
shaking. The following day, plasmid DNA was isolated and purified using Qiagen 
miniprep reagents according the manufacturer's instructions. The purified DNA was 
digested with restriction enzymes of Neal and NotI, as described previously for analysis of 
the secondary stock of the Griffin.l library. 1 0 ~l of the digestion products were 
electrophoresed on a 1 % agarose gel for 45 min at 100 V, stained with ethidium bromide, 
and photographed under UV light. 
Production of soluble scFv fragments 
Four clones from round four of selection that had full-length scFv inserts and one 
clone that had a smaller insert size, were taken forward to production of soluble scFv 
antibodies. Selection took place with the phagemids in E. coli TG 1 cell because of its 
ability to suppress translational termination at the TAG codon lying between the scFv and 
gIn sequences. For scFv expression, the chosen phage were infected into the non-
suppressing E. coli strain HB2151 (K12 ara !J(lac-proAB) ThilF'proA+B laclq lacZ!JMJ5). 
To achieve this transfer, a colony (TG 1) of each sample was picked from TYE plates and 
grown in S ml of 2xTY overnight at 37°C with shaking at 200 rpm. The following day, 
500 ~l of culture was added to 50 ml of2xTY media and was grown at 37°C with shaking 
until the OD at 600 11111 was about O.S. VCS-MI3 helper phage was then added to the 
cultures at the appropriate ratio (see above). The cultures were then incubated at 30°C and 
were then spun at 3300g for 10 minutes. The pellets were resuspended in SO ml of 2xTY 
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containing 100 Ilg/ml ampicillin and 50 Ilg/ml kanamycin. Cells were grown overnight at 
30 DC with shaking at 200 rpm to allow replication and rescue of the phage antibodies. The 
next day, the cultures were centrifuged at 3300g for 10 minutes. Samples from each 
supernatant (50 Ill) were then used for infection of exponentially growing E. coli HB 1251 
cells (1 ml), prepared to an OD 600 nm of about 0.5. The cultures were incubated at 37 DC 
water bath for 30 minutes to allow for infection. Then 50 ~Ll, 50 III of a 1: 102 dilution, 50 
III of a 1: 1 04 dilution and 50 III of a 1: 106 dilution of infected bacteria were plated onto 
TYE plates containing 100 Ilg/ml ampicillin, 1 % glucose. Plates were then incubated 
overnight at 30 DC. The following day, one colony of each sample was grown in 5 ml of 
2xTY overnight at 37 DC with shaking at 200 rpm. 500 III of overnight cultures were then 
were grown in 50 ml of 2xTY containing 1 00 ~lg/ml ampicillin and 0.1 % glucose to an OD 
approximately 0.9 at 600 nm. At this point, IPTG (Isopropyl-~-D-thiogalactopyranoside) 
was added to each culture to a final concentration of ImM of IPTG to induce expression. 
The cultures were incubated for a further 21 hI'S at 30 DC with shaking to allow expression 
of soluble scFv antibodies. 
50S-PAGE analysis 
After growing selected clones for expression of soluble scFv fragments, the cultures 
were centrifuged at 5000g for 20 minutes. The culture supernatants were then filtered 
through a 0.45 ~lm filter and concentrated about 30-fold using an Amicon Ultra-4 
centrifugal filter (Millipore, UK). Samples were boiled for 5 minutes in a reducing sample 
buffer for analysis on 12 % discontinuous SDS- polyacrylamide gels (Laemmli, 1970). 
After rumling the gels in a BioRad apparatus at 200 volts for 1 hI', one gel was stained with 
Coomassie brilliant blue stain and another gel was used for Western blotting. 
Western blotting 
Proteins were transferred from the gel to nitrocellulose membrane using a standard 
protocol for blotting (Sambrook et al., 1989). After transfer, the membrane was washed 
three times with PBS and was blocked with 3% MPBS for 1 hI' at room temperature with 
shaking. The membrane was washed three times with PBS and was incubated in a 1 :200 
dilution of anti-c-myc polyclonal antibody (Sigma, UK) in 2 % MPBS for 1.5 hr at 37 DC 
with shaking at 200 rpm. After washing the membrane three times with PBS containing 
0.05 % Tween 20 and three times with PBS, a goat anti-rabbit-HRP conjugate (Sigma, 
UK) was added at 1:1000 dilution in 2 % MPBS and incubated for 1.5 hI' at 37 DC with 
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shaking. The membrane was washed as before and 4-chloro-1-naphthol substrate (Sigma, 
UK) added. 
Recloning into plMS147 
In an attempt to increase the expression level of soluble scFv fragments and provide 
better detection, the scFv antibody sequences from a number of clones were transferred 
into pIMS 147 (Figure 3.3) (Schafer et al., 1999). This places expression of the construct 
under the control of the strong, synthetic tac promoter, retaining induction with IPTG. It 
also fuses the scFv gene with sequence encoding a human C K domain to form a single 
chain antibody or scAb. This provides a larger target than c-myc for immunochemical 
detection. A hexahistidine tail lies at the carboxy-terminus of the translation product 
allowing for purification by nickel chelate affinity chromatography. Finally, the vector 
provides for co-expression of the Skp periplasmic chaperone to assist folding of the 
exported product. The antibody expression vector plMS 147 was maintained in E. coli XL-
I Blue (Stratagene) (Strachan et a!., 2002). 
Preparation of the scFv fragments and plMS147 vector 
Digestion of selected clones 
Plasmid DNA was prepared from five clones chosen from round 4 of selection. DNA 
was isolated and purified using Qiagen miniprep reagents. Purified plasmids were then 
digested using the restriction enzymes Neal and Natl to isolate the scFv inserts. 150 J.lI 
reaction mixtures were set up for each sample comprising 120 J.lI of plasmid DNA, 4 J.lI 
(40U) of Neal (Promega, UK), 4J.lI (40U) of Not! (Promega, UK), 55 J.lI of distilled water, 
1.5 J.lI of BSA and 15 J.lI of buffer D (60 mM Tris-HCL (pH 7.9), 1.5 M NaCI, 60 mM 
MgCh and 10 mM DTT). The reaction mixtures were incubated at 37°C for 1.5 hrs. Each 
entire reaction was run on a 1 % agarose gel at 100 volts for 45 minutes were stained with 
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Digestion of plMS147 vector 
E. coli strain XL-l Blue carrying plMS147 was grown overnight in 25 ml ofLB broth 
(Tryptone, 109; Yeast extract, 5 g; N aCl, 109; Distilled water up to 1 litre) containing 100 
flg/ml ampicillin and 1% glucose at 37°C and 200 rpm shaking. The following day, 
plasmid DNA was extracted and purified using Qiagen miniprep reagents. Purified plasmid 
DNA was then digested using the restriction enzymes Ncol and Notl to prepare the vector 
for ligation. Details of the reaction mixture, incubation time and extraction of vector 
fragment were as described above. 
Purification of inserts and vector 
DNA was isolated from the gel slices usmg QlAQuick@ Gel extraction reagents 
following the instructions provided. To increase the concentrations of DNA, elution from 
the filter units was with only 15 fll of distilled water. The concentrations of the purified 
fragments was estimated by running 5 ~ll samples of each on an agarose gel. 
Cloning of scFv antibody fragments into plMS147 
To ligate the scFv antibody fragments into plMS 147, 20 fll ligation reactions were set 
up containing 2 fll of vector, 5 ~tl of insert (this ensured approximately equal molar 
concentrations of vector and insert), 2 fll of T4 DNA ligase (Promega) at 3 units/fll and 2 
fll of lOx buffer (300mM Tris-HCl pH7.8, 100mM MgCb,100mM DTT and 10mM ATP) 
and 9 fll of distilled water. Reactions were then incubated at 16°C for about 18 hrs. 
Transformation of ligation products 
E. coli XL-I-Blue super competent cells (Stratagene) were used for transformation. 
After thawing the cells on ice from -80°C, 0.85 fll of 1.42 M ~-mercaptoethanol provided 
by the manufacturer was added to each 50 fll aliquot of cells giving a final concentration of 
25 mM. Cells were kept on ice for 10 minutes before adding 5 fll of each ligation reaction. 
They were then incubated on ice for a further 30 minutes. Transformation with 0.1 ng of 
pUC 18 plasmid (provided with the cells) was used to estimate transformation efficiency. 
After 30 minutes incubation on ice, the cells were heat shocked by transferring to a water 
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bath at 42 DC for 45 second, then returned to ice for 2 minutes before addition of 950 /-tl of 
SOC medium (Tryptone 20 g; Yeast extract 5 g; NaCl 0.5 g; Distilled water up to 980 ml; 
after outoclaving, lO ml of 1 M MgCh and 10 ml of 1 M MgS04 added). The cultures were 
incubated at 37 DC with shaking for 1 hour and then lOO /-tl of each was plated on LA 
(Tryptone, 109 ; Yeast extract, 5 g; NaCl, 109; Agar 6 g, Distilled water up to 1 litre) 
containing lOO /-tg/ml ampicillin and 1 % glucose. Plates were incubated at 37 DC overnight 
and next day were checked for the appearance of colonies. 
To confirm that successful ligation had taken place, one colony was picked from 
each transformation plate and was grown in 5 ml of LB broth containinglOO /-tg/ml 
ampicillin and 1 % glucose for overnight at 37 DC and 200 rpm shaking. The following 
day, plasmid DNA was extracted and purified using Qiagen miniprep reagents. Purified 
plasm ids were then digested using the restriction enzymes Neal and Notl to detect the 
presence of inserts. The composition of reaction mixtures, incubation times and analysis 
were as described earlier. 
To fmiher confirm successful ligation, 5 /-tl of each recombinant plasmid was digested 
with EeoRI restriction enzyme to check the size of the linearised plasmid. The lO /-tl 
reaction mixture contained 2 /-tl of EeoRI enzyme, 1 /-tl of lOx buffer, 1 /-tl of distilled water 
and 5 /-tl of plasmid DNA. The entire reaction was then run on 1 % agarose gel at 120 
Volts for 45 minutes, stained with ethidium bromide and photographed under UV light. 
Characterisation of recloned antibodies 
Expression and isolation of soluble secreted scFv fragments 
After confirmation of the presence of scFv inserts, colonies to be characterised were 
grown in 5 ml of LB broth containing 1 00 /-tg/ml ampicillin and 1 % glucose at 37 DC and 
200 rpm shaking overnight. 2 ml of each overnight culture was inoculated into 50 ml of LB 
broth containinglOO /-tg/ml ampicillin and 1 % glucose and grown on at 37 DC with shaking 
at 200 rpm until the OD at 600 nm was 0.8-0.9. At this point, IPTG was added to a final 
concentration of lmM and growth continued overnight at the lower temperature of 30 DC 
with shaking at 200 rpm. The cultures were then centrifuged at 5000g for 20 minutes at 4 
DC. The supernatants were collected and after filtration, were stored at 4 DC. Periplasmic 
extracts were prepared from the bacterial pellets as described by Kipriyanov (Kipriyanov, 
2002)((O'Brien and Aitken, 2002) by gently resuspending to 5 % of the initial culture 
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volume in cold 50 mM Tris-HC1, 20 % sucrose, 1mM EDTA, pH 8.0. The cell suspensions 
were then incubated on ice for 60 minutes with occasional stirring and then were 
centrifuged in microfuge tubes at 25000g for 30 minutes at 4 DC. The supernatants - the 
soluble periplasmic extracts - were carefully collected and filtered through filters with a 
pore size of 0.2 micrometres. Samples were stored at 4 DC for future analysis. 
Western blotting analysis 
The expreSSIOn of scFv fragments was assessed in culture supernatants and 
periplasmic extracts by Western blotting. 20 III of each culture supernatant and periplasmic 
extract and also a positive control scFv were run on a 12% SDS-acrylamide gel and 
transferred to a nitrocellulose membrane as described previously. After blocking with 3 % 
MPBS and washing three times with PBS, the membrane was incubated in a 1 :500 dilution 
of goat anti-human-cK in 2% MPBS at 37 DC for 60 minutes with 200 rpm shaking. After 
that, the membrane was washed three times with PBS containing 0.05% Tween 20. The 
bound antibody was detected using rabbit anti-goat-HRP at a dilution of 1:1000 in 2 % 
MPBS. Finally, the reaction was developed using 4-chloro-N-naphthol substrate. 
Screening by ELISA 
Supernatants from induced cultures of E. coli were applied to ELISA plates coated 
with K99 30 Ilg/ml or a goat anti-human kappa antibody at 1 :500 dilutions. Next day after 
blocking with 3% BSA/PBS, binding of protein was detected by addition ofa goat anti-
human kappa HRP conjugate and OPD substrate. Colour change was recorded 450 nm. 
Soluble scFv-plll fusion proteins 
Since the expression of soluble scFvs from selected clones in E. coli HB2151 was 
unsuccessful and recloning into pIMS 147 vector did not solve the problem, expression of 
these antibodies as scFv-pIlI fusion proteins as described by Mersmann M. et. 
al.(Mersmmm et aI., 1998) was attempted. 
In this method, scFv constructs were translated as fusions to pIlI by inducing 
expression in the suppressor strain E. coli TG 1. This leads to accumulation of the scFv-plIl 
protein in the cytoplasmic membrane from which it can be released with detergents and 
detected with anti-pIlI antibodies(Tesar et aI., 1995). 
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Expression of scFv-plll fusion proteins 
Single colonies of the clones for analysis were grown overnight in 5 ml of 2xTY 
containing 1 00 /-Lg/ml ampicillin and 1 % glucose at 37 DC and 200 rpm shaking. Next day, 
250 /-LI from each culture was added to 25 ml of fresh 2xTY media containing 100 /-Lg/ml 
ampicillin and 1 % glucose. The cultures were grown at 37 DC with shaking until OD at 
600 nm reached about 0.5. The cultures were then spun at 3300g for 10 minutes. The 
supernatants were discarded and the pellets were resuspended in 25 ml of fresh 2xTY 
containing 100 /-Lg/ml ampicillin (without glucose) and 1 mM IPTG (Kipriyanov et al., 
1997). Then, cultures were incubated at 30 DC for 20 hours. To extract proteins from the 
cells, cultures were centrifuged at 5200g for 20 minutes and the pellets were resuspended 
in 1.6 ml of Bugbuster protein extraction reagent (Novagen, UK) containing 1.5 /-LI of 
RNAase. The suspensions were left shaking at 30 DC for 30 minutes and then were spun at 
20,000g for 40 minutes at 4 DC. The supernatants predicted to contain the extracted scFv-
pIlI fusion proteins were collected and concentrated to 1/3 their initial volumes for use in 
ELISA and Western blotting. 
Detection scFv-plll fusion proteins by Western blotting 
The concentrated Bugbuster extracts were run on 8 % SDS-polyacrylamide gels and 
transferred to a nitrocellulose membrane as described earlier. The membrane was blocked 
with 5 % MPBS at room temperature and after washing three times with PBS containing 
0.05 % Tween 20, the membrane was incubated in a 1:1000 dilution of monoclonal anti-
pIlI antibody (Mo Bi Tec, Germany) in blocking buffer at 37 DC for 90 minutes. Next, the 
membrane was washed and a I: 1 000 dilution of an HRP-conjugated anti-mouse antibody 
was added for a further 90 minutes. After washing, the reaction was developed with 4-
chloro-I-naphthol substrate. 
ELISA assay of scFv-plll recognition of K99 
Wells of one row of an ELISA plate were coated overnight at 4 DC with 100 /-LI of K99 
at 100 /-Lg/ml. A second row was coated with 100 /-LI of 2 % MPBS as a negative control. 
The coated wells were washed three times with PBS and blocked with 200 /-LI of 3 % 
BSAIPBS for 2 hours at 37 DC. After washing, 100 /-LI of Bugbuster extracts, diluted 2:3 in 
blocking buffer, were added to designated wells. The plate was then incubated for 60 
minutes at 37 DC and then washed three times with PBS containing 0.05 % Tween 20. To 
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detect bound scFv-pIIls, 100 III of a 1: 1 000 dilution of monoclonal anti-pIlI antibody was 
added and plate was left for 90 minutes at room temperature. Next, the plate was washed 
and 100 III of a 1: 1 000 dilution of HRP anti-mouse antibody was added to each well After 
incubating for 90 minutes at room temperature, the plate was washed and developed using 
OPD substrate. The reaction was measured at 450 nm after 10 minutes. 
Sequencing of clones from round 4 
Individual colonies were grown in 5 ml of 2xTY containing 100 Ilg/ml ampicillin and 
1 % glucose overnight at 37 DC with shaking. Plasmid DNA was isolated from 3 ml of 
culture using Qiagen miniprep reagents. The primers pelB and gIll were chosen for 
sequencing. Each was diluted to 3.2 IlM. Sequencing was done at the MBSU, University of 
Glasgow using Big Dye (Applied Biosystems) and ET-Dye Terminator (Amersham 
Bioscience) chemistries. Samples were analysed on a MegaBACE1000 (96 capillary) 
sequencing machine. The reaction chemistry is based on the dideoxy method developed by 
Sanger (Sanger et at., 1977). The sequence data was analysed using DNA Star software. 
Sequences were aligned to V BASE using DNAPLOT database at the Centre for Protein 
Engineering, MRC, Cambridge, UK (www.mrc-cpe.cam.ac.uk/vbase-ok.php?menu=901 ). The 
confirmed nucleic acid sequences were translated and aligned using MEGALIGN 
software. Since clone E4 had an unexpected sequence, matches on the GenBank database 
were sought by BLAST (http://www.ncbi.nlm.nih.gov/BLAST/). 
Screening of additional clones from rounds 3 and 4 of selection 
The outcome of analysis forced the screening of additional clones from round 4 of 
selection. Purified DNA was prepared from overnight cultures as previously described and 
full-length inserts sought by PCR with primers LMB3 and gIll. An anti-thyroglobulin scFv 
construct was used as a positive control. For the expression of soluble scFv proteins, 
purified DNA was introduced into E. coli HB2151 made competent for transformation 
(Chung and Miller, 1988). Briefly, 500 III ofa overnight culture ofHB2151 was added to 
50 ml of 2xTY at 37 DC and grown with shaking at 200 rpm until the OD at 600 nm 
reached 0.3-0.4. The culture was centrifuged at 1000g for 10 minutes at 4 DC. The pellet 
was then resuspended in 5 ml of an ice-cold solution containing 10 mM MgCb, 10 mM 
MgS04, 10 % PEG and 5 % DMSO (Sigma) and was incubated on ice for 10 minutes. 
After that 1 III of a 1 in 10 dilution of each plasmid was added to 100 III of competent 
cells. The plasmids were transferred to cells during fifteen minutes incubation on ice. The 
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bacteria were grown in 900 fll ofLB broth for 1 hour at 37 DC and 200 rpm shaking before 
plating 30 fll of each culture onto LB agar plates containing 100 flg/ml ampicillin. Plates 
were incubated overnight at 37 DC. 
Single transformants were then grown and expression of soluble scFv induced with 
IPTG as described earlier. Concentrated culture supernatants were analysed by ELISA and 
Western blotting for recognition of K99 and the presence of scFv protein. These analyses 
were carried out with anti-c-myc reagents. Sequencing of scFv inserts was carried out as 
described earlier. 
Large scale screening for scFv expression 
Three different capture protocols were tested with a culture supernatant known to 
contain an anti-thyroglobulin scFv. In group A, wells of an ELISA plate were coated with 
a rabbit polyclonal anti-c-myc antibody at a dilution of 1 :200 dilutions in PBS. For group 
B, the coating was a 1 :500 dilution of a mouse monoclonal anti-c-myc in PBS. For group 
C, wells were coated with recombinant protein L (rProtein LTM from Peptostreptococcus 
magnus binds immunoglobulins (Ig) primarily through the K light chain without interfering 
with the antigen binding site. Specifically it has been shown to bind strongly to human K 
light chain subclasses I, III, and IV and to some K chains from other species such as rat and 
mouse) at a concentration of 1 ~Lg/ml. As negative controls, for each group, two wells were 
coated only with PBS. Coating was done by incubation overnight at 4 DC. After the wells 
had been washed three times with PBS, the plastic was blocked by addition of 200 fll of 
3% BSAIPBS and incubation for 2 hours at 37 DC. After that, the wells were washed three 
times with PBS and 100 fll of unconcentrated culture supernatant containing the anti-
thyroglobulin scFv was added to half of the prepared wells; to the other half, 100 fll of 
PBS was added to serve as a negative control, testing for cross-reactions between capture 
and detection layers in the assay. The ELISA plate was then incubated for 90 minutes at 37 
DC. After washing three times with PBS containing 0.05 % Tween 20, bound scFvs were 
detected as follows. To wells in group A, a 1 :1000 dilution of mouse monoclonal anti-c-
myc antibody was added. Groups Band C received a 1 :500 dilution of rabbit polyclonal 
anti-c-myc. The plate was incubated for further 90 minutes at 37 DC. Finally, wells were 
washed and were incubated for 1 hour at 37 DC with a 1:1000 dilution of anti-mouse-HRP 
(group A) or goat anti-rabbit-HRP (groups B and C). The wells, after washing, were 
developed using OPD substrate and the reaction was measured after 10 minutes at 450 nm. 
The format of this ELISA experiment is illustrated in Figure 3.4. 
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To assess the expression of scFv fragments, the clones to be tested (typically 94 
picked from the original Griffin.1 library or a round of selection, along with an anti-
thyroglobulin positive control) were grown in microtitre plates to aid the analysis of large 
numbers. For secondary stocks of the Griffin.1 library, phage antibodies were prepared 
from E. coli TG 1 stocks by superinfection as described earlier. These were used to infect 
E. coli HB2151 and clones transduced to ampicillin resistance were picked into microtitre 
plates for analysis (see below). Phage eluted at rounds 3 and 4 of selection against K99 
were infected into E. coli TG 1 to determine phage recoveries. These clones were carried 
forward individually to produce phage for infection of E. coli HB2151 and then analysis 
for scFv expression. This was carried out as follows. E. coli TG 1 carrying the phagemids 
were picked and grown at 37°C in the wells of microtitre plates containing 100 III of 
2xTY, lOOllg/ml ampicillin and 1 % glucose. Plates were shaken at 200 rpm. The 
following day, 2 III of each overnight culture was transferred to a fresh plate with wells 
containing 200 III of 2xTY containinglOOllg/ml ampicillin and 1 % glucose. The plates 
were shaken at 37°C for 1.5 hrs to reach an OD 600 nm of about 0.4. Then 25 III of 2xTY 
containing 100 Ilg/ml ampicillin, 1 % glucose and 10 9 pfu helper phage (final 
concentration) was added to each well to allow superinfection. Plates were left to stand at 
37°C for 30 minutes and then shaken at 200 rpm for a further 1 hour at 37 °c. The plates 
were centrifuged in a Sigma centrifuge fitted with plate carriers at 1800g for 10 minutes 
and the supernatants were aspirated off. Each pellet was resuspended in 200 III of 2xTY 
containing 100 Ilg/ml ampicillin and 50 Ilg/ml kanamycin. Cells were grown overnight at 
30°C with shaking at 200 rpm to allow replication and rescue of the phage antibodies. The 
next day, plates were spun at 1800g for 10 minutes. The culture supernatants were used as 
monoclonal phage antibodies. 
To express soluble scFv antibodies in HB2151 cells, 0.5 ml of an overnight culture of 
HB2151 cell was grown in 50 ml of 2xTY until OD at 600nm reached about 0.5. 200 III 
aliquots were dispensed to the wells of a microtitre plate. Then 10 III of each phage 
antibody was added an held for 30 minutes at 37°C without shaking to allow infection to 
take place. The infected bacteria were then allowed to grow overnight at the same 
temperature with 200 rpm shaking. Next day, using a multi-channel pipette, about 2 III 
samples from these wells were transferred to a further microtitre plate containing 200 III of 
2xTY, 100 Ilg/ml ampicillin and 0.1 % glucose per well. The cultures were grown at 37°C, 
shaking until OD at 600 nm was approximately 0.9.25 III of 2xTY containing 100 Ilg/ml 
ampicillin and 9 mM IPTG was added and growth continued at 30°C for a further 20 
hours. At the same day, ELISA plates were prepared to the optimal capture format as 
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Figure 3.4 Three formats for a capture ELISA for detection of scFv 
Group A: wells of an ELISA plate were coated with polyclonal anti-c-myc 
Group B: wells of an ELISA plate were coated with monoclonal anti-c-myc 
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Group C: wells of an ELISA plate were coated with recombinant protein L 
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determined by the experiments described earlier. The plates containing bacterial cultures 
were centrifuged at 1800g for 10 minutes at 4°C and 100 /-Ll samples of the supernatants 
were used for ELISA. As a negative control, a culture supernatant from E. coli HB2151 
without the pHEN2 plasmid was added. 
Western blotting 
F or independent confirmation of the expression of soluble scFv fragments, E. coli 
HB2151 clones and an anti-thyroglobulin positive control were grown and induced by 
addition of IPTG. Culture supernatants were concentrated about 20 times and after running 
on SDS-PAGE, transferred to nitrocellulose membranes. The membranes were then 
blocked and probed with anti-c-myc reagents and a diaminobenzidine substrate (Harlow 
and Lane, 1988) comprising 6 mg of diaminobenzidine (Sigma) in 10 ml of 50 mM Tris 
(pH 7.6). Before application, 10 /-Ll of 30 % H20 2 was added. The membranes were 
incubated in this solution at room temperature for about 20 minutes. 
To enhance the sensitivity of this reaction, membranes were washed with PBS three 
times and then developed with a chemiluminescent substrate (Dunbar, 1994). Briefly, two 
detection reagents were prepared. ECL reagents A contained 1 ml of luminol solution 
(0.8858g 5-amino-2,3-dihydro-1,4 phethalazine in 20 ml of DMSO) 0.44 ml of a p-
coumeric acid solution (0.2956g coumeric acid in 20 ml ofDMSO) and 10 ml of 1M Tris, 
pH 8.5. ECL reagents B comprised 10 ml of 1 M Tris pH 8.5 and 64 /-Ll of 30 % H202. 
Equal volumes of A and B reagents were mixed to give sufficient working solution (125 /-Ll 
for each cm2 of membrane). Membranes were allowed to drain briefly and were placed 
between two plastic sheets. The mixture of solutions A and B was added to membranes just 
prior to development. After 1 minute incubation, blots were placed into an X-ray cassette 
against a sheet of X-ray film, the protein-coated side facing the film, was put onto two 
blots and left to expose for 30 second. Next, the x-ray film was removed and was 
developed in an automatic film processor. 
ELISA 
ELISA was used to compare the activity of polyclonal phage isolated from the 
secondary stock of library with scFv isolated from the same source. The assay was 
conducted against purified K99 fimbriae and 2 % MPBS using variations to ELISA 
methods described earlier. 
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Wells of an ELISA plate were coated with 100 III of purified K99 at 90 Ilg/ml and 2 % 
MPBS. To capture phage antibodies or soluble scFv fragments, wells were also coated 
with a 1: 1 000 dilution of monoclonal anti-c-myc. The plate was incubated overnight at 4 
°c then washed three times with PBS and blocked with 200 III of 3 % BSAlPBS for two 
hours at 37°C. 
After washing wells three times with PBS, 100 III of a 115 dilution of phage rescued 
from the secondary stock of library was added to half the coated wells. To the remaining 
coated wells, 100 III of supernatant was added, taken from an induced culture of HB2151 
infected with phage rescued from secondary stock of library. The plate was incubated for 
90 minutes at 37°C. 
All wells were washed three times with PBST (0.05 %) and three times with PBS. To 
detect bound phage, 100 III of a 1:1000 dilution of monoclonal anti-M13-HRP was 
dispensed to those wells to which the phage antibodies had been added. To wells 
previously incubated with scFv, 100 III of a 1 :500 dilution of polyclonal anti-c-myc was 
added for 60 minutes at 37°C, followed by 100 III ofa 1:1000 dilution ofanti-rabbit-HRP. 
Reactions were developed with OPD substrate as described earlier. 
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Results 
peR screening of the Griffin. 1 library for full-length scFv genes 
Twenty colonies were picked at random from the secondary stock of the Griffin.1 
library. Crude lysates were prepared and screened by PCR using primers LMB3 and gIll 
for the presence of full-length scFv inserts. The products were analysed by agarose gel 
electrophoresis. This showed that less than 1/3 of the colonies had full-length inserts 
comprising VH, linker and VL sequences (Figure 3.5). No products were recovered from 
three clones, and for others, PCR indicated that only the V H or the V L fragments were 
present. Overall, the results indicate the possibility that phage might be amplified from the 
library carrying only V H or V L components during selection for anti-K99 antibodies. 
Restriction analysis of plasm ids from the Griffin. 1 library 
Plasmid DNA was isolated from 12 colonies picked at random from a secondary stock 
of the Griffin.1 library. Samples were digested with the restriction enzymes Ncol and Notl 
and analysed on an agarose gel. Since sites for these enzymes lie at the 5' terminus of the 
VH (Ncol) and the 3' terminus of the VL (Notl) sequences, the size of the released fragment 
can be used to confirm the presence of full-length insert. The results showed 1/3 of 
plasmids contained full-length inserts of approximately 720 bp. Other plasmids were not 
cut by both enzymes suggesting the absence of one or other of the scFv components (data 
not shown). 
Phage library preparation and titration 
The Griffin.1 library was supplied in E. coli TG 1. A stock was grown and infected 
with VCS-M13 helper phage, thereby amplifying and releasing to the culture supernatant 
phage displaying scFvs. These phage antibodies were isolated by precipitation with 
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Crude lysates were prepared from 20 colonies picked from the library. Amplicons 
generated with primers LMB3 and gIIl were analysed by agarose gel electrophoresis. 
Clone numbers are indicated at the top of each photograph. PCR of lysate from an anti-
thyroglobulin scFv (control) confirmed the size of a full-length scFv insert (indicated). M 
indicates the migration of a 1 kb DNA ladder (Invitrogen, UK). The migration of markers 
of 1.016 bp and 506 bp are indicated. 
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PEGlNaCl and resuspended in PBS. Phage numbers were assessed by preparing serial 
dilutions of the phage stock, infecting E. coli TG 1 and plating to TYE containing 
ampicillin. The resulting titration showed the phage titre to be 2.6x 1 013 pfu/ml, sufficient 
for panning the library for the selection of anti-K99 scFvs. 
Panning the Griffin. 1 library against purified K99 
Data supplied with the Griffin. 1 library indicated that it contained about 1 x 10 9 unique 
scFvs. Phage antibodies against K99 fimbriae were isolated through four rounds of 
conventional panning using immunotubes coated with the purified K99 target at 90 )lg/ml 
in round 1 and 30)lg/ml in rounds 2, 3 and 4. The number of phage added to the 
immunotube and the number recovered at elution was determined for each round of 
selection by infecting TG 1 cells with serial dilutions. Table 3.1 shows this input and output 
data and also the percentage of phage recovered after each round of selection. The results 
show that the percentage of phage recovered increased slightly in the second round of 
selection over that recorded for round one. A sharp rise was noted from round two to round 
three. This was taken to indicate that phage carrying antibodies specific for K99 were 
isolated and enriched by panning. In the fourth round, the titre of output phage decreased. 
Screening phage antibodies by monoclonal phage ELISA 
Ninety-six colonies were picked from TYE titration plates after each round of 
selection. After superinfection with helper phage, the clones were analysed by monoclonal 
phage ELISA to determine the frequency with which they reacted with purified K99. The 
phage antibodies were also screened on ELISA plates that were coated with 2% MPBS, the 
blocking buffer used in selection, to check for the specificity of any reaction with K99. The 
results of analysis with K99 coated plates is shown in Figure 3.6. As the Figure shows, the 
number of clones that recognised K99 increased through rounds of selection and at round 
4, all clones showed a marked recognition of the fimbriae. The results of screening against 
a coating of skimmed milk indicated that some clones that reacted with K99 fimbriae also 
bound to milk proteins. This was observed most commonly amongst clones isolated from 
rounds 2 and round 3 but not from round 4 (data not shown). 
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Table 3.1 Phage titres obtained during selection of anti-K99 antibodies from the Griffin.1 
library 
Phage titre (CFU/ml) 
Selection Inpue Outputa % recoverl 
Round 
1 1 x 10 13 3.9x 10 4 3.9xl0-7 
2 3.2xlO13 SAx 10 4 2.6xl0 -7 
3 2Ax 10 14 4.7x 10 9 l.9xl0 -3 
4 5.3xlO14 5.6x10 5 l.Oxl0 -7 
a Input and output phage titres were determined by transduction of E.coli to ampicillin 
resistance using serial dilutions of sample 
b Percentage recovery was determined by division of the output phage titre by the input 
titre, and multiplication by 100 
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Figure 3.6 Monoclonal phage ELISA against K99 
Ninety six clones picked at random after each round of selection (as indicated) were 
superinfected with helper phage to generate monoclonal phage antibodies. The phage were 
then applied to ELISA plates coated with K99 and binding detected with anti-M13 
reagents and OPD substrate. Final ODs were measured at 450 nm (data not shown) and 
images of plates were captured. 
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Plasmid analysis of clones from round 4 
Given the apparent high frequency of recognition of the K99 target amongst clones 
recovered from round 4, plasmid DNA was isolated from 13 clones for further analysis. 
Clones were chosen because they showed the strongest signals in ELISA against K99. To 
test for the presence of full-length insert, plasmid DNA was digested with the restriction 
enzymes NcoI and NotI. Recognition sites for these enzymes are located at the 5' and 3' 
termini of the scFv sequence in the pHEN2 vector in which the Griffin.1 library was 
constructed (Figure 3.1). 
The digestion products were analysed by agarose gel electrophoresis (Figure 3.7), it 
being predicted that release of a DNA fragment of about 720 bp would indicate the 
presence of full-length scFv insert. The results showed that only 4 clones of the 13 chosen 
were likely to carry a full-length insert. Based upon this result, clones E1, E7, CS, G6 were 
taken forward to further analysis with clone E4 was chosen because release of a small 
DNA fragment suggested the presence of a V H or V L component. 
Production of soluble scFv proteins 
After choosing five clones from round 4 of selection, E. coli HB2151 cells were 
infected with phage to allow expression of soluble scFv fragments. The infected cells were 
grown on TYE plates and one colony from each plate was transferred to liquid culture and 
induced with IPTG. The culture supernatants were then isolated and tested for the presence 
of scFv fragments by SDS-P AGE analysis and Western blotting using polyclonal anti-c-
myc antibody. SDS-PAGE analysis of the concentrated culture supernatants (Figure 3.S) 
showed some evidence of proteins of the size predicted for a scFv (30 kDa; clones G6 and 
CS). Induction of clone E1 with IPTG consistently resulted in the release of a large number 
of proteins to the culture supernatant suggesting that partial lysis of the bacteria was 
triggered. It was hoped that Western blotting would provide confirmation of the presence 
of scFv products but no signal could be detected around 30 kDa (Figure 3.9). For clone Ei, 
a component of the culture supernatant appeared to react with the anti-c-myc reagents, but 
its size was higher than expected. Despite extensive investigation of culture and induction 
conditions (temperature, IPTG concentration, addition of sucrose (Kipriyanov, 2002),) the 
overall conclusion was that soluble anti-K99 scFvs could not be expressed from the clones 
chosen for investigation. 
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Recloning into plMS147 
Some investigators have reported that expression of scFvs as fusion proteins with an 
attached human kappa constant domain can stabilise the products and enable easy and 
sensitive detection with anti-kappa reagents. The vector pIMS 147 has been designed to 
create these fusions with scFv sequences recovered from phage display vectors (Strachan 
et al. J 2002). The scFv sequences were recovered as NcoI I NotI fragments from clones 
picked from round 4 of selection and ligated into pIMS 147 prepared with the same 
restriction enzymes. Ligation products were transformed into E. coli. Without a scFv 
insert, the predicted size of the pIMS 147 vector is 5988 bp. Hence the migration of 
linearised plasmid DNA at around 7 kb showed that the scFv sequences had been 
successfully ligated into the new vector (Figure 3.10A). Since pIMS147 and the pHEN2 
phage display vector differ significantly in size (Figure 3.10B), the data exclude the 
possibility that religation of the original constructs had taken place. 
The recloned scFvs were transformed into E. coli XL 1 Blue competent cells and after 
growing, expression was induced with IPTG. Although the presence of recombinant 
protein could be confirmed by capture via the human kappa domain and detection of the 
same component, culture supernatants showed no significant activity against K99 (Figure 
3.11). 









Clones were taken from the fourth round of selection against K99. They were chosen for 
their high apparent reaction against K99 in monoclonal phage ELISA. Plasmid DNA was 
isolated from each clone, digested by the restriction enzymes NcoI and Not I and analysed 
by agarose gel electrophoresis. The expected size of fragment released from a full-length 
scFv insert (about 720 bp) is indicated on the right. The migration of the vector fragment is 
also shown. Clone designations are shown at the top of the figure, M loading of a 1 kb 
DNA ladder (Invitrogen). The migration of markers of 506 bp, 1,016 bp and 5,090 bp are 
indicated on the left of the figure. 




Figure 3.8 SDS-PAGE analysis for the presence of scFvs in concentrated culture 
supernatants 
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Supernatants from induced cultures of E. coli HB2l5l were concentrated about 30-fold 
and analysed on SDS polyacryamide gels. The image from a Coomassie Blue stained gel is 
shown. M indicates the loading of Rainbow protein molecular weight marker (Pharmacia). 
The migration of standards of 45, 30 and 20.1 kDa is indicated. Clone designations are 
shown at the top of the figure. The expected size for a soluble scFv is about 30 kDa. 




Figure 3.9 Western blotting of concentrated culture supernatants of selected clones after 
atempting to express soluble scFv fragments with HB2151 E coli strain 
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Supernatants from induced cultures of E. coli HB2l5l were concentrated about 3D-fold 
and analysed on SDS polyacryamide gels. Proteins were transferred to nitrocellulose and 
probed with anti-c-myc reagents and diamino benzidine substrate before image capture. M 
indicates the loading of Rainbow protein molecular weight marker (Pharmacia). The 
migration of standards of 45, 30 and 20. 1 kDa is indicated. Clone designations are shown 
at the top of the figure. The expected size for a soluble scFv is about 30 kDa. 
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Figure 3.10 Restriction analysis of recornbinant plMS147 containing anti-K99 scFvs 
Plasmid DNA was isolated from transformed E. coli, linearised by digestion with EcoRI 
and analysed on agarose gels. Panel A: recloning of scFv sequences from clones E1, E4, 
E7, C8 and G6 into pIMS147. Clone designations are shown at the top, M indicating 
loading of a 1 kb ladder to the gel. The migration of markers of 1,636 bp and 6,1 08 bp is 
indicated. Panel B: analysis of clone E 1 in the original pHEN2 phage display vector. The 
migration of markers of 1,636 and 5,090 bp is indicated. 
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Figure 3.11 Expression of scFv fusion proteins in plMS147 
Supernatants from induced cultures of E. coli were applied to ELISA plates coated with 
K99 (Pink) or a goat anti-human kappa antibody (yellow). Binding of protein was detected 
by addition of a goat anti-human kappa HRP conjugate and OPD substrate. Colour change 
was recorded at450 nm. 
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Expression scFv-plll fusion proteins 
Given the failure to confirm the anti-K99 specificity of clones from round 4 by 
expression of soluble scFv fragments or kappa fusion proteins, the expression of scFv-pIII 
fusion proteins was attempted as an alternative strategy. 
In the pHEN2 vector, an amber stop codon lies between the scFv coding sequence and 
the phage gIll gene. Conventionally, suppressor strains of E. coli such as TG 1 are used for 
the propagation of phage that bear phagemid-encoded scFvs fused to the viral minor coat 
protein, pIlI. The constructs are transferred to non-suppressor strains such as HB2151 for 
expression of the scFv in its soluble form. Detection of the recombinant antibody then 
depends upon use of peptide tags at the carboxy-terminus of the scFv (e.g. histidine repeats 
or the c-myc epitope). Expression of phagemids in suppressor strains triggers synthesis of 
the scFv-plII fusion which in the absence of superinfecting helper phage, accumulates in 
the bacterial membrane. If liberated from this location with detergent, the attached pIlI 
sequence provides a tag which is readily detectable with anti-pIlI reagents (Mersmann et 
at., 1998). The expression of candidate anti-K99 scFv-pIII proteins was assessed by 
Western blotting and the activity of these proteins against K99 antigen was tested by 
ELISA. 
In preliminary experiments, the expression of scFv-plII fusion proteins was tested for 
clones E1 and G6 and their detection with an anti-pIlI monoclonal antibody was confirmed 
(data not shown). The clones chosen from round four of selection (see above) grown in E. 
coli TG 1, induced with IPTG and the cells collected by centrifugation. The cell pellets 
were lysed by resuspension in Bugbuster reagent and extracts were run on an 8 % SDS-
polyacrylamide gel. The proteins were then transferred to a nitrocellulose membrane and 
the presence of scFv-pIlI fusion proteins was detected using a mouse monoclonal anti-pIlI 
antibody and anti-mouse-HRP reagents. The Western blotting result (Figure 3.12) 
demonstrated that a scFv-plII fusion protein of about 80 kDa size was expressed in all 
clones. A second protein present in the samples and reactive with the anti-pIlI antibodies 
was of a size (approximately 60 kDa) consistent with that of the wild type pIlI. This result 
is as reported by others (Mersmann e! at., 1998). Since the TG 1 clones carry only the 
recombinant phagemid, the appearance of wild type pIlI most likely arises through the 
proteolytic cleavage of the scFv from the pIlI fusion. 
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For ELISA experiment, the wells of a microtitre plate were first coated with purified 
K99 or 2 % MPBS. The bacteriallysates prepared with Bugbuster reagent and confirmed 
to contain pIlI fusion proteins, were added and the binding of scFv- pIlI proteins to either 
target was detected with monoclonal anti-pIlI and anti-mouse-HRP reagents. The 
experiment showed that scFv-plII fusion proteins from each of the clones bound to milk 
proteins to a low but detectable level. However, binding to K99 fimbriae generated signal 
that was at least 5-fold higher (Figure 3.13). 
Clones chosen from round 4 of selection were sequenced. DNA and ammo acid 
sequence results of 5 selected clones from round four were analysed by DNAstar software 
and VBASE database. The analysis of heavy chain sequences showed clones El, E7 and 
C8 were related to VHl family and elone 06 to the VH3 family (Figure3.14). Clones El 
and C8 had very similar sequence in their CDRs and there was a stop codon in the same 
position in both CRD3. CDR3 sequence of Clone E7 was completely different from the 
others. For clone E4 no VH component was recognized by comparison with VBASE 
database. 
The V L sequences revealed that expect for clone E4, other clones had consensus 
sequence of VK subgroup and VL 1 family with high diversity. The clone E4 had a 
truncated VL domain (Figure 3.15). The VBASE database analysis did not show consensus 
sequence of CDR 1 and CDR2 of this clone. 
Further screening of clones from round 4 of selection 
Another 10 clones from the fourth round of panning against K99 were chosen on the 
basis of their high reaction with K99 antigen in monoclonal phage ELISA. These were 
taken forward to PCR analysis for the presence of full-length scFv inserts and for 
expression and analysis of soluble scFv antibodies. 




Figure 3.12 Western blot analysis of expression of scFv-plll fusion proteins 
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ScFv-nIII 
Wild tvne nIII 
Detergent extracts were prepared from induced cells of E. coli TG 1 and separated by SDS-
P AGE. Proteins were transferred to nitrocellulose membrane and probed with an anti-pIlI 
monoclonal antibody and anti-mouse-HRP reagents. The blot was developed with 
chloronaphthol substrate and the image captured. M indicates the loading of Rainbow 
protein molecular weight markers (Pharmacia). The migration of standards of 45, 66 and 
97 kDa is indicated at the left. Clones are as shown at the top of the image. The predicted 
migration of scFv-plIl fusions (80 kDa) and wild-type pIlI (60 kDa) is shown at the right 
of the image. 
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Figure 3.13 Reaction scFv-plll fusion proteins with K99 and milk proteins 
Wells of an ELISA plate were coated with K99 (pink) or skimmed milk (yellow). 
Detergent extracts were prepared from induced cells of E. coli TG 1 and applied to the 
coated surfaces. Binding of the scFv-pIII fusion proteins was detected with an anti-pIlI 
monoclonal antibody and anti-mouse-HRP reagents. The assay was developed with OPD 
substrate and absorbance values at 450 nm measured in a microplate reader. Clones are 
indicated along the x axis of the histogram. 
Clone Subgroup CDRl CDR2 CDR3 
El VHl family GYYMH WINPTSGGTNY AQKFQG CVRNVV.LSE 
E7 VHl family NNFMH WINAGNGNTTY AQKFQG HCARHTWNR 
C8 VHl family GYYMH WINPNSGGTNY AQKFQG CVRNVV.LSE 
G6 VII3 t~lmily GFTFDDYAMH GISWNSGSIGY ADSVKG CERHTQ 
E4 . , .......... ............. , ......................... . ... , .......... 
Figure 3.14 Heavy chain amino acid sequence of five best clones from round 4 of selection 
Clone Subgroup CDRl CDR2 CDR3 
El VL2 family TGTSSDVGDYDHVF NVNTRPS SL YSSSYCSL YSSS 
E7 VKI subgroup RASQGISSYLA WY AASTLQS QQLNSYPACQQLNSYPAA 
C8 VKI subgroup RASQGISSWLA AASSLQS QQANRFPPCQQANRFPPF 
G6 VLl family SGSSSNIGNNA VN YDDLLPS AA WDDSLLCAA WDDSLL 
E4 YKvI subgroup .................. ., ............ HQSSSLPR 
Figure 3.15 Light chain amino acid sequence of five best clones of round 4 of selection 
EIO CI2 G8 D5 G9 M E6 GIO C9 G6 F6 Control 
1.016 bp --
506 bp --




Plasmid DNA was prepared from 10 colonies picked from the fourth round of panning 
against K99 and used as template in PCR with primers LMB3 and gIll. Amplicons were 
analysed by agarose gel electrophoresis. Clone numbers are indicated at the top the 
photograph, "Control" indicating sample from a construct confirmed to carry a full-length 
scFv. M indicates the migration of a 1 kb DNA ladder (Invitrogen, UK). The migration of 
markers of 1.016 bp and 506 bp are indicated. 
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Plasmid DNA was purified from the 10 clones and was peR carried out using the 
primers LMB3 and gIlL Figure 3.16 shows the results of this screening. The Figure 
illustrates that of the 10 samples analysed only three peR products were of a size (about 1 
kb) similar to the positive control and therefore consistent with the presence of a full-
length scFv insert. 
The three clones identified by peR as carrying full-length scFv inserts were carried 
forward to expression and analysis of soluble scFvs. Plasmid DNA was transformed into 
competent HB2151 cells. After growth in liquid culture and induction with IPTG, culture 
supernatants were collected by centrifugation and added to an ELISA plate coated with 
K99 and 2 % MPBS. The binding of scFvs to these target proteins was detected using a 
monoclonal anti-c-myc antibody and anti-mouse-HRP reagents. The resulting 
immunoassay data (Figure 3.17) showed that scFvs from all three clones reacted very 
weakly with K99 fimbriae. The final absorbance values in wells coated with K99 were 
similar to those in wells coated with skimmed milk. 
The culture supernatants used in ELISA were also tested in Western blotting to assess 
if scFvs were present. The results (data not shown) revealed that none of the selected 
clones appeared to express scFv since bands of the predicted molecular weight (about 30 
kDa) were absent. Overall, the analysis suggested that these three clones were unable to 
express scFv antibodies. 
Screening of clones from round 3 of selection 
From the 96 clones originating from round 3 of selection and previously tested in 
monoclonal phage ELISA, 12 were chosen for further characterisation. Of these, 6 showed 
activity against K99 and 6 showed activity against skimmed milk. The selected clones 
were checked for the presence of full-length scFv inserts, the expression of soluble scFv 
antibodies and they were sequenced. 
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Figure 3.17 ELISA analysis of culture supernatants from 3 clones chosen from round 4. 
Supernatants from induced cultures were applied to wells coated with purified K99 (blue) 
or skimmed milk (Pink) and the binding of scFv detected with anti-c-myc antibodies, anti-
mouse HRP conjugate and OPD substrate. The absorbance at 450 nm was recorded (y 
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Figure 3.18 peR screening of clones from round 3 of selection 
Purified plasmid DNA from clones E6, ElO, A2, H7, ClO and Fl (candidate anti-K99 
antibodies), and Cll, B2, G8, Bl, G12 and GIl (candidate anti-milk antibodies) was used 
in PCR with primers LMB3 and gIn. Amplicons were analysed by agarose gel 
electrophoresis and images captured. M shows the loading of a 1 kb DNA ladder 
(Invitrogen, UK). The migration of markers of 506 bp and 1,016 bp is indicated (left) with 
the predicted size of a full-length scFv amplicon (right). Clone designations are shown at 
the top of the photograph. 
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Plasmid DNA was purified from the 12 selected clones and used as template in PCR 
with primers LMB3 and gIlL Figure 3.18 shows that half of the clones chosen appeared 
contain full-length inserts. Interestingly, these were evenly divided between clones chosen 
for their activity against K99 and against skimmed milk. 
All six clones carrying full-length inserts were transformed into competent E. coli 
HB2151. The transformants were grown in liquid culture and induced by addition of IPTG 
in an attempt to express soluble scFv protein. As a positive control, a clone carrying an 
anti-thyroglobulin scFv was grown in parallel. Untransformed E. coli HB2151 lacking a 
plasmid was grown as a negative control. The culture supernatants were concentrated 
about 50 times and were used for further analysis. 
SDS-PAGE analysis (Figure 3.19A) showed the presence of many proteins in culture 
supernatants from clones EI0 (a candidate anti-K99 construct) and the anti-thyroglobulin 
positive control. Supernatants from other clones had very few proteins despite extensive 
concentration from the original cultures. The proteins were transferred to nitrocellulose 
membrane by Western blotting and probed with anti-c-myc and anti-mouse-HRP 
antibodies (Figure 3.19B). The results showed that scFv protein was clearly detectable 
from the positive control and that other clones failed to express this recombinant protein. 
ELISA 
Culture supernatants prepared from clones chosen at round 3 were tested in ELISA 
against purified K99. This analysis was carried out as previously described for clones 
chosen from round 4. None of the culture supernatants showed significant activity against 
K99 (results not shown). 
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Figure 3.19 SDS-PAGE and Western blotting of full-length scFv clones from round 3 
Concentrated supernatants from induced cultures were separated by SDS-PAGE, stained 
with Coomassie Blue and photographed (panel A). M shows the loading of a set of 
molecular weight markers with the migration of standards of 45 and 30 kDa indicated. 
Clone designations are shown at the top with "a" and "b" showing the loading of positive 
and negative control supernatants respectively. Blots (panel B) were probed with anti-c-
myc reagents and DAB substrate before image capture. 
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Table 3.2 Summary of the properties of 12 clones chosen from round 3 of 
selection 
Clone name Dominant Insert Anti-K99 scFv Sequencing 
reactivity· activityb expressionc 
E6 K99 VH orVL .......... .......... .......... 
EIO K99 VWVL Negative Negative Stop codon 
CII Milk VH orVL .......... .......... .......... 
A2 K99 VH or VL .......... .......... .......... 
CIO K99 VWVL Negative Negative Intact 
sequence 
B2 Milk VH orVL .......... .......... .......... 
FI K99 VH or VL .......... .......... .......... 
Gl2 Milk VWVL Negative Negative Stop codon 
G8 Milk VH orVL .......... .......... .......... 
BI Milk VWVL Negative Negative Stop codon 
H7 K99 VwVL Negative Negative Intact 
sequence 
GIl Milk VWVL Negative Negative Stop codon 
a Reactivity as assessed by monoclonal phage ELISA against K99 or 2% MPBS 
b Reactivity towards K99 as assessed by ELISA using supernatant from induced HB2151 
cultures 
C Expression of soluble scFv protein as assessed by Western analysis of supernatant from 
induced HB2151 cultures 
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The six plasmids that contained full-length scFv inserts were prepared for sequencing 
with primers PelB and gIlL Analysis of the sequence data revealed that only two clones 
(H7 and C 1 0, both putative anti -K99 constructs) had scFv sequences free of stop codons in 
either framework or CDR regions. Table 3.2 summarises the data gathered on the 
properties of all 12 clones chosen from round 3 of panning. 
High-throughput methods to assess expression of soluble scFv 
Since screening of clones from rounds 3 and 4 failed to identify any able to express 
soluble scFv antibodies, methods were sought that could be applied in large scale screening 
to meet this goal. ELISAs were tested using the anti-thyroglobulin clone known to express 
a scFv protein. 
Briefly, wells of an ELISA plate were coated with either recombinant protein L, a 
mouse monoclonal against c-myc or polyclonal anti-c-myc antibodies. After blocking the 
wells, supernatant from an induced culture of HB2151 carrying the anti-thyroglobulin 
construct was added. Binding of the scFv to protein L was then detected using polyclonal 
anti-c-myc and goat anti-rabbit-HRP antibodies. In wells coated with monoclonal anti-c-
myc, binding ofthe scFv was assessed with the same reagents. Finally, binding of the scFv 
in wells coated with polyclonal anti-c-myc was detected with the monoclonal anti-c-myc 
reagent and anti-mouse-HRP antibodies. Figure 3.20 shows the results of these three tests. 
Signal strength was highest when monoclonal anti-c-myc was used as the capturing layer, 
implying that this assay format had the highest sensitivity. This method also showed the 
highest specificity when compared with controls which either lacked the capture layer, or 
the scFv ligand (Figure 3.20). 
Screening clones from rounds 3 and 4 for scFv expression 
Ninety four clones from round 3, and ninety four from round 4 were picked at random 
and grown to produce phage that were then infected into exponentially growing E. coli 
HB2151 cells. As a positive control, a clone carrying an anti-thyroglobulin scFv was also 
prepared, with HB2151 lacking plasmid serving as a negative control for the experiment. 
The cells were grown in the wells of microtitre plates and induced by addition of IPTG. 
The culture supernatants were then used in a capture ELISA set up to the format described 
above. 
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The ELISA results showed that all clones from round 4 were unable to produce a 
soluble scFv product and reactions in the assay were similar to the negative control. Three 
clones from round three showed a very weak: reaction in the assay but further experiments 
with these clones was unable to confirm the production of soluble scFv fragments (data not 
shown). Results from the anti-thyroglobulin control were strongly positive as in 
preliminary experiments (Figure 3.20). 
Screening secondary stock of Griffin.1 library for expression of 
soluble scFv fragments 
Since large scale screening of clones from rounds 3 and 4 of selection against K99 
revealed an inability to express soluble fragments, the assay was repeated with clones 
picked at random from the original Griffin.I. This attempted to establish if selection for 
binding to K99 had in some way driven the isolation of clones unable to express a soluble 
scFv product, or if this was a feature of the original library. 
Library clones in TG 1 cells were picked at random, grown and phage antibodies 
produced by infection with VCS-M13 helper phage. The phage were then precipitated by 
PEGlNaCI and resuspended in PBS. Exponentially growing E. coli HB21S1 cells were 
infected with diluted aliquots of the phage stock and then used for screening. 
Ninety four individual HB21S1 clones were grown in the wells of a microtitre plate 
and soluble scFv expression was induced by the addition of IPTG. After collection, the 
culture supernatants were tested by ELISA using the capture format described earlier. The 
assay showed some clones were able to produce soluble scFv. Fourteen clones that showed 
the strongest reaction in the assay were chosen for further analysis. 
Crude lysates of all 14 clones was used as template in PCR with the primers LMB3 
and gIll. Although the crude lysates gave results that were not as clear-cut as in reactions 
using purified plasmid DNA (e.g. Figure 3.18), the experiment indicated that most of the 
clones probably carried full-length scFv inserts (Figure 13.21). Only three clones (A3, H3, 
HS) showed sharp products that were too small for full-length scFv sequences. For the 
remainder, there was some evidence of amplicons of the size predicted for a full-length 
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Figure 3.20 Capture ELiSAs for the detection of scFv 
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Wells of an ELISA plate were coated with the reagents indicated on the x-axis of the 
histogram. Culture supernatant containing soluble scFv was added and scFv binding was 
detected as follows: Protein L capture layer, rabbit polyclonal anti-c-myc reagents; mouse 
monoclonal anti-c-myc capture, rabbit polyclonal anti-c-myc reagents; rabbit polyclonal 
anti-c-myc capture, mouse monoclonal anti-c-myc reagents. After addition of OPD 
substrate, absorbance at 450 nm was recorded (y-axis). Test ractions are shown in blue. 
Controls lacked either the scFv ligand (purple) or the capture reagent (yellow). 
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Supernatants from induced cultures of the 14 clones chosen by capture ELISA and 
from an anti-thyroglobulin positive control were analysed by Western blotting. The 
samples were concentrated about 20-fold and after separation by SDS-PAGE, they were 
transferred to nitrocellulose membranes and probed with anti-c-myc reagents and diamino 
benzidine substrate. Only clone F6 and the positive control showed reaction with a protein 
of about 30 kDa (data not shown). 
To increase the sensitivity of detection, Western blotting was repeated and the 
reactions developed with a chemiluminescent substrate. As shown in Figure 3.22, there 
was convincing reaction of the anti-c-myc antibody with proteins of 30 kDa expressed by 
clones E9 and F6. The Figure also shows some evidence of low level production of scFv 
by clones A5, B2, B5, and Cl. Overall, the results of ELISA and Western blotting 
suggested that most clones from the original library expressed scFv antibodies poorly. 
Final ELISA analysis 
To conclude experiments with the Griffin.! library, a comparison was made between 
the reactivity of polyclonal, unselected phage antibodies prepared from the library on wells 
coated with K99 and skimmed milk. The assay was also conducted with scFv made from 
the library stock. The binding of phage antibodies was detected with a monoclonal anti-
M13-HRP conjugate and the binding of scFv antibodies was detected with anti-c-myc 
reagents. The Figure 3.23 shows the results of this comparison. The assay showed low 
levels of reactivity with milk protein when phage or scFv were applied. Whilst the scFv 
reaction with K99 was somewhat lower than with milk, the phage ELISA generated a 
signal on K99 that was twice that on milk. 
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Fourteen clones were chosen from screening the unselected Griffin.l library in scFv 
capture ELISA. Crude bacteriallysates were prepared and used as templates in PCR with 
the primers LMB3 and gIll along with a full-length anti-thryoglobulin scFv as a positive 
control. Products were analysed by agarose gel electrophoresis and photographed. Clone 
numbers and products from the positive control are indicated, "M" showing loading of a 1 
kb DNA ladder. The migration of markers of 506 bp and 1,016 bp is indicated, with the 
predicted size (1 kb) of a full-length scFv insert. 
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Figure 3.22 Western blotting of 14 clones positive in a scFv capture ELISA 
Fourteen clones were chosen from screening the unselected Griffin.1 library in scFv 
capture ELISA. Phagemids were transfected to E. coli HB2151 and supernatants collected 
from cultures induced with IPTG. After SDS-P AGE separation, samples were transferred 
to nitrocellulose and probed with anti-c-myc reagents and chemiluminescent substrate. The 
image was captured to x-ray film. Clone designations are indicated with "Control" 
indicating loading of an anti-thryoglobulin scFv. The migration of marker proteins of 45 
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Figure 3.23 Polyclonal phage and scFv ELISA with the Griffin.1 library 
Phage antibodies and scFvs were prepared from aliquots of the unselected Griffin. I library. 
The antibodies were then applied to wells of ELISA plates coated with K99 (blue) and 
skimmed milk (purple). Binding of phage was detected with a monoclonal anti-M13-HRP 
conjugate; the binding of scFv antibodies was detected with anti-c-myc reagents. After 




Progress in antibody engineering has been directed toward the expression of antibody 
fragments in bacterial and phage display systems, leading to increase in application of 
these antibodies in research, biology, clinical diagnosis and therapy. The power of the 
phage display system to express antibody fragments offers several advantages over 
hybridoma technology. Making these antibodies is quick and cheap, the affinity can be 
increased and it is easy to manipulate them. 
Many investigations have been done to study the applications of recombinant antibody 
technology for human or animal diseases. Most of these are focused on the study of 
tumors, viral and parasites diseases but less on bacterial diseases. Our aim was to choose a 
virulence factor from a well-known bacterial agent and to isolate small antibody fragments 
(scFvs) from a large synthetic single chain antibody library for further characterisation. 
Griffin.1 is a very large library of about 109 clones that was chosen for the study. 
Initial attempts used a fimbriae extract containing K99 antigen for selection. After four 
rounds of selection, many phage antibodies were found to have higher activity with 
contaminant proteins rather than the fimbrial major subunit. Thus, this protein was purified 
by ion-exchange chromatography and its activity was checked by several tests. Before 
using the secondary stock of the library for selection, the frequency of full-length inserts 
was estimated by PCR and restriction enzyme analysis of clones chosen at random. The 
results indicated only about 113 selected clones had full-length insert. Similar findings with 
the Griffin.1 library have been reported (de Bruin et al., 1999; de Greeff et al., 2000) and 
have been discussed (http://www.mrc-cpe.cam.ac.ukI~plw/phageqa.html) by several 
investigators previously. De Bruin et al. (de Bruin et al., 1999) showed that the percentage 
of phage with full-size inserts decreased at every cycle of enrichment. They also reported 
PCR and sequencing of clones from the final round of panning revealed that the only one 
from 100 phage antibodies carried a complete scFv insert, the majority lacking the V H 
component. 
During the screenmg of clones isolated throughout four rounds of selection, we 
observed the number of positive clones rose from one round to the next but many positive 
clones had reaction with either K99 or with 2 % MPBS. Also the plasmid digestion of 
thirteen positive clones from round 4 with restriction enzymes, revealed only 4 clones were 
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contained full-length inserts, two clones had truncated inserts and the rest did not show any 
inserts. Similar results were observed for clones isolated from round 3 of selection that 
appeared to react with K99. Moreover when we repeated monoclonal phage ELISA, levels 
of different background reaction were seen each time. These results could be due to the 
quality of the library and using VCS-MI3 helper phage. A well-known problem in phage 
display is the inefficient incorporation into the phage coat of phagemid-encoded scFv-plII, 
compared with native pIlI encoded by the helper phage genome. As a result the majority of 
phage do not contain scFv in their coat. In addition, phagemid libraries often contain many 
clones that do not express a scFv-pIlI fusion, due to stop codons and frame shifts 
introduced during library construction. Unwanted emichment of such aberrant phagemids 
may result during amplifcation steps, caused by enhanced growth rates of bacteria not 
expressing scFv-plII. As a consequence, rescue of phages using conventional helper phage 
like VCSM13 generally results in a high frequency (up to 99.5%) of phages not displaying 
the protein of interest (Azzazy, 2002). This could explain why the emichment rate of 
specific antibodies appeared to decrease from round 3 to round 4. To overcome this 
problem with VCS-M13 helper phage, several strategies have been attempted by 
investigators such as making KM13 helper phage (Kristensen and Winter, 1998), which 
has a proteolytic cleavage site, and construction of CT helper phage (Kramer et al., 2003). 
Rescue of a library with these novel helper phage yields virus that are only infectious when 
they contain a phagemid-encoded pIlI-fusion protein (Kramer et at., 2003) using VCS-
M13 and CT helper phage in three experiments showed 28% of the clones infected with 
VCSM13-rescued phages produced scFv, whereas 84% of CT-rescued phages produced 
scFv. Also ELISA analysis of scFv incorporation in rescued phages showed about 8-fold 
higher absorbance when CT helper phage was used instead ofVCSM13. 
After choosing clones from round 4 that had higher reaction than most in monoclonal 
phage ELISA, attempts were made to express soluble scFv fragments in the non-
suppressor E. coli strain HB2151. This was not successful. Working on the idea that this 
was due to low level of expression and inefficient detection, inserts from the chosen clones 
were transferred into pIMS 147 expression vector and transformed into E. coli XL-I blue 
(Strachan et ai., 2002). This strategy was also unsuccessful. Moreover, changing 
expression conditions (Kipriyanov et ai., 1997; Kipriyanov, 2002) like temperature, the 
concentration of IPTG and addition of sucrose did not affect the expression level. In 
contrast, the expression of these clones as scFv-plII fusion proteins (Mersmann et ai., 
1998) in TG 1 cells, showed activity with K99 in ELISA and expression was confirmed by 
Western blotting. To find the reason for the failure to express soluble scFvs, the DNA 
sequences of these clones and others from round 4 were determined. The results revealed 
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all of these clones had at least one stop codon. These stop codons were located either in 
CDRs or frameworks. Since the Griffin.1 library was constructed from random residues in 
CDRs, it was natural to find some clones containing TAG stop co dons in these positions. 
These clones can express phage antibodies in suppressor E. coli strains like TG 1 but could 
not express scFv antibodies in non-suppressor strains. Unexpectedly, we found some 
clones had stop codons in their frameworks. This was observed particularly in one 
position of framework two of heavy chain in several clones. We can explain that the above 
problem could happen during construction of the library when the frameworks were 
isolated and amplified by PCR. 
By comparing the sequences of clones from the secondary stock of library, from round 
three and from round four of selection, it was observed that the number of clones 
containing stop co dons rose. This indicates that these clones were amplified during 
selection. 
Following screening of many clones from round 4 and round 3 that had higher reaction 
with K99 in monoclonal phage ELISA, but failed to express soluble scFv fragments, a 
sensitive and specific method to detect the expression of soluble scFvs was devised for 
large scale screening. Using a positive control clone, an ELISA method was established 
that was sensitive for estimation of expression of scFv antibodies but also is probably 
sensitive for estimation of expression of any c-myc tag recombinant protein. Using this 
technique, 94 clones from round 4 and 94 clones from round 3 were screened but no 
reaction was seen. When 94 clones from the secondary stock of library were tested to 
assess the ability of the library to express soluble fragments, different levels of expression 
were discovered in ELISA. Further analysis by PCR and western blotting of fourteen 
clones with higher signals in above ELISA revealed that most of these clones contained 
full-length inserts but except for two clones, the isolates were unable to express soluble 
scFv antibodies at high levels. This result supports the sensitivity of the ELISA method for 
estimation of expression of soluble scFvs and also indicates the expression of these 
recombinant proteins depends upon other factors. It is known that the expression of 
recombinant antibodies can vary widely on a case by case basis. For example, some 
antibody frameworks (like VH3 family) have better expression levels than the majority. 
Proper folding of antibody within the bacterial periplasm has effect on levels of active 
antibody (Knappik et al., 1993; Bothmann and Pluckthun, 1998). Some recombinant 
antibodies are toxic to their host cells (Krebber et al., 1996). Growth temperature 
(Somerville et al., 1994; Kipriyanov et al., 1997), addition of osmotic stress reagents 
(Kipriyanov et al., 1997), strength of promoter (Clark et al., 1997) and the concentration of 
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IPTG and the time of growth culture (Kipriyanov et al., 1997) may have an effect on the 
expression of recombinant proteins. Moreover, O'Brien et al. showed the E. coli strain can 
also affect the level of expression of soluble Fab fragments (O'Brien et ai., 2002). 
Therefore the variation of expression level of clones of library could be the result of some 
of the above factors. Since these clones were chosen from the library before selection, the 
effect of each factor upon expression of scFv was not investigated. 
The overall activity of unselected phage from the library and scFv product was tested 
with K99 and BSA (as comparison antigen) in an ELISA experiment. This experiment 
clearly revealed that although unselected phage antibodies in the library have higher 
activity with K99 than 2% MPBS, the reaction of population of soluble scFvs with K99 is 
much lower than the reaction with 2% MPBS. Thus, this result indicated the chance of 
finding high affinity soluble scFv antibodies against K99 antigen with this library was very 
low. Also, the experience of using this library with two other antigens in our lab had 
similar results (unpublished data). 
Despite these results and the problems that were encontered with the library during 
these experiments, it may be still possible to use the library for the isolation of single chain 
antibodies against some antigens as a few previous reports have shown. It is possible that 
helper phage like KM13 will assist the isolation of phage antibodies with complete inserts 
at each round of selection. The success of Strachan et al. (Strachan et al., 2002) for 
isolating anti-hapten scFvs from the Griffin.1 library shows that this should be possible. 
Moreover, the polyclonal phage ELISA and polyclonal scFv ELISA will help quick review 
of the selection procedure. One important lesson leared from use of the Griffin.1 library 
was the value of screening the ability of any antibody display library to produce soluble 
scFv before starting selection. 
Chapter 4 
Tomlinson scFv libraries 
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4. Tomlinson scFv libraries 
Introduction 
The Tomlinson I and J libraries are the latest semi-synthetic libraries to be distributed 
by the MRC. Each library comprises over 100 million different scFv fragments cloned in 
an ampicillin resistant phagemid vector, pIT2 (Figures 4.1, 4.2) which is derived from 
pHENl (Hoogenboom et ai., 1991). The libraries are distributed in E. coli TGl. The scFv 
is conventional, consisting of a single polypeptide with the VH and VL domains attached 
to one another by a flexible Glycine-Serine linker. Using these libraries, specific binders to 
target molecules can be selected by normal panning methods. Typically two or three 
rounds of selection are required to ensure that more than half of the scFvs in selected 
population bind to the target molecule. The monoclonal scFvs can then be screened for 
binding and then used for further analysis of the target molecule. All the functional scFvs 
in the Tomlinson I and J libraries can bind Protein A (Protein A from Staphylococcus 
aureus has five domains that mediate interaction with the Fc region of most mammalian 
IgGs. Protein A also binds to the Fab region of a subset of Ig with heavy chains belonging 
to the VHIII family) (Harboe and FoIling, 1974) through the VH domain (Sasso et ai., 1989; 
Sasso et al., 1991) and Protein L through the VK domain (Bjorck, 1988). This allows either 
of these secondary reagents to be used for detection, purification or immobilisation. 
Alternatively, secondary reagents that bind the attached myc or histidine tags can be used. 
Both libraries are constructed on single human frameworks for the VH (V3-23IDP-47 
and JH4b) and VK domains (012/02/DPK9 and JK1). The canonical structure (VH: 1-3, 
VK :2-1-1) encoded by the chosen frameworks are by far the most common in the human 
antibody repertoire (de Wildt et ai., 1999). Diversity is incorporated at positions that make 
contacts to antigen in known structures and are known to be highly diverse in the mature 
antibody repertoire. This comprises a total of 18 residues - H50, H52, H52a, H53, H55, 
H56, H58, H95, H96, H97, H98, L50, L53, L91, L92, L93, L94 and L96. The CDR3 of the 
heavy chain was designed to be as short as possible yet still able to form an antigen 
binding surface. In library I, diversity is created through incorporation of DVT (D: A, G or 
T; V: A, C or G) codons at these positions. In library I, NNK (N: any base; K G or T) 
co dons is used instead. Both libraries are constructed in the vector pIT2 which provides 
HIS and myc tags (Figures 4.1 and 4.2). After selection, scFvs can be matured by 
incorporating additional diversity based on somatic mutation. Both libraries contain about 
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The main features of the vector are indicated. Transcription takes place from a lac 
promoter and in a suppressor strain of E. coli, the translated product comprises a PelB 
leader, the single-chain antibody created by insertion of VH and VL sequences at the sites 






AGTCATA ATG AAA TAC CTA TTG CCT ACG GCA GCC GCT GGA TTG TTA 
M K Y L L P T A A A G L L 
Sfir Ncol 
TTA CTC GCG GCC CAG CCG GCC ATG GCC GAG GTG TTT GAC TAC TGG 
L L A A Q p A M A E V F D Y W 
XhoI 
GGC CAG GGA ACC CTG GTC ACC GTC TCG AGC GGT GGA GGC GGT TCA 
G Q G T L V T V S S G G G G S 
linker SaIl 
GGC GGA GGT GGC AGC GGC GGT GGC GGG TCG ACG GAC ATC CAG ATG 
G G G G S G G G G S T D I Q M 
~----------------------------------
Link seq new 
Notl HIS-tag 
ACC CAG GCG GCC GCA CAT CAT CAT CAC CAT CAC GGG GCC GCA GAA 
T Q A A A H H H H H H G A A E 
-
myc-tag 
CAA AAA CTC ATC TCA GAA GAG GAT CTG AAT GGG GCC GCA TAG ACT 
0 K L 1 S E E D L N G A A * T 
~---------------------------
pHEN seq 
Figure 4.2 DNA sequence of plT2 vector 
The Figure presents part of the DNA sequence of the pIT2 vector. The restriction enzyme 
sites are underlined. The VH sequence is located between Ncol and Xhol sites and the VL 
sequence is located between Sall and Notl sites. Primers are shown by dotted arrows. The 
amber stop codon is presented as a star. The amino acid sequences ofHlS and myc tags are 
underlined. 
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1.4 x 108 clones and it is estimated that 96% of clones in library I contain an insert whereas 
the value is somewhat lower (88%) for library J. 
KM13 he/per phage 
The KM13 helper phage was created by Kristensen and Winter (Kristensen and 
Winter, 1998) to overcome problems inherent to use of other helper systems. In the 
modified helper phage, a trypsin cleavage site was introduced into the pIlI gene between 
the coding regions for the second and third domains of the protein (indicated as II in Figure 
4.3). While it is possible to attach sequence to the amino terminus of pIlI or even to insert 
peptides between domain boundaries without abolishing infectivity (Smith, 1985; 
Endemann et aI., 1992; Krebber et aI., 1997b), all three domains of pIlI are essential for the 
successful infection of bacteria (Riechmann and Holliger, 1997). Hence, trypsin treatment 
of phage destroys the participation of helper phage-derived pIlI in bacterial infection. In 
contrast, the phagemid-encoded gene for pIlI to which the scFv for display is attached, is 
wild-type and is insensitive to trypsin (indicated as I in Figure 4.3). Protease treatment 
therefore leaves intact the ability of this protein to mediate infection of bacteria. By placing 
a trypsin-sensitive site between the scFv and pIlI, Kristensen and Winter broadened the 
utility of protease treatment to include an efficient elution method. Since the method was 
published, proteolytic selection has been employed for other kinds of selection (Demartis 
et ai., 1999; de Wildt et ai., 2000; Riechmann and Winter, 2000; Goletz et ai., 2002). 
Application of Tomlinson / and J libraries 
These scFv libraries can be used to derive binders to almost any target molecule using 
phage display and selection. These binders can be used for all the same applications as 
conventional monoclonal antibodies like ELISA, Western blotting, F ACS, 
immunochemistry etc. The sections that follow illustrate some of the investigations carried 
out using these libraries. 
Human fibrin clots 
A scFv antibody was developed against human fibrin clots by using the Tomlinson 
libraries. One purified soluble scFv was verified by Western blot analysis. It specifically 
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The Figure shows an scFv-phage from a phagemid library prepared using KM13 as helper 
phage. During packaging and rescue of the library, the pIlI from the helper phage (II) 
competes with the scFv-pIII fusion protein (I) for incorporation into phage particles. The 
helper phage KM13 encodes a modified pIlI with an additional trypsin-sensitive site 
between domains D2 and D3 (II). All three domains of pIlI are essential for phage 
infectivity hence trypsin treatment inactivates the function of these proteins. The trypsin 
cleavage site in the myc tag of the scFv-pIII (wt) fusion protein allows the proteolytic 
elution of an infective phage from its antigen but in the absence of other trypsin-sensitive 
sites, the infective function of this form of pIlI is not lost after protease treatment. The 
Figure has taken from (Kristensen and Winter, 1998). 
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analysis. The potential of this scFv for the diagnosis and therapy of thrombus-correlated 
diseases is being explored (lun Peng Yan, 2004). 
Antiidiotypic antibodies as immunogens 
Antiidiotypic antibodies that mimic carbohydrate or conformational epitopes (Ab2~) 
are of considerable interest as surrogate immunogens for cancer vaccination. To investigate 
this area, scFvs from the Tomlinson libraries were isolated against an idiotypic antibody 
(Goletz et al., 2002). Elution of binders was accomplished with the original antigen 
followed by trypsin treatment of the recovered phages before rescue with the protease 
sensitive helper phage KM13. These methods were compared with various conventional 
selection and elution methods and the diversity of the scFv clones was determined. 
Antibody arrays 
The Tomlinson I and J libraries have also been used to develop a novel technique for 
high-throughput screening of recombinant antibodies, based on the creation of antibody 
arrays. Using robotic picking and high-density gridding of bacteria containing antibody 
genes followed by filter-based ELISA screening, clones were identified that expressed 
scFvs of interest. The investigators applied this technique in several different applications, 
including isolating antibodies against impure proteins and complex antigens, where several 
rounds of phage display often fail (de Wildt et a!., 2000). 
Protein arrays 
To identify highly specific antibody-antigen interactions by protein array screening, 
12 well-expressed antibody fragments were chosen from the Tomlinson I and J libraries. 
After capturing the scFv antibodies, their interaction with 27 648 human foetal brain 
proteins arrayed on a PVDF membrane was tested. The authors suggested that this 'naive' 
screening approach could be applied to the high throughput isolation of specific antibodies 
against many different targets in the human proteome (Holt et a!., 2000). 
Bovine complex I 
The Tomlinson I and J libraries have also been used to isolate an antibody that binds to 
a specific 51kDa subunit of complex I, a macromolecular assembly. Antibodies that bound 
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to the intact complex were selected and screened with a high-density Western blot to 
identify a subunit-specific binder. Conventional Western blotting and competition ELISA 
were then used to confirm the identity of the target subunit and that the antibody bound to 
the native protein complex and not to an epitope that is only revealed when the antibody is 
immobilized for phage selection (Rubinstein et at., 2003). 
Objectives 
Since the results of previous chapter did not fulfil our aims, the Tomlinson libraries of 
I and J were chosen. It was planned to use these two semi-synthetic libraries for isolation 
of recombinant single-chain antibodies against purified K99 major subunit. Then we 
wanted to characterise the isolated antibodies and assess the biological activities of them 
and then find out whether these antibodies have the ability to neutralise the attachment of 
B41 E. coli strain to villi in vitro. 
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Materials and methods 
Tomlinson library / and library J 
The human synthetic scFv libraries of Tomlinson I + J (MRC, Centre for Protein 
Engineering, Cambridge, UK.) were used to select antibodies against purified K99 
fimbriae. The materials supplied comprised 500 fll of library I and 500 fll of library J in 
TG 1 E. coli cells, glycerol stocks of positive control scFvs against BSA and ubiquitin in 
bacterial strain TG 1, a glycerol stock of T -phage resistant E. coli TG 1 for propagation of 
phage (K12 iJ.(lac-proAB) supE thi hsdD5IF' traD36 proA+B laclq lacZiJ.M15), a glycerol 
stock of E. coli HB2151 for expression of antibody fragments (K12 ara iJ.(lac-proAB) 
thilF' proA+ B laclq lacZiJ.M 15) and 100 fll of phage KM 13 at 107 pfu/ml. All materials 
were stored frozen. Before screening, some initial preparations were carried out. 
Production of large quantities of KM13 he/per phage 
To make a stock ofKM13 helper phage, one colony ofTGl from a plate of minimal 
medium was grown overnight in 5ml of 2xTY containing 100 flg/ml ampicillin and 1 % 
glucose at 37°C with shaking at 200 rpm. 500 fll of this culture was inoculated into 50ml of 
2xTY and was grown until OD at 600 nm was 0.3-0.4. Then 200 fll aliquots of the culture 
were infected with 10 fll of lOx serial dilutions of KM 13 helper phage and incubated at 37 
°c in a water bath for 30 min. 3ml of H-top agar (Tryptone 109, NaCI 8g, Agar 6g and 
distilled water up to 1 litre) warmed at 42°C was added to each tube and after mixing, 
poured onto warm TYE plates. The plates were allowed to set and then incubated 
overnight at 37°C. Next day a single small plaque was picked into 5 ml of fresh TGI at an 
OD 600 nm of 0.4, grown for 2hr with shaking at 37°C and then added to 500ml of 2xTY 
in a 2 litre flask to grow with shaking at 37°C for Ihr. After that kanamycin was added to 
a final concentration of 50 flg/ml and the culture was grown overnight with shaking at 30 
°C. The overnight culture was centrifuged at 10800g for 15 minutes and 100ml PEGlNaCI 
(20 % polyethylene glycol 6000, 2.5 M NaCI) was added to 400 ml of supernatant. After 1 
hr incubation on ice, the mixture was spun at 1 0800g for 30 min. The pellet of precipitated 
phage was resuspended in 8 ml of PBS and 2ml ofPEGlNaCl. After mixing and incubation 
for 20 minutes on ice, the mixture was spun at 11600g for 10 min in a micro centrifuge to 
remove any remaining bacterial debris. The supernatant containing prepared phage was 
then stored at -20°C. 
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Titration of KM13 he/per phage stock 
To titre the helper phage, 5 ).11 of trypsin stock solution was added to 45 ).11 of phage 
and incubated for 30 min at 37°C. 1 ).11 of trypsin treated phage was diluted into Iml of 
PBS and five 100 fold serial dilutions prepared in Iml aliquots of PBS. Then 50 ).11 from 
each dilution was added to separate tubes containing 1 ml of TG 1 at an OD 600 nm of 0.4. 
After mixing, 3 ml of molten H-Top agar was added to each tube and poured evenly onto 
TYE plates. Dilutions were also prepared using 1 ).11 of non-trypsin treated phage. These 
were processed as described for trypsin treated phage. The difference between titres of 
trypsin treated and trypsin non-treated phage was calculated. 
Growing the libraries 
Library stocks of Tomlinson I and Tomlinson J (500 ).11) were added to 200 ml of pre-
warmed 2xTY containing 100 ).1g/ml ampicillin and 1 % glucose and grown with shaking at 
37°C until the OD at 600 nm was 0.4. 150 ml of these cultures were used for making 
secondary stocks and the remaining cultures were infected with 2xl0I1 (1.88 ).11) pfu of 
KM13 helper phage. Cultures were incubated without shaking in a 37°C water bath for 30 
minutes, spun at 3300g for 10 minutes and the bacterial pellets resuspended in 100 ml of 
2xTY containing 100 ).1g/ml ampicillin, 50 ).1g/ml kanamycin and 0.1 % glucose. The 
suspensions were incubated overnight with shaking at 30°C. The next day, after spinning 
at 3300g for 30 minutes, 20 ml PEGlNaCl was added to 80 ml of each supernatant. The 
mixtures were incubated for an hour on ice, spun at 3300g for 30 minutes and the pellets 
resuspended in 4ml PBS. After a further spin at 11600g for 10 minutes, the supernatants 
containing prepared phage libraries were stored at 4°C. 
Titration of phage libraries 
To titre the library phage stocks, 1 ).11 of each phage library was diluted into 100 ).11 
PBS. 1 ).11 of was withdrawn and diluted in a further 100 ).11 PBS and so on until there were 
6 dilutions in total. 900 ).11 of TG 1 at an OD 600 nm of 0.4 was added to each tube and 
incubated at 37°C in a water bath for 30 minutes. 10 ).11 of each dilution was spread onto a 
TYE plate containing 100 ).1g/ml ampicillin and 1 % glucose and grown overnight at 37°C. 
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Growing TG1 and HB2151 cells 
To generate secondary stocks of of T01 and HB2151, about 10 III of each strain was 
withdrawn from the glycerol suspensions and streaked onto minimal agar plates for 
overnight growth at 37°C. One colony from each plate was grown on in 5 ml of 2xTY 
overnight with shaking at 37°C. The following day, the cultures were centrifuged at 3300g 
for 10 minutes and pellets resuspended in 1 ml 2xTY containing 15 % glyceroL Secondary 
stocks were then stored at -80°C. Also minimal media agar (di-Sodium Hydrogen 
orthophosphate 6g, Potassium dihydrogen orthophosphate 3g, NaCl 0.5g, Ammonium 
Chloride Ig, Agar 15g and distilled water up to 1 litre) plates of these cells were stored at 4 
°c for future use. 
Initial experiments before selection 
Before usmg the libraries for selection of phage antibodies, some preliminary 
experiments were performed. 
Activity of purified K99 at low concentration 
In order to check that purified K99 would retain integrity at the low concentrations to 
be used for selection in immunotubes (Nunc, Denmark), duplicate wells of an ELISA plate 
(Nunc, Denmark) were coated overnight at room temperature with K99 diluted to 20, 10, 5, 
2.5, 1.25, 0.625, 0.312 Ilg/mL As a negative control, two wells were coated with PBS. The 
wells were blocked with 3% BSAIPBS for 2 hr at 37°C and then probed with lOOlll of 
1: 1 000 dilution of anti- K99 mouse monoclonal antibody (Biogenesis, UK) in blocking 
buffer for 90 minutes at 37°C. After probing with an anti-mouse peroxidase conjugate at 
1: 1 000 dilutions, the reaction was developed with 100 III of substrate solution (1 mg/ml 
OPD in 0.1 M citrate buffer pH 4.5 and 0.012% (v/v) H20 2) and stopped after 10 minutes 
with 50 III of 1M sulphuric acid. The absorbance was measured at 492 nm. 
Growing positive controls 
To generate positive control scFvs for future experiments, TO 1 cells carrying anti-
BSA and anti-ubiquitin antibodies were grown on TYE plates containing 100 Ilg/ml 
ampicillin and 1 % glucose overnight at 37°C in an incubator. A single colony from each 
plate was grown in 5 ml of 2xTY containing 100 Ilg/ml ampicillin and 1 % glucose 
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overnight at 37 DC with 200 rpm shaking. Plamsid DNA was isolated from 3ml of these 
cultures using a Qiagen miniprep kit. Plasmid purification was done as recommended by 
the manufacturer. 2 III of each purified plasmid was transformed into 100 III of competent 
HB2151 (K12 ara LJ(lac-proAB) ThilF' proA+B laclq lacZ!JM15) using standard protocols 
(Sambrook et al., 1989). Transformants were plated onto TYE plates containing 100 Ilg/ml 
ampicillin and 1 % glucose and grown overnight at 37 DC. 
Expression soluble positive control scFvs 
For expressiOn of soluble anti-BSA and anti-ubiquitin scFvs, single colonies of 
HB2151 cells carrying the respective plasmids were grown in 5 ml of 2xTY containing 100 
Ilg/ml ampicillin and 1 % glucose overnight at 37 DC with shaking (200 rpm). Iml of these 
cultures were added to 100 ml of fresh 2xTY containing 100 Ilg/ml ampicillin and 0.1 % 
glucose. The cultures were grown with shaking (200 rpm) at 37 DC until the OD 600nm 
was approximately 0.8-0.9. IPTG (Roche, Germany) was added to a final concentration of 
ImM and incubation continued with shaking (200 rpm) at 30 DC for about 20 hr. The 
cultures were centrifuged at 5200g for 20 min and the supernatants concentrated 
approximately 20 times, with simultaneous exchanged of buffer to PBS using Amicon 
Ultra-4 centrifugal filters with a 10 kDa cut-off (Millipore, UK). The filtrates were then 
stored at -20 DC for future use. 
Activity of anti-BSA and anti-ubiquitin scFvs with Protein L-HRP, 
LA-HRP and anti-c-myc antibody 
In order to optimise a high sensitivity detection method with for checking expression 
of scFvs, three equally concentrated culture supernatants of anti-BSA and anti-ubiqitin 
scFvs were run on an SDS-P AGE gel and transferred to a nitrocellulose membrane 
(Amersham, UK) at 100v for Ihr. After blocking the membrane with 3% MPBS for Ihr at 
room temperature, the membrane was cut into three parts. To the first, recombinant Protein 
LA-HRP which is a combined L and A protein with the binding characteristics of both, 
conjugated to HRP (Actigen, Norway), was added at 1:1000 dilutions. The second strip 
was probed with recombinant Protein L-HRP (Actigen, Norway); the third part was 
incubated with anti-c-myc mouse monoclonal antibody (Sigma, UK) at 1 :3000 dilution in 
2% MPBS for 90 min at 37 DC with 200 rpm shaking. A secondary rabbit anti-mouse 
(Sigma, UK) at 1: 1 000 dilutions in 2%MPBS was added to the third strip only to detect 
binding of the mouse monoclonal antibody; this was incubated at 37 DC with shaking for an 
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hour. Finally, all complexes were developed with 4-chloro-l-naphthol substrate (Sigma, 
UK). 
peR screening for full-length scFv genes 
It is common that recombinant scFv antibody libraries contain some clones containing 
only the V H or the V L components or totally lacking inserts. Any truncated scFvs able to 
react with a target antigen can then be isolated by selection and may come to dominate the 
population of recovered phage if they have marginally faster replication times or other 
selective advantages. To assess the presence of truncated inserts in the Tomlinson library I 
and Tomlinson library J, 21 colonies were picked at random from TYE plates used to titre 
each library. A colony carrying the anti-ubiquitin scFv was also taken as a positive control. 
Bacterial DNA was obtained by suspending each colony in 50 III of H20 and boiling at 100 
°c for 10 minutes. Primers LMB3 and pHEN seq (Tables 4.1 and 4.2) were used to 
amplify across the inserts in 25-lll PCR reactions containing 0.5 IlM concentrations of each 
primer, 0.25 mM concentrations of each dNTP (Promega), 4mM MgCh, Ix reaction buffer 
(containing 50 mM KCL, 10 mM Tris-HCL pH 9.0 and 0.1 % Triton®X-100), 2.5 units of 
Taq DNA polymerase (Promega) and 2 III of bacterial lysate. Samples were amplified on a 
Techne thermal cycler under the following conditions: the reaction was heated to 94°C for 
3 min and then 35 cycles of 1 min denaturation at 94 °c, 1 min annealing at 55°C, 2 min 
extension at 72 °C. Final extension was for 10 min at 72°C. 
PCR products were analysed on a 1 % agarose gel for 45 min at 100 V, stained with 
ethidium bromide, and photographed under UV light. 
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Table 4.1 List of primers used for characterisation of scFv genes in pIT2 vector 
Primers Sequences from 5' to 3' 
LMB 3: CAGGAAACAGCTATGAC 
Link seq new: CGACCCGCCACCGCCCGCTG 
DPK9 FRI seq: CATCTGTAGGAGACAGAGTC 




Table 4.2 Expected sizes of peR products using different primers 
Primers Isolation of fragment(s) Expected size (bp) 
with insert = 527 LMB3-link seq new VH only without insert = 227 
with insert = 368 DPK9 FR1 seq-pH EN seq VK only Without insert = no band 
with insert = 935 LMB3-pHEN seq VH and VK without insert = 329 
with insert = 885 peIB-pHEN seq VH and VK without insert = 279 
with insert = 1035 glll-LMB3 VH and VK without insert = 429 
with insert = 985 glll-pelB VHand V" without insert = 379 
with insert = 477 pelB-link seq new VH only without insert = 177 
with insert = 468 DPK9 FR1 seq-gill V" only without insert = no band 
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Selection procedure 
Panning Tomlinson library I and library J against purified K99 
First round of selection 
Two immunotubes (Nunc, Denmark) were coated overnight at room temperature with 
4 ml of purified K99 at 20 mg/ml in PBS. The following day, the immunotubes were 
washed 3 times with PBS by pouring into the tubes and pouring out again immediately to 
remove unbound antigen. The immunotubes were blocked by filling with 2% MPBS and 
incubating at room temperature for 2 hrs. Immunotubes were washed again 3 times with 
PBS. After that, 1.28 x 1013 phage of library J were added in 4 ml of 2% MPBS to one 
immunotube and approximately 1.28 x 1013 phage of library I in 4 ml of 2% MPBS were 
added to a second. To block phage that might be specific for milk consitutents, the phage 
suspensions were incubated for about 30 minutes at room temperature before addition to 
the K99-coated immunotubes. The tubes were incubated for 60 minutes at room 
temperature with continuous rotation, and then allowed to stand for a further 60 minutes at 
room temperature. The supernatants were discarded and the tubes were washed 10 times 
with PBS containing 0.1 % Tween 20. After shaking out the excess PBS, phage were 
eluted by adding 500 ~l of trypsin-PBS solution and rotating for 10 minutes at room 
temperature. The trypsin solution was prepared by sampling 50 ~l of a stock solution 
prepared at 10mg/ml (Fluka, UK) in 50mM Tris-HCI pH 7.4, ImM CaCh and adding this 
to 450 ~l PBS. 
Infecting TG1 cell with eluted phage antibodies 
The day before selection, one colony of E. coli TG 1 was taken from a minimal 
medium plate and grown in 5 ml of 2xTY overnight at 37 DC with shaking at 200 rpm. On 
the day of selection, 50~1 of this culture was inoculated to 50 ml of 2xTY and incubated at 
37 DC with shaking until the culture entered exponential growth and the OD 600nm was 
0.45. Then 250 ~l of the eluted phage from each immunotube was added to 1.75 ml of 
exponentially growing TG 1 cells and incubated at 37 DC in a water bath for 30 minutes. 
1O~1 of infected TG 1 cells, 1 0 ~l of a 1 in 102 dilution and 1 0 ~l of a lin 104 dilution were 
spotted on TYE plates containing 1 00 ~g/ml ampicillin and 1 % glucose and grown 
overnight at 30DC to titre the phage. The remaining 250 ~l of phage were stored at 4 DC for 
later use. The following day, after calculating the output of phage from the first round of 
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selection from the number of colonies on titration plates and first round titre, these plates 
were stored at 4 °c for future analysis of first round phage antibodies 
The remaining cultures of infected TG 1 were spun in a microcentrifuge at 11600 g for 
5 minutes. The pelleted bacteria were resuspended in 50 III of 2xTY and plated on two 
TYE plates containing 100 Ilg/ml ampicillin and 1 % glucose and grown overnight at 30°C. 
Colonies were then scraped from the plates with a glass spreader and inoculated into 2 ml 
of 2xTY containing 100 Ilg/ml ampicillin and 1 % glucose. Care was taken to keep the I 
and J libraries separate throughout. One ml of these bacteria were stored at -80°C in 15% 
glycerol and 50 III of the remaining bacteria were used in phage rescue for the next round 
of selection. 
Rescue of selected phage antibodies 
50 III of bacteria from each library from the first round of selection were inoculated to 
50 ml of 2xTY containing 100 Ilg/ml ampicillin and 1 % glucose and grown at 37°C with 
shaking at 200 rpm until OD 600 nrn was approximately 0.4. At this OD, 5 x 1010 pfu of 
KM13 helper phage were added to 10 ml of culture and incubated without shaking at 37°C 
in a water bath for 30 minutes. The cultures were then centrifuged at 3000g for 10 minutes. 
The pelleted bacteria were resuspended in 50 ml of 2xTY containing 100 Ilg/ml ampicillin, 
50 Ilg/ml kanamycin and 0.1 % glucose and incubated shaking at 30°C overnight. The 
following day, overnight cultures were spun at 3300g for 25 minutes. 
To precipitate phage from the culture supernatants, 10 ml of cold PEGlNaCI (20% 
polyethylene glycol 6000, 2.5 M NaCl) was added to 40 ml of each supernatant. After 
mixing well, the mixtures were left for 1 hr on ice and then centrifuged at 3300g for 30 
minutes. Supernatants were poured away to remove PEGlNaCI and the precipitated phage 
were resuspended in 2 ml of PBS and spun at 11600g for 10 minutes in a micro centrifuge 
to remove remaining bacterial debris. 1ml of each rescued phage library (supernatant) was 
stored at 4 °c and remaining 1 ml was used for next round of selection. 
Titration of rescued phage 
To assay the titre of phage rescued from the first round of selection and thereby 
determine the phage input for the second round of selection, 1 III of rescued phage from 
each library was diluted into 100 III PBS and the dilution repeated to generate six serial 
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100-fold dilutions in total. 900 ).11 of TG 1 at an OD 600 nm of about 0.4 was added to each 
tube and incubated at 37 DC for 30 minutes. 10 ).11 of each dilution was spread onto a TYE 
plate containing 100 ).1g/ml ampicillin and 1 % glucose and grown overnight at 30 DC. 
Second round of selection 
In the second round of selection, two immunotubes (Nunc, Denmark) were coated 
overnight at room temperature with a lower concentration of purified K99 (10 ).1g/ml) to 
isolate phage antibodies with higher specificity and affinity as were done previously by 
some other investigators (Shadidi and Sioud, 2001). 
The next day, immunotubes were washed and blocked as for the first round of 
selection. 1.4 x 1012 PEG precipitated phage in 2% MPBS from the first round of selection 
oflibrary I were added to one immunotube and 1.3 x 1012 PEG precipitated phage in 2% 
MPBS from the first round of selection of library J were added to a second tube as input 
phage. Immunotubes were incubated for 1hr with rotation and for 1hr standing at room 
temperature and were washed 20 times with PBS containing 0.1 % Tween 20. The 
remaining procedures including elution of selected phage, infection of TG 1 cells, 
superinfection with KM13, recovery of phage and titration were done as described for the 
first round. 
Third round of selection 
All procedures in the third round of selection of phage library I and library J were 
done as for previous rounds. The coating of immunotubes with purified K99 and washing 
steps were carried out as for round two. The titre of input phage antibodies for library I was 
1.4 x 1012 and for library J, it was 3 x 1010 pfu in 2% MPBS. 
Screening phage antibodies by ELISA 
After three rounds of selection, phage antibodies from each round were screened for 
reaction against purified K99. Screening was done with the entire population of phage 
eluted at each round of selection; this is termed "polyclonal phage ELISA". It was also 
carried out with individual phage clones generated from single colonies of each round of 
selection; this is tenned "monoclonal phage ELISA". 
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Polyclonal phage ELISA 
Antigen coating 
Two rows of an ELISA plate (Nunc, Denmark) were coated with 100 ).11 of purified K99 
at 20 ).1g/ml in PBS. As 2% MPBS was used during phage antibody selection, another two 
rows of the plate were coated with 100 ).11 of 2% MPBS to check the specificity of the 
selected phage antibodies (Table 4.3). The plate was incubated at room temperature 
overnight to allow antigen binding. 
Blocking 
Next day, unbound antigen was discarded by inverting the plate, shaking it, wells were 
washed three times with PBS. The wells were then blocked by adding 200 ).11 of2% MPBS 
and incubating for 2 hrs at 37°C. 
Preparation and addition of phage antibodies 
40 ).11 of PEG precipitated phage from the original libraries prior to selection, and from 
each round of selection was diluted in 400 ).11 of 2% MPBS. As a negative control for this 
experiment, 10 ).11 ofKM13 helper phage was diluted in 100 ).11 of2% MPBS. 
The blocked wells of the ELISA plate were washed three times with PBS and 100 ).11 
of each diluted phage stock was added to wells coated with K99 and milk as shown in 
Table 4.3. The plate was incubated for Ihr at room temperature. 
Detection of bound phage antibodies 
After washing three times wells with PBS containing 0.1 % Tween 20 to remove 
unbound phage, 100 ).11 of a 1:2500 dilution of HRP-anti-M13 monoclonal antibody 
(Amersham Pharmacia Biotech, UK) in 2% MPBS was added to all wells. By binding to 
p VIII protein on the phage capsid, this antibody detected phage captured to the coated 
plastic. The plate was incubated at room temperature for 1 hr. 
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Development 
Wells were washed three times with PB S containing 0.1 % Tween 20 to remove 
unbound antibodies. 100 ).11 of developer solution was added to each well. The composition 
of this solution was 0.1 M citric buffer pH 4.5, 0.4 mg/ml o-phenylenediamine (Sigma, 
UK) and 0.4 ).1l/ml of 30% hydrogen peroxide. The colorimetric reaction was read after 5 
min at 450 nm on an ELISA reader. 
Monoclonal Phage ELISA 
Preparation of monoclonal phage antibodies 
20 individual colonies picked at random from the original libraries, the first, and the 
second rounds of selection and 36 individual colonies from the third round of selection 
were inoculated into 100 ).11 of 2xTY containing 100 ).1g/ml ampicillin and 1 % glucose in 
96 well plates. Separate plates were used for library I and for library J. Colonies were taken 
from plates used to titrate phage stocks. The plates were incubated overnight at 37°C with 
shaking at 200 rpm. 
The following day, approximately 2 ).11 of overnight cultures were transfered to further 
96 well plates containing 200 ).11 of 2xTY, 100 ).1g/ml ampicillin and 1 % glucose per well 
using a multi-channel pipette. Plates were incubated at 37°C for 2 hrs to reach to an OD 
600 nm of about 0.4. Then 25 ).11 of 2xTY containing 100 ).1g/ml ampicillin, 1 % glucose 
and 109 helper phage was added to each well to initiate superinfection. Plates were 
incubated again at 37°C with shaking at 200 rpm for 1 hr to allow infection of the TG 1 
cells with helper phage. The plates were then centrifuged at 1800g for 10 minutes and the 
supernatants were aspirated off. Each pellet was resuspended in 200 ).11 of 2xTY containing 
100 ).1g/ml ampicillin and 50 ).1g/ml kanamycin. Cells were grown overnight at 30°C with 
shaking at 200 rpm to allow replication and rescue of the phage antibodies. 
The next day, plates were spun at 1800g for 10 minutes. Each supernatant was then 
recovered for use as monoclonal phage antibody III ELISA assay. 
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Table 4.3 Adding phage antibodies to ELISA plate 
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Antigen coating 
Two ELISA plates (Nunc, Denmark) were coated with 100 j.ll per well of 10 j.lg/ml of 
purified K99 in PBS. Plates were left overnight at room temperature to allow the K99 
antigen to bind to the plastic wells. 
Blocking 
The next day, unbound antigen was discarded and the wells were washed three times 
with PBS. The wells were blocked by addition of200 j.ll of2% MPBS and incubation for 2 
hrs at 37°C. 
Addition monoclonal phage antibodies 
After washing the wells three times with PBS, each culture supernatant containing 
phage antibodies was diluted 1/2 in 2% MPBS and 100 j.ll was added to each well to check 
their reaction against K99. Plates were left for 1 hr at room temperature for binding. 
Detection of bound phage antibodies 
After washing three times wells with PBS containing 0.1 % Tween 20 to remove 
unbound phage antibodies, 100 j.ll of 1:2500 dilution of HRP-anti-M13 monoclonal 
antibody (Amersham Pharmacia Biotech, UK) in 2% MPBS was added to all wells. Plates 
were then incubated at room temperature for 1 hr. 
Development 
Wells were washed three times with PBS containing 0.1% Tween 20 to remove 
unbound antibodies. 100 j.ll of developer solution (composition as described previously) 
was added to each well. The colorimetric reactions were stopped after 10 minutes by 
adding 50 j.ll of 1 M sulphuric acid and read at 490 nm in an ELISA reader. 
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Production soluble scFv fragments 
Expression of soluble scFv antibodies can be achieved by induction of individual 
colonies of TG 1 cells picked from the various rounds of selection. Since TG 1 cell is able to 
suppress tennination at the TAG codon by introduction of a glutamate residue, this will 
ensure the expression of all clones including those in which the TAG codon lies in the scFv 
coding sequence. Since this stop codon also lies between the scFv and gIll sequences, 
expression of a scFv-pIll fusion occurs which tends to lower the overall levels of antibody. 
To overcome this problem, the selected phage can be used to infect HB2151 (K12 ara 
iJ.(lac-proABj ThilF' proA+B laclq lacZiJ.M15j which is a non-suppresor strain and can be 
induced to give soluble scFv fragments. Expression in this strain produces higher levels of 
soluble scFv than in TGI but scFvs with TAG stop co dons in the reading frame are not 
expressed. 
Transfection of E.coli HB2151 cell by phage antibodies 
To infect E. coli HB215l, a single colony was picked from a minimal medium plate 
and was grown in 5 ml of 2xTY overnight at 37°C with shaking at 200 rpm. The following 
day, 300 III of culture was added to 30 ml of 2xTY media and was grown at 37°C with 
shaking until the OD at 600 nm was about 0.4. At this point, 10 III of phage antibodies 
taken from the original I and J libraries or eluted from each round of selection were added 
to 200 III aliquots of culture in microfuge tubes. The tubes were incubated at 37°C in a 
water bath for 30 minutes to allow infection of the exponentially growing HB2151 bacteria 
to take place. Then 50 Ill, 50 III of a 1: 1 02 dilution, 50 III of al: 104 dilution and 50 III of a 
1: 1 06 dilution of infected bacteria were plated onto TYE plates containing 100 Ilg/ml 
ampicillin, 1 % glucose. Plates were incubated overnight at 30°C in an incubator. 
Growing selected colonies 
From the TYE plates, 20 colonies from the original libraries, from round one and from 
two, and 36 colonies from round three were picked into 100 III aliquots of 2xTY 
containing 100 Ilg/ml ampicillin, 1 % glucose set out in two 96 well plates. Separate plates 
were used for each library. The samples were grown overnight at 37°C with shaking at 
200 rpm. 
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The next day, small inocula (about 2 /-Ll) were transferred to two fresh 96 well plates 
containing 200 /-Ll per well 2xTY containing 100 /-Lg/ml ampicillin and 0.1 % glucose. 
Cultures were grown on at 37 DC with shaking until the OD 600 nm was approximately 0.9 
(about 3 hrs). Then, 25 /-Ll 2xTY containing 100 /-Lg/ml ampicillin and 9 mM IPTG was 
added to each well to initiate expression. Plates were incubated for a further 20 hrs at 30 DC 
with shaking to allow expression of soluble scFv antibodies. 
Isolation and preparation of scFv antibodies for ELISA 
Since scFvs expressed in HB2151 cells are released into the culture supernatant, plates 
were centrifuged at 1800g for 10 minutes to pellet the bacteria. 50 /-Ll of each supernatant 
was diluted with 50 /-Ll of BSAIPBS to a final concentration of 3% for use in ELISA 
screenmg. 
Screening monoclonal soluble scFvs by ELISA 
Antigen coating 
Two ELISA plates (Nunc, Denmark) were coated with 100 /-Ll per well of 20 /-Lg/ml 
purified K99 in PBS. Plates were left overnight at room temperature to allow binding of 
K99 to the plastic. 
Blocking 
The next day, wells were washed three times with PBS and then blocked by adding 
200 /-Ll of 3% BSAIPBS for incubation at 37 DC for 2 hrs. 
Addition of scFv antibodies 
After washing wells three times with PBS, 100 /-Ll of the diluted culture supernatants 
were added to wells of the ELISA plates to check their reaction against K99. Plates were 
left for 1.5 hr at room temperature to allow binding of scFvs to antigen. 
Detection bound scFv antibodies 
All wells were washed three times with PBS containing 0.1 % Tween 20 to remove 
unbound scFv antibodies. 100 /-Ll of a 1 :3000 dilution of recombinant Protein L-HRP 
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(Actigen, Norvey) in 3% BSA/PBS was added to all wells. Protein L-HRP recognises to 
scFv antibodies from the Tomlinson I and J libraries via the kappa light chain but this 
interaction does not effect the binding of the antibody to its antigen. Plates were then 
incubated at room temperature for 1 hr. 
Development 
Wells were washed three times with PB S containing 0.1 % Tween 20 to remove 
unbound Protein L-HRP. 100 fll of developer solution (composition as described 
previously) was added to each well. The colorimetric reactions were stopped after 10 
minutes by adding 50 fll of 1 M sulphuric acid and read at 490 nm on an ELISA reader. 
peR characterisation of selected scFvs 
To assess the presence of scFv genes in 10 selected clones from the Tomlinson library 
I and 5 from library J, the following PCR was performed. The clones were chosen because 
of the strength of their recognition of purified K99 in ELISA. 
Single colonies were picked from TYE plates into 5 ml of 2xTY containing 100 flg/ml 
ampicillin and 1 % glucose and grown overnight at 37°C. Plasmid DNA was isolated and 
purified from 3 ml of culture by using a miniprep kit (Qiagen, UK). As a positive control, 
plasmid DNA was prepared from a clone carrying the sequence of an anti-ubiquitin scFv. 
Primers pelB and pHEN seq were chosen to amplify across the full insert in each clone. 
The 25-fll PCR mixture contained each primer at 0.5 flM of, dNTPs 0.25 mM (Promega), 
4mM MgCh, Ix reaction buffer (containing 50 mM KCL, 10 mM Tris-HCL pH 9.0 and 
0.1% Triton®X-100), 2.5 units ofTaq DNA polymerase (Promega) and 1 fllofplasmid 
DNA as template. The samples were amplified in a Techne thermal cycler under the 
following conditions: the reaction was heated to 94°C for 10 min and then 35 cycles of 
amplification were performed beginning with a 1 min denaturation at 94 °c, primer 
annealing at 55°C for 1 min, and extension at 72 °c for 3 min. Final extension took place 
for 10 min at 72°C. 
10 fll samples of the PCR products were analysed by electrophoresis on 1 % agarose 
gels for 45 min at 100 V. Gels were stained with ethidium bromide, and photographed 
under UV light. 
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Plasmid digestion with restriction enzymes 
Purified plasmids of clones chosen for detailed analysis (10 from library I and 5 from 
library J isolated from rounds 2 and 3) were digested with restriction enzymes to confirm 
the size of the inserts. 20 III reaction mixtures were set up for each sample comprising 6 III 
of plasmid DNA, 1 III (10U) of Neal (Promega, UK), Illl (10U) of Notl (Promega, UK), 
10 III of distilled water, and 21ll of buffer D (60 mM Tris-HCL (PH 7.9), 1.5 M NaCl, 60 
mM MgCb and 10 mM DTT). The reaction mixtures were incubated at 37°C for 2 hrs. 
4 III of the digestion products was electrophoresed on a 1 % agarose gel for 45 min at 
100 V, stained with ethidium bromide, and photographed under UV light. 
Western blotting of selected clones from library I and library J 
Western blotting experiments were performed to characterise the scFv antibodies from 
libraries I and J. 
Sample preparation 
One colony of each selected clone in HB2151 was picked from TYE plates and grown 
in 5 ml of 2xTY containing 100 Ilg/ml ampicillin and 1 % glucose overnight at 37°C. The 
following day, 500 III of overnight culture was added to 50 ml of 2xTY containing 100 
Ilg/ml ampicillin and 0.1 % glucose and incubated at 37°C with 200 rpm shaking until the 
OD at 600 nm was about 0.900. IPTG was then added to a final concentration of 1 mM to 
induce expression of scFv antibodies. Cultures were grown on at 30°C for 22 hrs with 
shaking at 200 rpm. The cultures were spun at 5000g for 20 minutes, the supernatants were 
recovered and after filtration, concentrated using Amicon Ultra-4 centrifugal filters 
(Millipore, UK) to approximately 1125 initial volume. All concentrated culture 
supernatants were exchanged into PBS to assist clear resolution on SDS gels and Western 
blots. 20 III of each sample was mixed with 10 III of 3x SDS boiling buffer and heated for 
5 min in boiling water. 15 III of each sample was then loaded to a 12.5 % SDS-




For blotting, nitrocellulose membrane (Amersham Pharmacia Biotech, UK) and four 
pieces of Watman filter paper were cut to the same size as the gel and soaked with the gel 
in transfer buffer for 20 min. For transfer, a fibre pad was overlayed with two pieces of 
filter paper, the gel, nitrocellulose membrane, and the final two layers of filter papers. 
After addition of a second fibre pad, the sandwich was assembled into a blotting cassette 
and loaded into a BioRad electrophoresis tank. Transfer buffer was added along with a 
frozen insert to avoid overheating during transfer. Care was taken to ensure that the gel lay 
to the anode (-) side of the assembly and the membrane lay to the cathode (+) side. 
Proteins were transferred from the gel to the membrane for 1 hr at 100 volts. After transfer, 
the membrane was carefully separated, washed three times with PBS and stained with 
Ponceau red dye (Sigma, USA) by shaking for 5 min at room temperature to confirm that 
proteins had been transferred from the gel to the membrane. The membrane was then 
washed with distilled water to remove the dye. The membrane was blocked with 3% 
MPBS for 1 hr at room temperature with shaking. The membrane was then washed three 
times with PBS and was incubated in a 1 :3000 dilution of anti-c-myc monoclonal antibody 
(Sigma, UK) in 2 % MPBS for 1 hr at 37°C with shaking at 200 rpm. After washing the 
membrane three times with PBS containing 0.05 % Tween 20, an anti-mouse HRP 
conjugate (Sigma, UK) was added at 1: 1 000 dilution in 2 % MPBS and incubated for 1 hr 
at 37°C with shaking. The membrane was washed as before and developed with 4-chloro-
I-naphthol substrate (Sigma, UK). 
Dot blotting of selected clones from libraries I and J 
Since previous experiments had shown that K99 is loses its reactivity with anti-K99 
mouse monoclonal antibodies after heating, dot blot experiments were performed to assess 
the binding of selected soluble scFvs to purified K99 on nitrocellulose. 
Sixteen small strips of nitrocellulose (Amersham, UK) were each spotted three times 
with two 2 ).!l aliquots of purified K99. The strips were allowed to dry between spotting to 
increase the concentration of antigen at the point of application. To test whether the anti-
K99 reactivity of selected scFvs was retained after heating the antigen, an extra spot of 
K99 that had been heated to boiling for 5 minutes in SDS boiling buffer was spotted out on 
11 of the strips. The nitrocellulose strips were then blocked with 3 % MPBS for 1 hr at 
room temperature with shaking. Strips were washed three times with PBS and then were 
incubated for 1 hr at 37°C with shaking with 200 ).!l of concentrated culture supernatants 
173 
containing the scFvs under analysis (1/2 diluted in 2 % MPBS). Next, the membrane strips 
were washed three times with PBS containing 0.05 % Tween 20, once with PBS and 
incubated with 1 :3000 anti-c-myc monoclonal antibody (Sigma, UK) in 2 % MPBS for 1 
hr at 37°C with shaking at 200 rpm. After washing membrane three times with PBS 
containing 0.05 % Tween 20, a l: 1 000 dilution of anti-mouse HRP conjugate in 2 % 
MPBS was added to all strips and incubated at 37°C for another 1 hr. Membrane strips 
were washed as previous step and developed with 4-chloro-l-naphthol substrate. 
Sequencing of selected clones 
To determine the diversity of the selected scFv genes (10 from library I and 5 from 
library J), their DNA and predicted amino acid sequences were determined. 
After growing individual colonies in 5 ml of 2xTY containing lOa /-lg/ml ampicillin 
and 0.1 % glucose overnight at 37°C with shaking, plasmid DNA was isolated from 3 ml of 
culture using Qiagen miniprep reagents. The primers forward pelB and reverse gIn (Table 
4.1) were chosen for sequencing and diluted to 3.2 /-lM. Sequencing was done at the 
MBSU, University of Glasgow using Big Dye (Applied Biosystems) and ET-Dye 
Terminator (Amersham Bioscience) chemistries. Samples were analysed on a 
MegaBACEIOOO (96 capillary) sequencing machine. The reaction chemistry is based on 
the dideoxy method developed by Sanger et al.(1977). The sequence data was analysed 
using DNA Star software. Sequences were aligned to V BASE using DNAPLOT database 
at the Centre for Protein Engineering, MRC, Cambridge, UK ( www.mrc-
cpe.cam.ac.uk/vbase-ok.php?menu=901 ). The confirmed nucleic acid sequences were 
translated and aligned using MEGALIN software. 
Final selection of scFv antibodies 
Four scFvs from the Tomlinson library I and two scFvs from library J, which had 
diverse sequences, high levels of expression as soluble protein and high activity in dot 
blotting experiments with purified K99 were chosen for purification and further 
investigation. 




In order to make large amounts of soluble scFv, one colony of each clone was grown 
overnight in 5 ml of 2xTY containing 100 /lg/ml ampicillin and 1 % glucose at 37°C with 
shaking at 200 rpm. The Sml overnight culture was added to 1 litre of 2xTY containing 
100 /lg/ml ampicillin and 0.1 % glucose in a 2 litre shake flask and grown on at 37 with 
shaking at 200 rpm. When cultures reached an OD at 600 nm of approximately 0.9, IPTG 
was added to ImM and incubation continued with shaking at 200 rpm at 30°C for 20-22 
hr. 
Concentration of culture supernatants 
As the expressed soluble scFvs are released into the culture supernatants, bacterial 
cells were removed by centrifugation for 20 minutes at 5000g at 4°C. Then the culture 
supernatants were concentrated using a tangential flow filter (Vivaflow 200, Vivascience, 
Germany) containing a polyethersulfone membrane using a peristaltic pump. Briefly, the 
membrane was initially washed by pumping 400 ml of deionised water through the system 
and recirculating at 90 mllmin to remove residual chemicals and any air pockets. Then, the 
culture supernatant was pumped through the system at the same rate. As the last few 
millilitres of sample entered the system, the input was switched to 100 ml of 20mM 
phosphate buffer containing 0.5M NaCl, pH 7.2, to adjust the buffer composition of the 
concentrated culture supernatant to those used for binding in subsequent affinity 
purification methods. As the desired volume of concentrate approached (20-25 ml), the 
recirculation rate was reduced to 30-40ml/min for 1-2 min to increase sample recovery. For 
recovery of concentrated protein, the feed line was removed from the sample and the 
residual volume present in the system was pumped back into a container. To increase 
efficiency of recovery, 25ml of 20mM phosphate, 0.5M NaCl, pH7.2 was rinsed through 
the system, and recovered as before. 
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Purification of soluble scFvs 
Buffer composition 
For preparation of binding buffer (starting buffer), 20mM sodium phosphate buffer pH 
7.6 was made first and then NaCI was added to a final concentration of 0.5 M. The final 
pH was about 7.3. Three elution buffers of were prepared in binding buffer containing 
20mM, 80mM and 200mM imidazole (Sigma, USA). All buffers were sterilised by passing 
them through a 0.2 flM filter before use. 
Column preparation and equilibration 
To purify soluble antibodies, a 1ml HiTrap Chelating HP column (Amersham 
Pharmacia Biotech, UK) was chosen, exploiting the histidine repeats present at the 
carboxy-terminus of scFvs from the Tomlinson libraries. To prepare this column, it was 
washed with 5 ml of distilled water at 1 ml/min by using a Pharmacia Biotech pump P-1 
(Amersham Pharmacia Biotech AB, Sweden). The column was then charged with 0.5 ml 
0.1 M NiS04 and washed again with 5 ml of distilled water. After that, a blank run was 
performed to elute non-specifically bound metal ions that might otherwise be eluted during 
the desorption. To do this, 5 ml of binding buffer was pumped through the column, 
followed by 5 ml of elution buffer (200mM imidazole). The column re-equilibrated with 5-
10 ml of binding buffer before application of the sample. 
Sample preparation 
The concentrated sample that had been exchanged into banding buffer during 
concentration of culture supernatant was filtered through a 0.2 flM filter immediately 
before applying to the column. 
Purification procedure 
20 ml of sample was applied to an equilibrated HiTrap column at 1 ml/min. The 
column was then washed with 5 ml of binding buffer and elution buffer containing 20 mM 
and 80 mM imidazole (Sigma,USA) to elute non-specifically bound proteins and thereby 
increase the purity of the final eluate. Finally, 5 ml of elution buffer containing 200 mM 
imidazole was pumped through to elute the attached scFv antibody. The eluate was 
collected in fractions and concentrated to 1/5 their initial volume using an Amicon Ultra-4 
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centrifugal filter (Millipore, UK) and exchanged into PBS buffer at 4°C by. The purified 
scFv was stored at -20°C for future use. 
Measurement of purified scFv concentration 
Before testing the biological activity of the 6 purified scFvs, their concentration and 
that of an anti-BSA scFv purified by the same methods were measured by BCA Protein 
Assay Kit (Collins et al.). The method has been described previously. 
Biological activity of selected scFvs 
Comparison of activity of purified scFvs by ELISA 
The purified scFvs were adjusted to the same protein concentration and their reactivity 
towards K99 was tested in an ELISA experiment. 
Antigen coating 
An ELISA plate (Nunc, Denmark) was coated with 100 III per well of 20 Ilg/ml of 
purified K99 in PBS. The plate was left overnight at 4°C to allow binding of the K99 
antigen to the plastic. 
Blocking 
The next day, the wells were washed three times with PBS. Then 200 III of 3% 
BSAlPBS was added to all wells except two wells that were to be probed with the anti-
BSA scFv negative control. These wells were blocked by adding 2% MPBS. The plate was 
then incubated for 2 hrs at 37°C. 
Addition of scFv antibodies 
After washing the wells three times with PBS, 100 III of the purified scFv samples 
were added, diluted to an scFv concentration of 8 Ilg/ml in blocking buffer. For a positive 
control, a sheep anti-K99 polyclonal antibody was used; for negative controls, the anti -
BSA scFv and a PBS blank were added to K99-coated wells. Each antibody was added in 
duplicate. Plates were left for 1.5 hr at room temperature to allow binding of the antibodies 
to antigen. 
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Detection bound scFv antibodies 
All wells were washed three times with PBS containing 0.1 % Tween 20 to remove 
unbound antibodies. 100 fll of 1 :3000 dilution of recombinant Protein L-HRP (Actigen, 
Norvey) were added in blocking buffer to all wells containing scFv antibodies.100 fll of 
anti-sheep HRP (Sigma, UK) at a dilution of 1: 1 000 was added to positive control wells. 
The plate was then incubated at room temperature for 1 hr. 
Development 
Wells were washed three times with PBS containing 0.1 %Tween 20 to remove 
unbound HRP conjugates. 100 fll of developer solution (composition described previously) 
was added to each well. The colorimetric reactions were measured after 10 minutes at 450 
nm on an ELISA reader. 
Haemagglutination inhibition assay 
Some erythrocytes (RBCs) such as those from sheep have on their surface receptors to 
which K99 fimbriae can bind, thereby modelling the interaction of the adhesion factor with 
enterocytes (Burrows et aI., 1976). Haemagglutination (HA) can thus occur with purified 
fimbriae or with bacteria such as the enterotoxigenic strain of E. coli B41 that express K99 
(Vazquez et aI., 1996). In some cases, this haem agglutination activity can be inhibited 
using anti-fimbrial antibody. Also some investigators have reported that antibodies with 
haemagglutination inhibiting activity can have the potential to block attachment of bacteria 
to epithelial cells (Burrows et aI., 1976). The following experiments were performed to 
assess if the selected scFvs possessed these biological activities. 
Titration of the haemagglutinating activity of E. coli 841 
This was assessed with a test for direct haem agglutinating activity. 
Preparation of bacteria 
One colony of E.coli B41 grown on sheep blood agar was grown in 5 ml of Minca 
medium at 37°C overnight with shaking at 200 rpm. Following previous investigations 
(Orskov et al., 1975), another colony was grown as a negative control in the same medium 
at 18°C since under these conditions, K99 fimbriae are not expressed. 50 fll of each culture 
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was added to the first well of a 96 well microplate (Iwaki, Japan). 25 fll aliquots were 
diluted two fold in PBS containing 1% mannose across the plate. Since the interaction 
between K99 and its receptor is resistant to mannose, this was intended to inhibit non-
specific haem agglutination or the interaction of mannose-sensitive factors with erythrocyte 
receptors. Bacteria were not added to the last well to provide an additional negative 
control. 
Preparation of sheep RBC and haemagglutination procedure 
To prepare washed suspensions of sheep red blood cells at a density of about 1.5 % 
(v/v), 270 fll of defibrinated sheep blood (E and 0 Laboratories, Scotland) was centrifuged 
at 13000 rpm for 4 min. The pellet was then washed three times with PBS containing 1 % 
mannose (Sigma, UK) by resuspension and spinning for 4 min. Finally the pellet (about 
100 fll volume) was resuspended in 7.5 ml PBS containing 1 % mannose. 
25 fll of this suspension was added to each well containing bacteria and, after mixing, 
the plate was incubated at 4 DC overnight. The titre was defined as the highest dilution of 
bacterial suspension that showed complete haem agglutination. 
Haemagglutination Inhibition 
The haem agglutination inhibition test was performed by setting up serial dilutions of 
the selected anti-K99 scFv antibodies, a polyclonal anti-K99 antibody as a positive control 
and an anti-ubiqutin scFv antibody as negative control. 50 fll of each of each purified 
antibody, adjusted to similar protein concentrations, was added to the first wells of a 96 
well U bottom microplate (Iwaki, Japan). 25 fll of each antibody was then diluted two-fold 
across the plate in 25 fll of PBS containing 1 % mannose. The last well in each row was left 
blank and contained only 25 fll of dilution buffer as an additional negative control. Then 
25 fll of 4 haem agglutinating units of bacterial suspension in PBS containing 1 % mannose 
were added to all wells. After mixing, plate was incubated at 37DC for two hrs. After that 
the plate was cooled and 25 fll of a 1.5 % suspension of sheep red blood cells was added to 
all wells. Haemagglutination inhibition (HI) titres were determined by the highest dilutions 
of antibodies that inhibited haem agglutination after 1 hr at 4 DC. 
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Indirect Fluorescent Antibody Test (IFA) 
Since K99 fimbriae are located at the surface of the E. coli strain B41, the binding of 
antibody against K99 should be visible under the immunofluorescent microscope using 
fluorescently labelled reagents. To detect whether the isolated scFv antibodies recognised 
K99 fimbriae on bacteria, they were tested by an indirect fluorescence antibody assay. 
Slide preparation 
Nine clean glass microscope slides (LDH, UK) were printed with a circle with a 
diameter of about 10 mm by using nail varnish. 5 /-ll of an overnight culture of B41 grown 
in Minca medium at 37°C was added to eight slides and as a negative control, 5 /-ll of the 
same strain grown at 18°C was added to the last slide. The bacteria were spread inside the 
circles and incubated at room temperature until dry. The bacteria were then fixed by 
adding 50 /-ll of 4 % paraformaldehydell % glutaraldehyde in PBS and incubating for 15 
minutes at room temperature. 
Blocking 
After fixation, the slides were washed three times with PBS to remove remammg 
paraformaldehyde, glutaraldehyde and unfixed bacteria. Then the isolated areas on the 
slides were blocked by adding 50 /-ll of 3 % BSA/PBS. Slides were incubated for 30 
minutes at room temperature inside a plastic container. 
Addition of scFv antibodies 
The excess blocking buffer was removed by washing three times with PBS. 50 /-ll of 
the purified scFvs, adjusted to similar protein concentrations, was added to each slide. As a 
negative control, an anti-BSA scFv antibody was added to one slide carrying fixed B41 
bacteria, grown at 37°C. Also, a commercial monoclonal anti-K99 antibody was added to 
one slide carrying B41 grown at 37°C and one slide with B41 grown at 18°C as positive 
and negative controls respectively. The monoclonal was diluted to 1 :500. Slides were then 
incubated at 37°C for 1 hr. 
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Addition of secondary and fluorescent antibodies 
All slides were washed three times with PBS, and 50 III of a mouse monoclonal 
antibody against c-myc at was added at a dilution of 1 :200 in 3 % BSA/PBS to all slides 
carrying scFvs. These slides were incubated for 1 hr at 37 DC. 
To label all samples with fluorescent antibody, 50 III of a 1 :200 dilution of a 
fluorescein linked anti-mouse Ig antibody (Amersham Life Science) was added to all. The 
incubation time for labelling was 30 minutes at 37 DC. 
To observe the binding of antibodies to the K99 fimbriae, all slides were washed with 
PBS and after adding cover slips, they were observed under normal and UV illumination 
on a Zeiss microscope under 1000x magnification. Images were captured to a computer 
running OpenLab software. 
Electron Microscopy and Immunolabelling 
Staining of fimbriae for EM observation 
In order to find an effective and convenient staining method for observation of K99 
fimbriae by electron microscopy, two different protocols were tested. 
Growing of bacteria 
A single colony of E. coli B41 was picked from a sheep blood agar plate and grown 
overnight with shaking in 5 ml of Minca medium at 37 DC. As a negative control, a second 
colony of bacteria was grown at 18 DC. At this temperature, the bacteria do not express 
K99 fimbriae (Orskov et aI., 1975). 
Preparation of grids 
Nickel 300 mesh grids coated with formvar and carbon were prepared in the Integrated 
Microscopy Facility, IBLS. Before using the grids for samples, they were pre-cooled on ice 
for 10 minutes. 
Droplets of 40 III of each bacterial culture were put onto a clean surface of Parafilm. 
Grids were then put on top of these droplets and incubated for 30 seconds. The excess fluid 
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from grids was removed by touching the edge to filter paper, held between the tips of a pair 
of forceps. 
Fixation 
Bacteria were fixed onto the grids by incubation on top of droplets of fixative buffer 
for 30 minutes, in a fume hood. The composition of the fixative buffer was 2 % 
paraformaldhyde in PBS containing 0.1 % glutaraldehyde. After that, the fixative buffer 
was removed from grids by touching the edge to filter paper and washing three times for 2 
minutes on droplets of PBS and distilled buffer under a plastic cover. 
Negative staining 
This staining was the method chosen since the K99 fimbriae are located around the 
bacteria. This staining is well-established, extremely simple and quick to execute. The 
grids were simply incubated on droplets of Nanovan stain (Nanoprobes, USA) by holding 
on forceps. The stain was then removed by touching the grids onto the edge of filter paper. 
Grids were rinsed by transferring grids six times (3 minutes each) to droplets of distilled 
water. After drying at room temperature, the bacteria were observed by electron 
mIcroscopy. 
Negative staining by methylcellulose method 
This staining was done by incubating the grids on 40 J..Ll droplets of 2 % uranyl acetate, 
0.15 M oxalic acid, pH 7.2 for 10 minutes. Grids were then washed four times for 30 
seconds aqueus on droplets of distilled water and briefly on droplets of containing 2 % 
methylcellulose and 0.1 % uranyl acetate. Excess stain was removed by touching the edge 
of filter paper to grids mounted on wire loops. Grids were then left overnight at room 
temperature to dry. 
Immunolabelling of K99 fimbriae 
To detect the binding of selected scFv antibodies to K99 fimbriae, all six scFvs were 
analysed by immunogold electron microscopy. B41 bacteria were grown in Minca medium 
at 37°C or 18 °c and were added to Nickel 300 mesh grids coated with formvar and 
carbon as described above. They were fixed as described for staining. 
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Washing and blocking 
In order to removed fixative, the grids were washed first four times for 2 minutes each 
wash on droplets of PBS and then three times for 5 minutes each on droplets of O.IM 
glycine in PBS. To prevent non-specific binding and suppress background in 
immunostaining, the grids were then blocked by incubation for five minutes for three times 
on droplets of 0.2% IPBS/acetylated BSA at room temperature. 
Addition of selected scFv antibodies 
For immunolabelling of the bacteria, 40 ).11 droplets of concentrated scFv antibodies 
were put on to a clean surface of Parafilm inside a petri dish. As positive controls, a drop 
of a 1 :500 dilution of mouse monoclonal anti-K99 antibody and a drop of a 1 :500 dilution 
of sheep polyclonal anti-K99 were also set up. For a negative control, a drop of anti-
ubiquitin scFv antibody used. Grids carrying fixed B41 grown at 37°C were placed on top 
of each droplet. Another negative control was prepared by adding a grid carrying fixed of 
B41 grown at 18°C to the top of a droplet of the mouse monoclonal antibody. The petri 
dish containing all samples and moist filter paper was incubated at 37 °c for 90 minutes. 
After incubation, the grids were washed six times for 5 minutes, each wash on droplets 
ofPBS/acetylated BSA (Aurion, Netherland) to remove unbound antibodies. 
Double labelling with protein A-gold 
Protein A from Staphylococcus aureus has five domains that mediate interaction with 
the Fc region of most mammalian IgGs. Protein A also binds to the Fabs or scFvs carrying 
heavy chains belonging to the VHIII family. Since all scFv antibodies in the Tomlinson 
libraries are derived from the V3-23IDP-47 and JH4b family segments, labelling with 
Protein A is possible. 
To label the scFv and control antibodies, 50 ).11 of 5nm Protein A - gold colloidal 
particles -5nm (EY Laboratories, CA) was diluted in 450 ).11 of 1 % BSA in PBS, pH 7.4. 
Then the grids were incubated on droplets of this diluted protein for 30 minutes at room 
temperature and washed six times for 5 minutes per wash on droplets of PBS/acetylated 
BSA three times. They were then further washed, six times for 3 minutes per wash on 
droplets of PBS and and six times on droplets of distilled water. Finally the grids were 
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stained with negative staining using methylcellulose uranylacetate as described above to 
stain the bacteria and fimbriae. 
Imaging colloidal gold by electron microscopy 
Images of the bacterial surfaces were obtained with a Zeiss 902 transmission electron 
microscope at 30,000 or 50,000 magnification. Images were then captured to computer and 
edited by SIS Esi Vision software. 
In vitro villus attachment assay 
Attachment ofK99 fimbriae to the villi of the small intestine villi in calves is essential 
for colonisation by enteropathogenic Echerichia coli and the stimulation of diarrhoea 
(Orskov et ai., 1975; Guinee et ai., 1976; Gaastra and de Graaf, 1982). This attachment can 
be modelled in vitro using isolated epithelial cells (Wilson and Hohmann, 1974), or 
preparations of the intestinal villi and brush border (Van den Broeck et aI., 1999). In the 
experiments that follow, in vitro assessment of bacterial colonisation was based on the 
method described by Girardeau previously (Girardeau, 1980). 
Preparation of bacteria 
E. coli strain B41 was grown on sheep blood agar overnight at 37°C. Next day, a 
single colony was picked from the plate and grown overnight in 5 ml of Minca medium at 
37°C with shaking to trigger expression of K99 fimbriae. As a negative control, a second 
colony was grown overnight in the same medium at 18°C with shaking. At this 
temperature, K99 is not expressed (de Graaf et al., 1980b). 
Preparation of villi 
The villi were isolated from a healthy calf, approximately 2 days old. At this stage, the 
villi are long and easily isolated. Slaughter and tissue isolation was carried out at the 
Moredun Research Institute, Edinburgh, by a qualified veterinary pathologist using 
authorised procedures. After slaughter, about 40 cm of jejunum was removed and opened 
longitudinally. The tissue washed immediately with ice-cold sterile Krebs buffer pH 7.2 
and transferred to a plastic bag containing cold Krebs buffer for transport back to Glasgow. 
There, a glass slide was used to gently detach the villi by scraping. The material was 
suspended in cold Krebs buffer and allowed to be settle. The villi were rinsed with the 
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same buffer several times until a clear supernatant was obtained. To store the villi and 
preserve the cells, the villi were taken up in Hank's-DMSO medium. The composition of 
the medium was 20 % calf serum containing ultra low levels of immunoglobulin (Gibco, 
UK), 10 % DMSO, 10 % glycerol, 15 % lactalbumin buffer (40mg/ml) and 45 % Hank's 
medium (Gibco, UK). The suspension was then divided between 1.5 ml cryotubes, placed 
at -20°C for several hours and then transferred for storage at -80 °c. 
Thawing and fixation of villi 
Cryotubes containing the villi suspension were thawed at room temperature for about 
lO minutes. The villi were placed into a Kerbs buffer with 2 % formaldhyde (Sigma, USA) 
for 1 hour in order to stop all enzyme activity which could potentially lyse the epithelial 
cells. Next, the villi were rinsed twice in 5 ml of Krebs buffer pH 7.2 to remove residual 
formaldehyde. The villi were then put in Krebs buffer pH 7.2 for at least 18 hours at 4 °c 
to stabilize. The stabilized villi were used within one week of fixation. 
Bacterial attachment 
To verify attachment of bacteria to villi via K99 fimbriae, villi were transferred with 
an automatic pipette into 1.5 ml of Krebs buffer pH 6.8. Overnight bacterial cultures were 
spun at 13000 rpm and resuspended in Krebs buffer pH 6.8 containing 1 % mannose to a 
final concentration of 4.8 x 10 8 bacteria. The denisty of bacteria was established by 
measuring OD at 600 nm and plate counts. The villi were transferred to the bacterial 
suspension, set up inside a sterile petri dish and the mixture was gently agitated at room 
temperature for 20 minutes or 1 hour. 
Observations 
After incubation, villi were removed with an automatic pipette and placed gently on a 
glass slide and covered with a cover slip. Observations were made on a Zeiss phase 
contrast microscope at 600 to 1000-fold magnification. The edge of villi, and in particular 
the brush-borders could be clearly distinguished. Bacterial attachment was confirmed by 
the presence of many cells on the villi surface or brush border after co-incubation for 20 or 
60 minutes. 
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Bacterial adherence inhibition assay 
The six selected, purified scFv antibodies were tested for their ability to inhibit the 
binding of E. coli B41 to isolated villi. 
Preparation of antibodies 
All six purified antibodies were diluted in PBS and adjusted to the same final 
concentration of 30 J..Lg/ml. As a negative control, a purified anti-BSA scFv was diluted to 
the same concentration. A sheep polyclonal anti-K99 antibody at a dilution of 1: 1 000 in 
PBS was used as a positive control. 
Preparation of bacteria 
B41 were added to 1.5 ml Eppendorff tubes and adjusted to a density of about 5 x 10 8. 
bacteria/ml. Bacteria grown at 18°C served as negative controls. All tubes were spun at 
13000 rpm for 1 min. The supernatants were discarded. The pellet was used for testing. 
In vitro inhibition assay 
The bacterial pellets were resuspended in each antibody to a final volume of 50 J..LI and 
incubated at 37°C for 45 min with agitation at 100 rpm. Then 500 J..LI of Krebs buffer pH 
6.8 / 1 % mannose containing about 50 stabilized villi were mixed with the bacterial 
suspension in sterile petri dishes. Next, the petri dishes were incubated at room 
temperature for 1 hour with gentle shaking. After incubation, the villi were examined by 
phase-contrast microscopy at a magnification of 600 or 1000x. The adhesion of bacteria to 
villi was observed along the length of the villi brush border at several random locations. 
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Results 
Production and titration of KM13 helper phage 
E.coli TG 1 cells were infected with serial dilutions of KM13 and plaques allowed to 
form in TYE H-top agar. A single plaque was isolated and used to infect a fresh 
exponential culture of TG 1 cells. Phage were precipitated from the culture supernatant 
with PEGlNaCl and resuspended in PBS. The titre of this helper phage stock was measured 
by infecting TG 1 cells with serial dilutions of trypsin treated phage, plating to TYE plates 
containing H-top agar, counting the resulting plaques and adjusting for dilution. As a 
control, the titre of non-trypsinised phage was also measured. As can be seen from the data 
in Table 4.4A, the difference in titre between treated and untreated phage was around 9 
orders of magnitude. The KM13 helper phage produced were then used for the preparation 
of the scFv antibody libraries. 
Preparation and titration of phage libraries 
TG 1 bacteria comprising the libraries were grown in 2xTY medium and infected with 
KM13 helper phage. Phage displaying the scFvs were then isolated from culture 
supernatants by precipitation with PEGlNaCl and resuspended in PBS. The size of the 
Tomlinson I and J libraries were then determined by infection of E. coli TG 1 cells with 
serial dilutions of phage and counting the number of ampicillin-resistant colonies that then 
grew on TYE plates. Table 4.4B shows the titre of each phage library as calculated in this 
way. 
Immunoreactivity of purified K99 at low concentrations 
To check that the K99 target would bind to plastic at low concentrations and remain 
detectable by specific antibody, ELISA was set up with serial dilutions of purified K99. 
The results are shown in Figure 4.4; it was clear that coating concentrations as low as 2.5 
~g/ml could still be efficiently detected with an anti-K99 monoclonal antibody. Phage 
antibodies are typically selected in immunotubes coated with target in the range 10-100 
~g/ml. It was clear from this preliminary experiment that purified K99 retains integrity 
when coated to plastic at low concentrations in this range. 
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SDS-PAGE and Western analysis of control scFvs 
Conditions for the detection of expressed scFvs were validated with anti-ubiquitin and 
anti-BSA control antibodies. Culture supernatants from E. coli HB2151 expressing each 
scFv were concentrated to about 1120 initial volume, exchanged into PBS and analysed by 
SDS-P AGE. Many proteins were detected on the gel (Figure 4.5) but bands of around 29 
kDa, the estimated molecular weight of a soluble scFv, could be seen in each sample. 
In principle, scFvs from the Tomlinson I and J libraries should be recognised by 
Protein L and the hybrid immunoglobulin-binding protein, Protein LA through their 
interaction with light and heavy chain frameworks. The scFvs from each library should 
also carry a c-myc tag at the carboxy-terminus, detectable with immunochemical reagents 
against this sequence. A Western blotting experiment was performed to compare detection 
with these three reagents. Concentrated supernatants from HB2151 expressing anti-BSA 
and anti-ubiquitin scFvs were loaded in triplicate to an SDS-PAGE gel, separated and then 
blotted onto nitrocellulose membrane. The membrane was then cut into three parts and 
each was probed with rProtein L-HRP, rProtein LA-HRP or anti-c-myc reagents. Figure 
4.6 shows both control scFvs were detectable by all methods with bands appearing at the 
expected molecular weight at different strengths. Detection through recognition of the c-
myc tag showed the greatest signal strength, probably because it is done with primary and 
secondary (HRP) antibodies. This method was therefore considered most appropriate when 
the expected concentration of a scFv is low. 
Table 4.4 A Titre of KM13 phage after production in large quantity (pfu/ml) 
Titre of trypsin treated phage Titre of non-trypsin treated phage Difference a 
1.66 x 10 14 1.2 x 10 5 0.46 x 10 9 
a Difference was calculated by the titre of trypsin treated phage minus non-trypsin 
treated phage 
Table 4.48 Titre of library phage (pfu/ml) 
Tomlinson library I Tomlinson Library J 
2.08 x 10 13 1.28 x 10 12 
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peR screening for full-length scFv genes 
To determine the frequency of full-length scFv genes in the Tomlinson I and J 
libraries, 21 colonies were picked at random from initial titration experiments for peR 
screening. Bacteria carrying genes for an anti-ubiquitin scFv served as a positive control. 
peR was performed on crude lysates using LMB3 and pHEN seq primers to amplify 
across the light chain, linker and heavy chain sequences. peR products were then analysed 
on 1 % agarose gels. Figure 4.4 shows that all clones from the Tomlinson library I had full 
length inserts according to the predicted sizes (935 bp) and comparison with the positive 
control although in several cases (lanes 16, 18 and 21) the amplification products were 
faint. Given that the lysates were very crude, the presence of non-specific products was 
unsurprising and they were also apparent in the positive control reaction. Only one clone 
from Tomlinson library J did not show insert (Figure 4.7, lane 6). The absence of non-
specific products in this reaction suggests either a fault with the reaction or low template 
concentration rather than absence of an scFv insert. These results indicated that both 
libraries had a very high percentage of inserts of full length, in contrast to the Griffin 
library used in earlier experiments. 
Panning Tomlinson library I and Tomlinson library J against 
purified K99 
The libraries used for this section of the project were each predicted to carry in excess 
of 108 unique specificities (Tomlinson library I: 1.47 x 108; Tomlinson library J: 1.37 x 
10 8). Phage antibodies against purified K99 were isolated in immunotubes coated with 
purified K99 at 20 /lg/ml in the first round of selection and 10 /lg/ml in the second and 
third rounds. The target antigen was coated at low concentrations in order to select 
antibodies of high specificity. Before and after each round of selection, the number of 
phage was determined by infecting TG 1 cells. The data in Table 4.5 shows the titre of 
input and output phage antibodies and the percentage recovery after each round of 
selection. Initial recovery of phage from library I was low but detectable. Thereafter, 
percentage recoveries rose by about 100-fold from round one to two and from two to three. 
Initial recovery of phage from Tomlinson library J was almost 10-fold higher than from 
library I (Table 4.5). Progression to round two of selection saw a rise in recovery that was 
lower than from library J, but phage output in round three was nearly lOOO-fold higher in 
percentage terms than from round two. These data and the emichrnent rates (Figure 4.9) 
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Figure 4.4 Recognition of purified K99 at different dilutions using an anti-K99 monoclonal 
antibody 
Purified K99 was coated to plastic at the concentrations indicated and then detected with a 
mouse monoclonal and HRP-conjugated antibodies. Coating was carried out in duplicate; 
the mean value is presented, the error bars indicating the standard deviation of the two 
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Figure 4.5 SOS-PAGE analysis of concentrated culture supernatants from bacteria 
expressing anti-ubiquitin and anti-8SA scFvs 
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After electrophoresis, the gels was stained with Coomassie Blue and photographed. Lane 
M shows the migration of Rainbow molecular weight markers. The migration of standards 
of 45,30 and 20.1 kDa is indicated 
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Figure 4.6 Western blotting analysis of concentrated culture supernatants from bacteria 
expressing anti-ubiquitin and anti-8SA scFvs 
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Culture supernatants from bacteria expressing an anti-ubiquitin (lane 1) and anti-BSA (lane 
2) scPvs were separated by SDS-PAGE and blotted to nitrocellulose. Membrane strips 
were probed with rProtein LA-HRP (panel A), rProtein L-HRP (panel B) and anti-c-myc 
reagents (panel C). Lane M shows the migration of Rainbow molecular weight markers. 
The migration of standards of 45, 30 and 20.1 kDa is indicated. The predicted molecular 
weight of a soluble scPv IS approximately 29 kDa. 
2 3 4 .5 M 
12 13 14 1.5 16 M 
1,636 bp 
1.018 bp 
6 1 8 9 10 11 
11 18 19 20 21 C0l1tt01 




Crude lysates from 21 clones (lanes 1 to 21) picked at random were amplified with primers 
flanking the scFv insert. The products were separated on a 12% agarose gel containing 
ethidium bromide and photographed under ultraviolet illumination. Lane M shows the 
migration of a 1 kb DNA ladder. The migration of markers of 1,018 bp and 1,636 bp is 
indicated. In the lane marked "Control", products from bacteria carrying genes for an anti-
ubiquitin scFv are shown. 
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Crude lysates from 21 clones (lanes 1 to 21) picked at random were amplified with primers 
flanking the scFv insert. The products were separated on a 12 % agarose gel containing 
ethidium bromide and photographed under ultraviolet illumination. Lane M shows the 
migration ofa 1 kb DNA ladder. The migration of markers of 1,018 bp and 1,636 bp is 
indicated. In the lane marked "Control", products from bacteria carrying genes for an anti-
ubiquitin scFv are shown. 
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Table 4.5 Progress of selection for anti-K99 scFv by panning 
Library Tomlinson I Tomlinson J 
Selection Input a Output a % of Recovery b Input Output % of Recovery 
Round 1 1.28 x 10 13 4.38 x 10 5 3.42 x 10-8 1.28 x 10 13 3.00 X 10 6 2.34 X 10-7 
Round 2 1.40 x 10 12 1.60 x 10 6 1.14 x 10-6 1.30 x 10 12 3.04 X 10 6 2.33 x 10-6 





- -- - -
a Input and output phage titres were determined by transduction of E. coli to ampicillin resistance using serial dilutions of sample 
b Percent recovery determined by division of output phage titre by input titre and multiplication by 100 
Enrichment ratea of phage in round 2 and 
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Figure 4.9 Enrichment rates during panning of the Tomlinson libraries I and J against K99 
a Enrichment rate was calculated by dividing the percentage recovery in the given round of 
selection by the percentage recovery achieved in the previous round 
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Polyclonal phage ELISA 
The populations of phage recovered after each round of selection from each library, 
were tested against purified K99 in ELISA. This screening was designed to test whether 
the elevated recoveries seen in Table 4.5 could be attributed to the selection of scFvs at the 
phage surface directed against target antigen or non-specific effects. Wells of an ELISA 
plate were coated with either 100 III of purified K99 at the concentration of 20 Ilg/ml or 
2% MPBS that was used as blocker during panning of the libraries. Samples of phage were 
taken from the original libraries prior to selection and after each round of panning. The 
phage were incubated in the coated wells, washed, and binding detected with virus-specific 
antibodies. Figures 4.10 and Figure 4.11 show the results of these assays for Tomlinson 
libraries I and J respectively. In each case, recognition of K99 or milk protein is very low 
in samples from the unselected libraries and comparable to the reaction of KM13 helper 
phage with K99. Only a slight bias towards K99 is evident after one round of panning. 
However, reactivity towards the K99 antigen rose sharply after round two and strong 
reaction against this target was evident after round three. Interestingly, phage antibodies 
isolated from library J after round two had a stronger reaction with 2% MPBS than at other 
stages of the screening or at any point from Tomlinson library J. This could be taken as 
evidence that in selection from the Tomlinson library I, about one third of phage isolated in 
rounds one and two had the potential to bind to milk protein but bias in favour of K99 was 
restored in round three. Overall, the results of polyclonal phage ELISA indicated that 
phage antibodies reactive with K99 fimbriae were successfully isolated and enriched from 
both Tomlinson libraries I and 1. 
Monoclonal phage ELISA 
A total of 96 bacterial colonies were picked at random from each library during 
selection against K99. Twenty colonies were chosen from each original library prior to 
panning, and after rounds one and two. A further 36 were picked after round three. These 
individual colonies were grown, infected with helper phage, culture supernatants were then 
used in monoclonal phage ELISA. The phage samples were added to wells of ELISA 
plates that had been coated with purified K99 at 20 Ilg/ml and blocked with 3% BSAIPBS. 
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Figure 4.10 Polyclonal phage ELISA of Tomlinson library I during panning against K99 
Phage from the original library and each round of selection by were tested in ELISA 
against purified K99 and 2% MPBS using an anti-M13-HRP monoclonal conjugate. The 
control shows the reaction of KM13 helper phage against the K99 antigen. Phage samples 
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Figure 4.11 Polyclonal phage ELISA of Tomlinson library J during panning against K99 
Phage from the original library and each round of selection by were tested in ELISA 
against purified K99 and 2% MPBS using an anti-M13-HRP monoclonal conjugate. The 
control shows the reaction of KM13 helper phage against the K99 antigen. Phage samples 
were tested against each antigen in duplicate and the mean value is presented. 
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Figures 4.12 (library I) and 4.13 (library J). The Figures show that none of the randomly 
chosen phage antibodies prepared from the original libraries recognised K99 fimbriae to a 
detectable extent. After a single round of selection, only one phage antibody selected from 
the Tomlinson library J had activity against K99 antigen and all clones isolated from 
library I at this point were unreactive. In contrast most of the phage antibodies isolated 
from each library after two and three rounds of panning showed strong reaction with the 
K99 target. These results indicate that selection for recombinant phage antibodies against 
K99 by phage display was successful. 
Screening monoclonal soluble scFv antibodies by ELISA 
In work with the Griffin library, a discrepancy was noted between the results of phage 
ELISA and the reactivity towards K99 of soluble svFvs produced from promising clones. It 
was therefore of considerable importance to assess carefully whether clones from the 
Tomlinson libraries behaved similarly. This was tackled by ELISA against purified K99. 
Soluble scFv antibodies were prepared from a number of phage clones picked at random 
and infected into E. coli HB2151. The infected cells were grown on TYE plates under 
ampicillin selection. Twenty clones were picked from the original libraries I and J before 
panning on K99 along with 20 from rounds 1 and 2, and 36 colonies from round 3. After 
infection to HB2151, bacteria were grown and expression of soluble scFvs induced by 
addition of IPTG. Culture supernatants containing each monoclonal, soluble scFv were 
used in immunoassay. ELISA plates were coated with purified K99 fimbriae, and were 
blocked with 2% MPBS. After adding the culture supernatants, bound scFvs were detected 
using rProtein L-HRP. Table 4.6 shows the number and percentage of scFvs that were 
judged positive in the assay for each library. The results from library I show that clones 
able to express soluble scFv with anti-K99 activity first become detectable after round 2 of 
selection and that they come to dominate the recovered population after round 3. This 
provides clear evidence that panning the library against K99 successfully selected and 
enriched antibodies against the fimbriae. It is interesting however to contrast the modest 
number of anti-K99 clones detected in this assay after round 2 with their apparent 
frequency in monoclonal phage ELISA (Figure 4.13). A different picture emerged from 
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Figure 4.12 Monoclonal phage ELISA of Tomlinson library I during panning against K99 
Individual phage clones from the original library and each round of selection by were 
tested in ELISA against purified K99 using an anti-M13-HRP monoclonal conjugate. 
Phage were applied as follows: 
section a: 20 clones picked at random from the Tomlinson library I before selection 
section b: 20 clones picked at random after round 1 of selection 
section c: 20 clones picked at random after round 2 of selection 
section d: 36 clones picked at random after round 3 of selection 





Figure 4.13 Monoclonal phage ELISA of Tomlinson library J during panning against K99 
Individual phage clones from the original library and each round of selection by were 
tested in ELISA against purified K99 using an anti-M13-HRP monoclonal conjugate. 
Phage were applied as follows: 
section a: 20 clones picked at random from the Tomlinson library J before selection 
section b: 20 clones picked at random after round 1 of selection 
section c: 20 clones picked at random after round 2 of selection 
section d: 20 clones picked at random after round 3 of selection 
The O.D was measured at 492 nm after 10 minutes. 
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K99 scFvs after round 2 is substantially high after round 3. Since the Tomlinson library J 
was diversified with NNK codons, this could be due to emichment of clones containing 
stop codons in round 3 of selection. 
peR analysis of genes encoding anti-K99 scFvs 
Ten clones from Tomlinson library I were chosen from rounds 2 and round 3 on the 
basis of their reaction against K99 in ELISA screening of soluble scFv antibodies. Their 
coding sequences were initially analysed by PCR using primers pelB and pHEN seq to 
screen for the presence of full-length inserts. The results are shown in Figure 4.14. All 10 
reactions yielded products that were identical in size to that from the positive control, an 
anti-ubiquitin scFv. Comparison of the sizes of these amplicons was consistent with that 
predicted for a full-length scFv insert (935 bp). 
Restriction analysis of genes encoding anti-K99 scFvs 
Plasmid DNA was isolated from 10 clones chosen from screenmg of Tomlinson 
library land 5 from library J. Clones were chosen because they showed higher reaction 
against K99 in ELISA assays of soluble scFv antibodies than the majority. DNA samples 
were digested with the restriction enzymes Neol and Notl to assess if all clones carried 
full-length scFv inserts. Figures 4.15 and 4.16 reveal that all the clones selected for 
detailed analysis contained full-length scFv genes. 
Western blotting of clones from libraries I and J 
The expression of scFv antibodies from the 15 clones selected for detailed analysis 
was confirmed by Western blotting. HB2151 clones were grown in similar conditions and 
induced by addition of lPTG. Culture supernatants were concentrated to approximately 
1/25 initial volume and similar volumes were run on SDS-P AGE gels. Proteins were 
transferred to nitrocellulose membrane and after blocking with 3% MPBS, single chain Fv 
fragments were detected using mouse monoclonal anti-c-Myc and anti-mouse-HRP 
antibodies. Figure 4.17 shows Western blotting analysis of the 10 clones chosen from 
Tomlinson library 1. The expected size of a scFv is approximately 29 kDa. The results 
confirm that scFv antibodies were expressed by all selected clones but it is apparent that 
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Table 4.6 ELISA screening of soluble scFv antibodies against K99 fimbriae 
Tomlinson library I Tomlinson library J 
Number of positives scFv, a Percentage of positive scFv Number of positive scFvs Percentage positive of scFvs 
Original library 0 0% Original library 0 0% 
Round I 0 0% Round 1 1 5% 
Round 2 1 5% Round 2 11 55 % 
Round 3 31 86% Round 3 3 8% 
Supernatants from induced HB2151 cultures were applied to K99-coated ELISA plates and the binding ofsvFvs detected with rProtein L-HRP. In all, 
20 clones were tested from the original libraries prior to selection, and the same number from rounds 1 and 2 of panning. Thirty-six clones were tested 
from round 3. All clones were picked at random. 
a: scFv antibodies that showed an OD at 492 nm of more than 0.1 after 10 minutes of development were considered positive 
b: The percentage of positive scFvs was calculated by dividing the number of positive scFvs by the total number of clones tested for each stage of the 
experiment and multiplication by 100 
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1,016 bp -
- 935t 
Figure 4.14 peR screening of 10 anti-K99 clones from Tomlinson library I 
Ten clones were chosen after screening of the Tomlinson library I on the basis of their 
strong reaction to K99 in ELISA of soluble scFv. The scFv inserts were amplified using 
primers of LMB3 and pHEN seq. For a full-length scFv insert, the expected size of the 
amplicon is about 935 bp (indicated). 
M: 1 kb DNA Ladder (Invitrogen, UK). The migration of a marker of 1,016 bp is indicated 
Control: Positive control PCR amplified from an anti-ubiquitin scFv. 
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Figure 4.15 Restriction analysis of of 10 anti-K99 clones from Tomlinson library I 
Ten clones were chosen after screening of the Tomlinson library I on the basis of their 
strong reaction to K99 in ELISA of soluble scFv. Plasmid DNA from each clone was 
digested with Neol and NotI. The expected size of the small fragment released is 708 bp 
(indicated). 
M: 1 kb DNA Ladder (Invitrogen, UK). The migration of markers of 506 bp, 1,016 bp and 
5,090 bp are indicated 
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Figure 4.16 Restriction digestion of plasm ids of selected colonies of Tomlinson library J 
Five clones were chosen after screening of the Tomlinson library J on the basis of their 
strong reaction to K99 in ELISA of soluble scFv. Plasmid DNA from each clone was 
digested with Neol and Not!. The expected size of the small fragment released is 708 bp 
(indicated). Plasmid DNA from each clone was digested with Neol and Not!. The expected 
size of the small fragment released is 708 bp (indicated). 
M: 1 kb DNA Ladder (Invitrogen, UK). The migration of markers of506 bp, 1,016 bp and 
5,090 bp is indicated 
208 
the proteins are expressed to quite widely differing levels and none of the signals match 
that from the anti-BSA control used in the experiment. 
Figure 4.18 shows the equivalent analysis ofthe 5 clones from library J. As we can see 
from the Figure, 4 clones showed good levels of expression of scFv antibody, only clone 
D4 had very low level of expression. In contrast to Figure 4.17, several clones appeared to 
produce recombinant protein to a higher level than that achieved by the anti-BSA positive 
control. 
Dot blotting of selected clones of library I and library J 
Attempts were made to test the reactivity of the anti-K99 scFvs against purified 
fimbriae using Western blotting. These were unsuccessful. In order to determine the 
reasons for this and to confirm that the recombinant antibodies would bind K99 after 
attachment to a substrate other than an ELISA plate, the following dot blot experiments 
were conducted. Purified K99 was boiled in SDS sample buffer and then spotted to strips 
of nitrocellulose along with unheated samples of the antigen. Concentrated supernatants 
prepared from induced cultures of the 10 clones selected from library I were added. The 
binding of scFvs-was then detected with anti-c-myc reagents and with 4-chloro-l-naphtol 
substrate. The results (Figure 4.19) clearly showed that some of the chosen scFv antibodies 
recognised strongly the purified K99 but that heat treatment abolished this binding. The 
same effect was observed when a mouse monoclonal antibody against K99 was used 
(Figure 4.19). In view of this, the experiment was repeated with the 5 clones chosen from 
analysis of library J, using only unheated samples of K99 (Figure 4.20). Overall, the 
strongest signals were obtained from clones C9 and FlO from library I and A7 and F7 from 
library 1. Comparison with previous Figure shows that this pattern does not simply reflect 
the levels of scFv expressed by these clones. The negative control scFv, an anti-BSA scFv, 
had no reaction with either heated or unheated K99 fimbriae. 
Sequencing of anti-K99 scFvs from Tomlinson libraries I and J 
DNA sequences of the 10 selected clones from library I and 5 from library J were 
analysed to confirm their reading frames were intact, to predict their amino acid sequences 
and thereby establish their diversity. The sequencing results were initially checked for the 
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Figure 4.17 Western blotting of 10 clones selected from Tomlinson library I 
Concentrated supernatants from induced cultures were separated by SDS-PAGE, 
transferred to membrane and probed with anti-c-myc reagents_ The predicted molecular 
weight of a scFv is approximately 29 kDa (indicated). In panel A, an anti-BSA clone 
served as a positive control; in panel B, an anti-ubiquitin scFv was used. In panel B, 
culture supernatant from an induced culture of E. coli HB2151 cell carrying plasmid but 
lacking a scFv insert was used as negative control (Neg). 
M: Rainbow protein molecular weight markers (Pharmacia). The migration of standards 
of 45, 30 and 20.1 kDa is indicated. 
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Figure 4.18 Western blotting of 5 selected colonies from Tomlinson library J 
Concentrated supernatants from induced cultures were separated by SDS-P AGE, 
transferred to membrane and probed with anti-c-myc reagents. The predicted molecular 
weight of a scFv is approximately 29 kDa (indicated). An anti-BSA clone served as a 
positive control. 
M: Rainbow protein molecular weight markers (Pharmacia). The migration of standards 
of 45, 30 and 20.1 kDa is indicated. 
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Figure 4.19 Dot blot analysis of 10 anti-K99 scFvs from Tomlinson library I 
Unheated (row A) and heated samples of K99 (row B) were spotted to nitrocellulose and 
the binding of anti-K99 scFvs detected with anti-c-myc reagents. 
+: Positive control, A mouse anti-K99 monoclonal antibody detected with anti-mouse 
reagents serving as positive control 
The anti-BSA scFv (indicated) was used as a negative control 
212 
D4 E 10 A7 F7 Fll 
A -
Figure 4.20 Dot blot analysis of 5 anti-K99 scFvs from Tomlinson library J 
Unheated (row A) samples ofK99 were spotted to nitrocellulose and the binding of anti-
K99 scFvs detected with anti-c-myc reagents. 
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presence of a complete Vwlinker-VL sequence. This is illustrated for clone C9 (library I) in 
Figure 4.21.The DNA and predicted amino acid sequences are presented in Tables 4.7 and 
4.8. Since both libraries were based on single human VH and VL frameworks, diversity was 
confined to the heavy chain complementarity determining regions CDR2 (residues HSO, 
HS2, HS2a, HS3, HSS, HS6, HS8), and CDR3 (H9S, H96, H97, H98), and CDRs2 (LSO, 
LS3) and 3 (L91, L92, L93, L94, L96) for the light chain component. The data indicate 
some clones are identical in their amino acid sequences through these regions. For example 
from library I, B7 and FlO are identical, as are A8, C9 and D9. For others, differences are 
limited to conservative substitutions. In this regard, the V H component of E9 (library I) 
only differs from the B7/FIO pair at 2 positions (HS8: N replaces D; H96: T replaces S). In 
some cases, identical sequences emerge from different libraries. This is illustrated by 
comparison of the VL components of G8 (library I) and Fll/A7 (library J). Whilst the 
sequences may be unique to a greater or lesser extent, the overall impression is that the 
clones carry broadly similar sequences. 
Purification of soluble scFvs 
Four scFvs from Tomlinson library I and two scFvs from library J were chosen for 
purification and analysis of biological function. On the basis of the sequence data and 
activity in dot blots, these were C9, FlO, F8 and FII from library I and F7 and A7 from 
library J. Supernatants from large scale cultures were concentrated in a tangential flow 
apparatus and purified by nickel chelating chromatography, exploiting the histidine repeats 
carried at the carboxyl termini of the scFvs. Fractions eluted from the affinity column were 
analysed by SDS-P AGE and Western blotting. To illustrate this, data is presented in 
Figures 4.22 and 4.23 from the purification of scFv C8. Analysis by SDS-P AGE (Figure 
4.22) confirmed the presence of a protein of the size expected for a scFv in concentrated 
culture supernatant (lane a). Some protein of this molecular weight could be observed in 
flow through and wash fractions (lanes b, c and d) along with material of a range of sizes. 
A single protein was successfully eluted by raising the imidazole concentration to 200 mM. 
While this was of the size expected for a scFv, its identity was confirmed by Western 
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Table 4.7 Amino acid sequence diversity of 10 selected clones from library I 
Heavy chain Light chain 
CDR2··· H ••• CDR3 ....... ······CDR2 ... ........................... CDR3 
Clone Name H50 H52 H52a H53 H55 H56 H58 H95 H96 H97 H98 L50 L53 L91 L92 L93 L94 L96 
A8 Y S D S T D S K T Y A N S Y S Y G S 
B7 S T D N N T D K S Y A N T Y N A G T 
C9 Y S D S T D S K T Y A N S Y S Y G S 
D9 Y S D S T D S K T Y A N S Y S Y G S 
EIO G A T A D T Y R A Y G G A Y Y Y S S 
E9 S T D N N T N K T Y A G D Y D D S D 
FlO S T D N N T D K S Y A N T Y N A G T 
F8 T S D D G S T K T Y G N D Y N S Y S 
G8 T E A W N Y V K K S A A S S Y S T N 
FI Y T D Y N D Y S Deletion N Y Y Y D Deletion 
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Table 4.8 Amino acid sequence diversity of 5 selected clones from library J 
Heavy chain Light chain 
CDR2 ................................ ........... CDR3·· .. ··CDR2 .. CDR3 
Clone Name H50 H52 H52a H53 H55 H56 H58 H95 H96 H97 H98 L50 L53 L91 L92 L93 L94 L96 
Fll T E A W N Y V K S A G A S S Y S T N 
F7 S V A A D L S N L P R S G G S R L S 
E 10 G A T A D T Y A Y G G A S S Y S T N 
D'4 Y V A S N T S C A K N S S G Y S S Y 
A7 S V A A D L S N L P R A S S Y S T N 
Figure 4.21 Complete nucleic acid sequence of clone C9 from library I 
Heavv chain 
FR1 
1 2 3 4 5 6 7 8 9 10 11 12 l3 14 15 
GAG GTG CAG CTG TTG GAG TCT GGG GGA GGC TTG GTA CAG CCT GGG 
16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 
GGG TCC CTG AGA CTC TCC TGT GCA GCC TCT GGA TTC ACC TTT AGC 
CDR1 FR2 ____ _ 
31 31a 31b 32 33 34 35 36 37 38 39 40 41 42 43 
AGC ... . .. TAT GCC ATG AGC TGG GTC CGC CAG GCT CCA GGG AAG 
44 45 46 47 48 49 50" 51 52" 52a" 52b 52c 53" 54 55" 
GGG CTG GAG TGG GTC TCA TAT ATT AGT GAT ... ... TCT GGT ACT 
CDR2 --------------------------
56" 57 58" 59 60 61 62 63 64 65 66 67 68 69 70 
GAT ACA TCT TAC GCA GAC TCC GTG AAG GGC CGG TTC ACC ATC TCC 
_____________ FR3 
71 72 73 74 75 76 77 78 79 80 81 82 82a 82b 82c 
AGA GAC AAT TCC AAG AAC ACG CTG TAT CTG CAA ATG AAC AGC CTG 
83 84 85 86 87 88 89 90 91 92 93 94 95" 96" 
AGA GCC GAG GAC ACG GCC GTA TAT TAC TGT GCG AAA TGT GCG 
-- CDR3 FR4 
97" 98" 99 100 101 102 103 104 105 106 107 108 109 110 III 




GGT GGA GGC GGT TCA GGC GGA GGT GGC AGC GGC GGT GGC GGG 
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Figure 4.21 (continued) 
Light chain 
FR1 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 
GAC ATC CAG ATG ACC CAG TCT CCA TCC TCC CTG TCT GCA TCT GTA GGA GAC 
-------------------------- CDR1 
18 19 20 21 22 23 24 25 26 27 28 29 30 31 31a 31b 31c 31d 
AGA GTC ACC ATC ACT TGC CGG GCA AGT CAG AGC ATT AGC AGC ... .. . ... . .. 
---------------------------- FR2 
31e 3lf 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 
... ... TAT TTA AAT TGG TAT CAG CAG AAA CCA GGG AAA GCC CCT AAG CTC 
--------- ---------CDR2 ----
47 48 49 50' 51 52 53" 54 55 56 57 58 59 60 61 62 
CTG ATC TAT AAT GCA TCC TCT TTG CAA AGT GGG GTC CCA TCA AGG TTC 
FR3 ________________________ _ 
63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 
AGT GGC AGT GGA TCT GGG ACA GAT TTC ACT CTC ACC ATC AGC AGT CTG CAA 
_________________ CDR3 ____ _ 
80 81 82 83 84 85 86 87 88 89 90 91 " 92· 93· 94· 95 96· 
CCT GAA GAT TTT GCA ACT TAC TAC TGT CAA CAG TAT TGT CAA CAG TAT TCT 
---------------- FR4 
97 98 99 100 101 102 103 104 105 106 107 108 109 110 11 1 112 
TAT GGT CCT AGT ACG TTC GGC CAA GGG ACC AAG GTG GAA ATC AAA CGG 
Co dons are numbered according to the Kabat convention with framework and complementarity 
determining regions indicated over the sequence. Positions that are diverse in the primary repertoire 
are indicated with an asterisk. 
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blotting by using monoclonal antibody against the c-myc tag carried by the recombinant 
antibody (Figure 4.23). The scFv and a cross-reacting contaminant could be detected in the 
concentrated culture supernatant (lane a). The high molecular weight contaminant failed to 
bind to the affinity column to a significant extent (lane b) and residual traces were 
successfully removed during initial washing (lane c). Protein of a size similar to a scFv 
noted from SDS-PAGE analysis to be present in the column flow through and washes 
failed to react with the anti c-myc reagents (lanes b-d). In contrast, the 29 kDa protein 
eluted with 200 mM imidazole reacted strongly in the analysis (lane e) confirming that it 
was indeed the scFv. 
Comparison of activity of purified scFvs by ELISA 
Purification of the scFvs and adjustment to equal protein concentrations allowed 
assessment of their relative reactivities with purified K99 fimbriae. K99 was coated to an 
ELISA plate, the scFvs added their binding detected using rProtein L-HRP. Results of this 
experiment are shown in Figure 4.24 and reveal that the purified scFv antibodies all 
recognised K99 fimbriae but there was a range of approximately 8-fold in the signals 
obtained from the assay from the lowest (F8) to the highest (F7). Interestingly, the 
strongest signals were obtained from the 2 clones chosen from library J. Signals from an 
anti-BSA scFv negative control were very low. 
Haemagglutination inhibition assay 
Suspensions of E. coli B 41 grown at 37°C caused haemagglutination of sheep red-
blood cells through expression of K99 fimbriae. By testing serial dilutions of the bacterial 
suspension, the haem agglutination activity could be titred to 1/64. Haemagglutination of 
sheep red-blood cells was not inhibited by the presence of 0.5 % D-mannose. Also, 
haemagglutination was not evident when the bacteria were grown at 18°C or when 
bacteria were not added to the erythrocytes (Figure 24.26). 
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Figure 4.22 50S-PAGE analysis of fractions recovered during the purification of scFv C 9 
Concentrated culture supernatant was equilibrated with column binding buffer by buffer 
exchange (lane a). The material was applied to an affinity column charged with nickel and 
the flow through collected (lane b). The column was washed first with 20 mM imidazole in 
binding buffer (lane c), then 50mM imidazole (lane d), before eluting bound proteins with 
200 mM imidazole. The recovered scFv was concentrated about 5 fold before loading to 
the gel (lane e). 
M: Rainbow protein molecular weight markers (Pharmacia). The migration of standards of 
45, 30 and 20.1 kDa is indicated. 
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Figure 4.23 Western blotting analysis of fractions recovered during the purification of scFv 
C9 
Concentrated culture supernatant was equilibrated with column binding buffer by buffer 
exchange (lane a). The material was applied to an affInity column charged with nickel and 
the flow through collected (lane b). The column was washed first with 20 mM imidazole in 
binding buffer (lane c), then 50mM imidazole (lane d), before eluting bound proteins with 
200 mM imidazole. The recovered scFv was concentrated about 5 fold before loading to 
the gel (lane e). Samples were run first on an SDS-PAGE gel, then transferred to 
nitrocellulose and probed with anti c-myc reagents. 
M: Rainbow protein molecular weight markers (Pharmacia). The migration of standards of 
45,30 and 20.1 kDa are indicated. 
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A7J C9 F11 anti- BSA. 
Figure 4.24 Activity of purified scFvs in ELISA 
The purified scFvs were adjusted to equal total protein concentrations and applied in 
duplicate to wells coated with K99. Binding was detected with rProtein L-HRP. An anti-
BSA scFv was used as a negative control. Error bars show the standard deviation of the 
duplicated samples. 
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Bacterial haem agglutination of sheep erythrocytes provided a convenient in vitro 
model in which the biological activity of anti-K99 scFvs could be tested. In these assays, a 
suspension of B41 bacteria was diluted close to its haem agglutinating titre and then 
incubated for 2 hrs at 37 DC with dilutions of the isolated scFv antibodies. By then adding 
sheep erythrocytes and testing for haemagglutination, the inhibitory activity of the 
antibody fragments could be assessed (Table 4.9). The results show that haemagglutination 
was inhibited by the binding of the scFvs to K99 fimbriae on the surface of bacteria. A 
purified scFv against ubiquitin had no effect on the haem agglutinating properties of the 
bacteria. In contrast, addition of an anti-K99 polyclonal antibody to B41 bacterial 
suspension grown at 37 DC successfully inhibited haemagglutination to high dilutions. 
Bacteria grown at 18 DC were unable to agglutinate erythrocytes. The monovalent binding 
of scFvs to their target in this assay effectively excluded the possibility that bacteria were 
themselves agglutinated and thereby prevented from interaction with the erythrocytes. It 
was not possible to rule this out as an explanation of the high HI titre of the polyclonal 
sheep antibody (Table 4.9). 
Indirect fluorescent antibody test (IFA) 
Indirect immunofluorescent staining was used to confirm that all six anti-K99 scFvs 
were able to bind to fimbriae on the surface of E.coli cells. Bacteria were grown at 37 DC, 
attached to glass slides and fixed. The recombinant antibodies were then added and their 
binding detected using an anti-c-myc monoclonal and an FITC-conjugated anti-mouse 
antibody. Fluorescence microscopy confirmed that all anti-K99 scFvs successfully adhered 
to the surface of bacteria grown at 37 DC though images were difficult to capture (data not 
shown). A positive control mouse monoclonal antibody against K99 produced identical 
patterns of greater intensity (Figure 4.26) and confirmed that antibody attachment was not 
detectable when bacteria were first grown at 18 DC. No binding could be observed when a 
control scFv against BSA was used (data not shown). 
223 
2 3 5 6 7 8 9 10 11 + 
A 
B 
Figure 4.25 Haemagglutination activity of E. coli 841 cells 
Bacteria were grown overnight at 37°C (row A) or at 18 °c (row B), then diluted two folds 
in PBS (wells 2 to 10) and mixed with sheep erythrocytes. Haemagglutination became 
evident after 2hrs incubation on ice. Undiluted suspensions of B41 were used as positive 
controls (+). As negative controls, sheep erythrocytes were incubated in the absence of 
bacteria (-). Titre was defined as the fmal dilution of overnight culture in which 
haemaglutination was evident (1/64; well 7) 
Table 4.9 The inhibition of haemagglutination activity of by anti-K99 scFvs 






F7 J ND 
Polyclonal antibody (+)b 111024 
Anti-ubiquitin (-t 112 
a HI titres were defined as the highest dilutions of antibody that successfully inhibited 4 
haemagglutinating units of B41 bacteria 
b A polyclonal sheep anti-K99 antibody was used as a positive control 
C A scFv against ubiquitin was used as a negative control 




Figure 4.26 Immunofluorescent staining of B41 bacteria using a monoclonal anti-K99 
antibody 
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E. coli B4l were grown at 37 DC (panel A) or 18 DC (panel B) and imaged by indirect 
immunofluorescence microscopy with a mouse monoclonal antibody against K99 and an 
FITC conjugate. 
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Electron microscopy and immunolabelJing 
To evaluate staining methods that would reveal K99 fimbriae for transmission 
electron microscopy, E. coli B41 were fixed to grids and treated by negative staining and 
Negative syaining by methy1cellulose. Observation in the EM revealed that fimbriae could 
be visualised by both staining methods but that the K99 structure was more visible when 
stained with the negative staining by methylcellulose. Also levels of background staining 
with this method were lower (Figure 4.27). K99 fimbriae could not be observed when 
bacteria were grown at 18°C. 
K99 fimbriae on the surface of E.coli B41 were labelled with the scFv antibodies 
selected from the Tomlinson I and J libraries for detailed analysis. To reveal the presence 
of the scFvs, samples were then incubated with a suspension of 5nm colloidal gold 
particles conjugated to Protein A and examined in the EM. Polyclonal and monoclonal 
anti-K99 antibodies served as positive controls while bacteria grown at 18°C before 
labelling provided a negative control (Figure 4.28). Control experiments clearly showed 
patches of immunogold staining with gold particles running along the fimbriae when 
polyclonal or monoclonal antibodies were applied. Bacteria prepared at 18°C were free of 
gold particles (Figure 4.28). Broadly similar patterns of staining were observed when scFvs 
from Tomlinson library I (Figure 4.29) or library J were used (Figure 4.30). Importantly, 
these results indicate that in all cases, the scFvs recognise epitopes present on fimbrial 
subunits present in multiple copies in the structure of the adhesin. To ensure that labelling 
with the recombinant antibodies was specific, bacteria grown at 37°C were labelled with 
an anti-ubiquitin scFv and Protein A-colloidal gold. No particles could be observed at the 
bacterial surface (Figure 4.31). Similar results were obtained when anti-K99 scFvs were 




Figure 4.27 Staining of E. coli 841 for electron microscopy 
E. coli B41 were grown overnight at 37°C, fixed to grids and prepared by negative 
staining (A) or negative staining by methylcellulose (B) for examination by transmission 
electron microscopy at magnifications of 50 k (A) or 30 k (B). 
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Figure 4.28 Immunogold labelling of K99 fimbriae with monoclonal and polyclonal 
antibodies 
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E. coli B41 were grown at 37 DC (A and B) or 18 DC (C) and prepared for electron 
microscopy. Grids were incubated with monoclonal (A) or polyclonal anti-K99 antibodies 
(B and C) and Protein A-colloidal gold reagents before examination in the electron 
microscope at 50 (A), 30 (B) or 7 k magnification (C). 
A R 
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Figure 4.29 Immunogold labelling of K99 fimbriae with scFv antibodies from Tomlinson 
library I 
229 
E. coli B41 were grown at 37°C and prepared for electron microscopy. Grids were 
incubated with scFvs F8 (A), FlO (B), Fll (C) or C9 (D) and Protein A-colloidal gold 
reagents before examination in the electron microscope at 30 k magnification. 
A 
R 
Figure 4.30 Immunogold labelling of K99 fimbriae with scFv antibodies from Tomlinson 
library J 
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E. coli B41 were grown at 37°C and prepared for electron microscopy. Grids were 
incubated with scFvs A 7 (A), or F7 (B) and Protein A-colloidal gold reagents before 
examination in the electron microscope at 30 k magnification. 
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Figure 4.31 Immunogold labelling of K99 fimbriae with an anti-ubiquitin scFv antibody 
E. coli B41 were grown at 37°C and prepared for electron microscopy. Grids were 
incubated with an anti-ubiquitin scFv and Protein A-colloidal gold reagents before 
examination in the electron microscope at 30 k magnification. 
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In vitro villus attachment assay 
Isolated calf villi were stored at -80°C in aliquots. For initial experiments to 
determine optimal fixation conditions, aliquots were thawed at room temperature before 
treatment with a range of reagents. It was established that 1 % formaldahyde was 
insufficient to stabilise the villi; they distintegrated within a few minutes of incubation at 
room temperature. Fixation with glutaraldehyde was unsuitable for different reasons. In 
this case, bacterial attachment to the villi was markedly reduced after treatment. Overall, 2 
% formaldehyde proved most suitable against both of these criteria: the isolated villi were 
sufficiently stable to withstand incubation with bacteria and subsequent washing steps and 
as shown in Figure 4.32, E. coli B41 expressing K99 fimbriae rapidly became attached at 
the brush border of the tissue fragments. The attachment of bacteria became greater with 
longer incubation at room temperature. Bacterial attachment could not be observed when 
E. coli B41 were grown at 18°C. 
Bacterial adherence inhibition assay 
The ability of six purified scFv antibodies to inhibit the attachment of B41 bacteria to 
viIi were assessed. ScFv antibodie at similar concentration (30 ~g/ml) were added to E. 
coli B41 strain and were incubated at 37°C with agitation for 45 min. Then about 50 
washed villi (with Krebs buffer pH 6.8 and 1 % mannose) were added to the mixture and 
the villi materials were incubated at room temperature for 1 hr. The observation results 
revealed that, except for the positive control, none of the purified scFv antibodies could 
show a significant inhibition of attachment at above concentration. 
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Figure 4.32 The villi after fixation with 2 % formaldhyde 
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Discussion 
Attempts to isolate recombinant soluble scFv antibodies against the major subunit of 
K99 using the Griffin. 1 library encountered several problems. Although antibodies 
expressed at the surface of phage appeared able to recognise the target, it was not possible 
to express soluble scFv fragments. The Tomlinson I and J semi-synthetic libraries were 
chosen as alternative resources from which the aims for the project might be met. To check 
the quality of these two libraries, they were initially analysed for the presence of full-
length inserts by screening clones picked at random. In contrast to the Griffin.I library in 
which only about 1/3 of clones chosen in this way carried full-length inserts, these 
experiments revealed that almost all clones from the Tomlinson libraries were intact. On 
this basis alone, the quality of the Tomlinson libraries appeared better than Griffin.I. This 
was reinforced by the expression of soluble scFv by a very high proportion of clones 
picked at random from the libraries. Positive control clones were then grown and 
characterised to ensure that methods were working effectively. The activity of the purified 
K99 antigen was also tested at a range of different concentrations using a monoclonal 
antibody before panning the libraries. 
Selection revealed a pattern of phage recovery that was consistent with the progressive 
emichment of target-specific clones and again, contrasted with data from screening the 
Griffin.I library. In percentage terms, recoveries rose steadily from round 1 to round 3 and 
were consistently higher than observed during from the Griffin library. This may be due to 
multiple factors: the greater proportion of phage in the Tomlinson libraries with full-length 
inserts and hence a more diverse starting resource; the use of the KM13 helper phage and 
trypsin-driven elution ensuring that only phage with intact reading frames progress from 
elution to rescue and amplification (Kristensen and Winter, 1998). Since recovery data 
only provide a preliminary indication of the progress of selection, monoclonal phage 
ELISA was a critical benchmark for these experiments. This clearly revealed that most 
clones in rounds 2 and 3 showed high reaction with K99 and there were far fewer false 
positive results than obtained with the Griffin.1 library, a problem that others have 
commented upon (Azzazy, 2002). Clones isolated from Tomlinson I and J libraries were 
also shown to be highly specific for K99 in polyclonal phage ELISA and, in contrast with 
Griffin.1 library, they showed almost no reaction with skimmed milk. Expression of scFv 
was further checked by picking at random a number of clones eluted after each round of 
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selection and infected into E. coli HB2151. Supernatants from induced cultures were 
screened by ELISA. In contrast to the analysis of samples from the Griffin. 1 library where 
scFvs were only rarely expressed, samples from the Tomlinson libraries expressed 
successfully. This indicated that stop codons occurred rarely and inserts were usually full-
length. 
In screening for anti-K99 antibodies, the Tomlinson I and J libraries were run in 
parallel. These resources only differ in the nature of their diversification. Library I is 
diversified by possessing DVT (D: A, G or T; V: A, C or G) codons at selected positions in 
the scFv insert. This only carries 9 possible nucleotide combinations but no stop codons 
arise. Library J is diversified by the NNK (N: any base; K G or T) motif, each encoding 32 
possible nucleotide sequences of which one (TAG) is an amber stop codon. Overall, 
similar results were obtained from these libraries but the percentage recovery rate was 
lower for J and a lower proportion of clones expressed soluble scFv at a detectable level, 
perhaps due to the occurrence of the amber codon. 
This said, there were ample clones able to express specific anti-K99 scFvs from which 
to choose several with high ELISA activity. The biological activity of these scFv 
antibodies was then assessed. Initial experiments attempted to confirm the specificity of 
the scFvs for FanC by Western blotting. No signal could be detected on the nitrocellulose 
membrane but as a similar problem was encountered with monoclonal anti-K99, the dot 
blotting was used to test for reaction with K99. The results showed that some scFv 
antibodies had stronger reaction in this assay than others, indicating either that the clones 
expressed the scFvs to different levels or that the scFvs were able to bind the target with 
different efficiencies. Although DNA sequencing of these clones revealed some similarity 
between them, this provided insufficient basis to discriminate between these possibilities. 
From this point, four clones from Tomlinson library I and two clones from Tomlinson 
library J were chosen, purified and taken forward to more detailed tests of their activities. 
It is known that the major subunit of K99 can adhere to erythrocytes from a variety of 
animal species due to recognition of a specific receptor on the surface of these cells 
(Burrows et ai., 1976; Gaastra and de Graaf, 1982; Jacobs et ai., 1987). This was 
demonstrated by mixing E. coli B41 of purified K99 with sheep erythrocytes and observing 
haem agglutination. This reaction was dependent upon culture of bacteria at 37oC. 
Haemagglutination could be inhibited by pre-incubation of bacteria with high dilutions of 
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anti-K99 antibodies (Burrows et a!., 1976; Morris et a!., 1980; Vazquez et a!., 1996), 
thereby providing a positive control for an in vitro assay for K99-neutralising activity. 
Anti-K99 scFvs were purified and tested in this assay, revealing that some possessed 
inhibitory activity. For those scFvs that showed promise, anti-haemagglutinating activity 
did not persist to high dilutions as was apparent for the polyclonal anti-K99 positive 
control. This observation needs further repetition and the assay could be expanded to a 
wider range of scFvs. However, an important difference between the properties of a scFv 
and a native immunoglobulin molecule should be noted. The scFv interacts with its target 
on a monomeric basis whereas the native immunoglobulin has the capacity for a dimeric 
interaction, assuming it to be IgG. On a simple molar basis, one would therefore predict 
that twice as much scFv compared with IgG would be required to achieve the same 
biological activity, ignoring the ability of the IgG to make contact with epitopes that might 
be close together. Perhaps more significant however is the ability of a dimeric molecule 
like IgG to physically agglutinate the bacteria or K99 in this assay, inhibiting attachment to 
the red blood cell target. It is also significant the some aggregation of some scFvs could be 
observed after purification that would probably lead to some reduction in the starting 
concentration in the assay. Therefore, this assay clearly shows the some anti-K99 scFvs 
possessed interesting biological properties but the significance of the outcome could be 
better assessed by comparing the data with Fab fragments generated from the polyclonal 
anti-K99 antibody that served as positive control and standardising the proteins under test 
to a common starting concentration. Further work on the stability of the purified scFvs, 
affinity maturation, or re-engineering so that were expressed as dimeric proteins 
("diabodies") might also raise their neutralisation activities. Finally, it did not prove 
possible to measure the affinity of the scFv antibodies for FanC; this would also be a 
valuable objective in future studies. 
Use of the purified scFvs in indirect immunofluorescent staining revealed their ability 
to bind to fimbriae on the surface of E. coli cells. This data might serve as the starting point 
for the use of the isolated scFv antibodies as diagnostic reagents. Since some investigators 
in recent studies have successfully shown that green fluorescent protein (GFP) or a red-
shifted mutant of green fluorescent protein (EGFP) can be fused to scFvs (Casey et a!., 
2000; Hink et a!., 2000), genetic conjugation of an anti-K99 to a reporter molecule that 
requires no substrate addition could make for faster and cheaper diagnosis of bovine ETEC 
infection. 
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The interaction between scFv antibodies and K99 fimbriae was also studied by 
electron microscopy using Protein A-gold colloidal particles. Initial efforts used simple 
negative staining (Duchet-Suchaux et at., 1988; Hernandez et at., 1989) to show the 
presence of fimbriae. Although this method was adequate for the intended purpose, it did 
create high background staining on the grids. This could be reduced using a 
methylcellulose method. Immunogold labelling of fimbriae using scFvs from Tomlinson 
libraries I or J generated similar patterns in the electron microscope compared with 
polyclonal or monoclonal anti-K99 and binding was noted at numerous positions along the 
fimbrial structure. For P (Lindberg et at., 1987) or I fimbriae (Buhler et at., 1991), the 
receptor-binding site of the major subunit only is exposed at the tip of the structure. For 
K99, multivalent interaction of the major subunit (Fan C) with its ganglioside receptor 
(Willemsen and de Graaf, 1993) is possible and it has been estimated that receptor can be 
bound at intervals of abour 20 nm (Willemsen and de Graaf, 1993). For all the scFvs tested 
in electron microscopy, the staining pattern is therefore consistent with recognition of an 
exposed epitope present on the FanC subunit. This does not necessarily equate with 
recognition of epitopes in or close to the receptor binding site and hence the capacity to 
neutralise K99 activity, though it is clear from the earlier discussion that some scFvs 
possessed this property. However, engineering of scFvs with this pattern of staining to 
divalent diabodies would likely create proteins with K99-specific agglutinating activity. 
This strategy for developing recombinant antibodies with agglutinating properties for 
diagnosis or therapy could be broadened for other microbial pathogens. 
Haemagglutination provided a useful model to identify scFvs with biological activities 
of potential value but it has its limitations as a model. Attempts were made to use the 
attachment of E. coli B41 to fixed intestinal villi to better assess the whether scFvs isolated 
from Tomlinson libraries I or J could inhibit bacterial attachment in vitro. The method of 
Girardeau (Girardeau, 1980) was sufficient for the isolation and storage of villi and the 
technique has been used by other in order to set up in vitro attachment assays (Van den 
Broeck et aI., 1999; Mercado et aI., 2003). Experience showed that thawing the villi from 
storage and fixation in 1 % formaldehyde was not sufficient to stabilise them. By raising 
the concentration of formaldehyde to 2 %, disintegration was prevented and after washing 
with Krebs buffer, they could be maintained for several days at 4 0c. K99-specific 
attachment to villi was confirmed by using B41 bacteria grown at 18°C versus 37°C and 
by inhibition of the attachment process using an anti-K99 monoclonal antibody. It proved 
difficiult to demonstrate inhibition of attachment with purified scFvs. When the inhibitory 
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effect of monoclonal anti-K99 was checked by light mIcroscopy, it revealed the 
aggregation of bacteria was talking place. This finding supports the idea proposed above 
that dimeric interaction of native immunoglobulin with K99 might prevent normal receptor 
binding at least in part because of agglutination of the bacteria under test. Again, the 
monomeric interaction of scFvs with their targets dictates that attachment can only be 
prevented by blocking the K99 receptor-binding site. The use of the anti-K99 scFvs in this 
model of attachment therefore needs further development, perhaps using scFv antibodies at 
higher concentration, or increasing the incubation time of the bacteria with the scFvs under 
test before addition to villi. An alternative model worth consideration might also be the 
erythrocyte-binding assay (Willemsen and de Graaf, 1993; Jay et aI., 2004) in which the 
attachment of bacteria to red cells (as opposed to the agglutination of these target cells) is 
studied. Also the binding of isolated fimbriae or bacteria expressing K99 to the receptor 
purified from solubilized pig brush border (Sun et ai., 2000) or calf ileal enterocytes 
(Isaacson et aI., 1978; Jay et aI., 2004) could be studied on artificial substrates such as 
plastic. It was noticeable with villus attachment that bacterial distribution was often 
irregular, perhaps reflecting the partial integrity of the brush border. The use of 
erythrocytes or the purifed ganglioside receptor might enable some of these variables to be 
eliminated. Finally, for those recombinant antibodies with best promise a mouse model for 
the study of the virulence of bovine ETEC strains has been developed (Duchet-Suchaux, 
1988; Duchet-Suchaux et al., 1992). It is only in an intact animal that the therapeutic 
potential of anti-K99 scFvs could be assessed. 
Overall, the use of the results Tomlinson I and J libraries enabled the goals of the 
project to be met: to use phage display for isolation of recombinant antibodies against K99, 
to express soluble scFv fragments, purify them and assess their biological activity. This 
phase of the project clearly showed that recombinant antibodies against a bacterial 
colonisation factor could be isolated with simple selection methods. There is every reason 
to expect that the strategy could be applied with equal success to human or animal 





The focus of this study has been to isolate recombinant antibodies against the K99 
fimbrial structure, a colonisation factor of major importance in the pathogenesis of E. coli 
infection in newborn calves. The goals of the project were to use K99 as a model virulence 
factor and thereby explore the utility of phage display and recombinant antibody 
technology as tools in the study of bacterial pathogenesis, specifically to see whether small 
antibody fragments with the capacity to neutralize bacterial products can be isolated from 
phage display libraries. 
The first objective was to isolate K99 fimbriae from a clinical isolate of E. coli and 
experience demonstrated that the purity of the major fimbrial subunit (Fan C) was a very 
important factor in the isolation of specific recombinant antibodies. Unless specifically 
guided, phage display is essentially blind to the nature of the target used in panning and 
with a large antibody library with millions of potential binding specificities, it seemed 
relatively easy for selection to drift away from the target of interest if the coated surface 
was heterogeneous. It was reasoned that if the recombinant antibodies were to possess the 
ability to neutralise the action ofK99, the target protein must not only be pure but also in a 
correctly folded and fully active state. In the event, methods were devised that successfully 
purified the major subunit of K99 with ease, at low lost and yielded protein with high 
biological activity. This method for the purification of K99 may find use in research but 
given the considerable body of data showing the value of the antigen in vaccination, it may 
also find commercial application. Future work might explore if simple ion exchange 
chromatography as used here could be also be applied to the isolation of other colonisation 
factors of importance in bovine ETEC infection (eg F4I and FI7). The K99 protein 
purified by this method showed all the characteristics of the native structure 
(immunological reactivity, haemagglutination) but formal demonstration of its ability to 
protect against ETEC infection was beyond the scope of this project. This might be 
addressed by work in a mouse model of ETEC infection. 
The results that were obtained from panning the Griffin. 1 library against purified K99 
showed that the quality of the recombinant antibody library is the single most important 
factor in work in this area. The crucial issues to emerge from this phase of the project were 
that the proportion of clones in the library with full-length inserts should be maximised and 
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the percentage of clones containing stop codons should be minimised, if at all possible. In 
an attempt to achieve this, some investigators have tried to make recombinant antibody 
libraries that do not contain stop codons (Knappik et ai., 2000). It is also likely that the 
properties of helper phage have a role in carrying phage antibodies containing full-length 
antibodies forward from one round of selection to the next and eliminating those with 
incomplete inserts. Attempts to isolate recombinant antibodies against K99 from the 
Griffin.1 library that could be expressed as soluble scFvs were time-consuming and 
ultimately unsuccessful but valuable experience was gained. It was clear from this phase 
of the project that at the outset, a recombinant antibody library should be tested before use. 
Specifically, the percentage of full-length inserts should assessed, the ability of clones 
picked at random to express soluble fragments should be tested, clones should be screened 
for the presence of stop codons, and good controls to confirm the progress of selection and 
expression levels are important. Experience with the Griffin. 1 library has shown that over-
amplification can sometimes lead to a drastic reduction in the diversity of the library, 
probably through the faster growth of clones containing incomplete inserts. After panning 
the library, polyclonal phage ELISA and enrichment rates appear to be the quickest way to 
evaluate the results of selection. It is now clear that if these tests fail to show substantial 
enrichment for clones reactive with the target, it is better to repeat the selection rather than 
pursuing further screening. Regarding the identification of clones with high activity against 
the target antigen, direct infection of HB2151 and assay of soluble antibody fragments 
seems inclined to fewer artefacts than monoclonal phage ELISA. Early progress to 
sequencing is also recommended as a means to explain low-level expression of antibodies 
that apparently react with the target. 
On the positive side, the Tomlinson libraries proved excellent resources from which to 
isolate anti-K99 scFvs. The libraries met the criteria of high frequency presence of full-
length inserts and the ease of expression of scFvs. It proved relatively straight-forward to 
isolate numerous anti-K99 scFvs, from which 6were chosen for detailed analysis. The 
properties of these met in full the goals of the project: they reacted specifically with K99, 
they could be used to determine the cellular location of the colonisation factor and the 
ability of some to block K99-mediated haemagglutination was of particular interest, 
showing the ability to inhibit the mode of action of the virulence factor. In future, these 
properties could be further explored with an in vitro model of E. coli colonisation using 
isolated intestinal villi from young calves or an in vivo mouse model (Duchet-Suchaux, 
1988). 
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Overall, the project has shown that phage display has a useful role as a tool to 
understand better molecules of importance in bacterial pathogenesis. Is it possible that 
recombinant antibodies isolated in this way could be used passively for the therapeutic 
treatment of livestock animals? Given the current economics of livestock farming, it would 
seem unlikely that purified antibodies against microbial pathogens could be administered 
for the treatment of disease except in species (eg horses) or individuals (eg breeding 
animals) of high commercial value. It may be possible that unit costs could be reduced by 
alternative delivery methods. For example, considerable effort has been invested in DNA 
vaccines as alternatives to protein immunogens for the vaccination of livestock animals. 
Recent work has shown that the expression of recombinant antibodies can be induced in 
animals via DNA immunisation with the encoding sequences and that this can protect 
against pathogen challenge (Lorenzen, 2000). It has also been shown that attenuated 
bacterial species able to colonise the host can express recombinant antibodies as either 
anti-idiotypic immunogens or protective proteins in their own right (Beninati, 2000). 
It is difficult to predict if these technologies will eventually impact on livestock animal 
healthcare but from the studies reported here, it would seem that antibody phage display is 
likely to find increasing use as a basic tool for the study of the pathogens of livestock 
animals. 
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